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Summary 
Schizophrenia is a highly heritable, common psychiatric disorder. Although onset 
generally occurs during adolescence, multiple lines of evidence point to a 
neurodevelopmental insult that occurs many years prior to the presentation of 
symptoms. Many different approaches have been used to elucidate the genetic risk 
factors and their impact; however, few unequivocal facts have been established. 
With a considerable amount of data publically available, integrative approaches look 
to leverage multiple data sources to identify coherent themes. This thesis 
investigates the neurodevelopmental hypothesis of schizophrenia by incorporating 
results from genome-wide association studies and copy number variation studies 
with gene expression datasets, with the overall aim of identifying functional 
pathways that may be disrupted in the aetiology of the disorder. 
 
This study used foetal and developmental expression datasets of the human brain 
and statistical approaches to characterise the expression profiles of schizophrenia 
risk genes. Both spatial profiles in the mid-foetal brain and temporal profiles across 
development were considered. Data from genome-wide association studies and 
copy number variation studies were used to test for an enrichment of risk genes; in 
addition the genetic overlap with bipolar disorder identified through genome-wide 
association studies was used for validation. Gene sets with a common expression 
profile enriched for schizophrenia variants were used to identify biological pathways 
and assessed for their polygenic contribution to schizophrenia risk.  
 
The results of this thesis converged on a common developmental expression profile 
for schizophrenia risk genes. Genes identified with this profile were shown to 
harbour multiple, common risk variants for schizophrenia and were implicated in 
epigenetic processes relating to the regulation of gene transcription. Together this 
suggests that schizophrenia associated genes are involved in brain development, 
particularly during foetal stages, and may play a role in the regulation of this process. 
 
  
iii 
 
Table of Contents 
 
Declaration and statements............................................................................................ i 
Summary ........................................................................................................................ ii 
List of Figures ............................................................................................................... vii 
List of Tables ................................................................................................................. xi 
Abbreviations .............................................................................................................. xvi 
Acknowledgments ....................................................................................................... xix 
Chapter 1: Introduction ................................................................................................. 1 
1.1 Introduction to disorders ..................................................................................... 1 
1.1.1 Schizophrenia ................................................................................................ 1 
1.1.2 Bipolar disorder............................................................................................. 1 
1.1.3 Schizophrenia and bipolar disorder as separate diagnostic entities ............ 2 
1.2 Neurodevelopmental hypothesis ........................................................................ 2 
1.2.1 Human brain development ........................................................................... 3 
1.2.2 Evidence of neurodevelopmental antecedents for schizophrenia ............... 4 
1.2.3 Evidence of neurodevelopmental antecedents for bipolar disorder ........... 8 
1.3 Genetics of schizophrenia and bipolar disorder .................................................. 9 
1.3.1 Heritability and family studies ...................................................................... 9 
1.3.2 Association studies...................................................................................... 10 
1.3.3 Copy number variation studies ................................................................... 18 
1.3.4 Rare variants: exome and whole genome sequencing ............................... 21 
1.3.5 Gene expression studies ............................................................................. 22 
1.3.6 Biological pathway analysis ........................................................................ 27 
1.3.7 Integrating the ‘omics ................................................................................. 28 
1.4 Aims and objectives of thesis ............................................................................. 30 
1.5 Outline of subsequent chapters ........................................................................ 30 
Chapter 2: The expression of schizophrenia and bipolar disorder risk genes during 
human foetal brain development ................................................................................ 32 
iv 
 
2.1 Introduction ....................................................................................................... 32 
2.1.1 Background ................................................................................................. 32 
2.1.2 Outline......................................................................................................... 33 
2.2 Results ................................................................................................................ 39 
2.2.1 Global pattern of gene expression and common risk variants ................... 39 
2.2.2 Regional characteristic gene expression and common risk variants .......... 52 
2.2.3 Global pattern of gene expression and schizophrenia structural variants . 66 
2.2.4 Regional characteristic gene expression and schizophrenia structural 
variants ................................................................................................................. 69 
2.2.5 Alternative splicing and common risk variants ........................................... 70 
2.2.6 Alternative splicing and schizophrenia structural variants ......................... 72 
2.2.7 Functional analysis of genes with enriched expression profiles ................ 72 
2.3 Discussion ........................................................................................................... 78 
2.3.1 Identification of common spatial expression profiles ................................ 78 
2.3.2 Identification of functional pathways from enriched expression gene sets
 .............................................................................................................................. 81 
2.3.3 Comparison of results with schizophrenia and bipolar disorder variants .. 82 
2.3.4 Comparison of results with Brown’s and Simes’ gene-wide p values ........ 82 
2.3.5 Summary of chapter findings ...................................................................... 83 
2.4 Methods ............................................................................................................. 83 
Chapter 3: Expression patterns of schizophrenia and bipolar disorder risk genes 
throughout human brain development ....................................................................... 94 
3.1 Introduction ....................................................................................................... 94 
3.1.1 Background ................................................................................................. 94 
3.1.2 Outline......................................................................................................... 95 
3.2 Results ................................................................................................................ 97 
3.2.1 Development stage characteristic gene expression and common risk 
variants ................................................................................................................. 97 
3.2.2 Schizophrenia risk genes co-expression models ....................................... 109 
v 
 
3.2.3 Bipolar disorder risk genes co-expression models ................................... 118 
3.2.4 Development stage characteristic gene expression and schizophrenia 
structural variants .............................................................................................. 122 
3.2.5 Functional analysis of genes with enriched expression profiles .............. 126 
3.3 Discussion ......................................................................................................... 129 
3.3.1 Identification of common developmental expression profile .................. 129 
3.3.2 Identification of functional pathways from enriched expression gene sets
 ............................................................................................................................ 131 
3.3.3 Comparison of results with Brown’s and Simes’ gene-wide p values ...... 133 
3.3.4 Technical replication across RNA-Seq and microarray expression data... 133 
3.3.5 Summary of chapter findings .................................................................... 134 
3.4 Methods ........................................................................................................... 135 
Chapter 4: Developing the polygenic model for application to expression derived 
gene sets .................................................................................................................... 142 
4.1 Introduction ..................................................................................................... 142 
4.1.1 Background ............................................................................................... 142 
4.1.2 Outline....................................................................................................... 144 
4.2 Results .............................................................................................................. 146 
4.2.1 Standard polygenic scores ........................................................................ 146 
4.2.2 Population weighted polygenic scores ..................................................... 147 
4.2.3 LD adjusted polygenic scores .................................................................... 152 
4.2.4 SNP-SNP interaction polygenic scores ...................................................... 160 
4.2.5 Summary of polygenic model adaptations ............................................... 163 
4.2.6 Application to gene set identified in Chapter 3 ........................................ 164 
4.3 Discussion ......................................................................................................... 167 
4.3.1 Extensions of polygenic model ................................................................. 167 
4.3.2 Assessing polygenic contribution of gene set identified from Chapter 3 170 
4.3.3 Summary of chapter findings .................................................................... 170 
Chapter 5: Discussion ................................................................................................. 172 
vi 
 
5.1 Identification of temporal expression profile for schizophrenia risk genes .... 172 
5.2 Identification of temporal expression profile for bipolar disorder risk genes 175 
5.3 Identification of functional pathways from genes with common expression 
profiles ................................................................................................................... 176 
5.4 Future work ...................................................................................................... 177 
5.5 Concluding statement ...................................................................................... 180 
Chapter 6: References ................................................................................................ 182 
Chapter 7: Appendix A ............................................................................................... 212 
7.1 Additional tables for Chapter 2 ........................................................................ 212 
7.2 Additional figures for Chapter 2 ...................................................................... 236 
Chapter 8: Appendix B ............................................................................................... 242 
8.1 Additional tables for Chapter 3 ........................................................................ 242 
8.2 Additional figures for Chapter 3 ...................................................................... 266 
 
  
vii 
 
List of Figures 
Figure 2.1: QQ plot to demonstrate distribution of gene-wide logP........................... 36 
Figure 2.2: Scatterplots of relationships between global metrics calculated in the 
Johnson dataset and Brown’s gene-wide p values. ............................................. 42 
Figure 2.3: Results from Mann-Whitney tests for genes ranked by global metrics 
calculated in the Johnson and Kang datasets. ..................................................... 44 
Figure 2.4: Scatterplots of relationships between testing global metrics calculated 
within neocortical regions in the Johnson dataset and Brown’s gene-wide logP.
 .............................................................................................................................. 46 
Figure 2.5: Results from Mann-Whitney tests for genes ranked by global metrics 
within neocortical regions calculated in the Johnson and Kang datasets. .......... 47 
Figure 2.6: Scatterplots of relationships between global metrics calculated in the 
Kang dataset and Brown’s gene-wide logP. ........................................................ 49 
Figure 2.7 Scatterplots of relationships testing global metrics calculated within 
neocortical regions in the Kang dataset and Brown’s gene-wide logP. .............. 51 
Figure 2.8: Results from Mann-Whitney tests to verify significant regression models 
with regional characteristic scores calculated in the Johnson and Kang datasets.
 .............................................................................................................................. 58 
Figure 2.9: Results from Mann-Whitney tests to verify significant regression models 
with regional characteristic scores calculated across Johnson and Kang datasets.
 .............................................................................................................................. 61 
Figure 2.10: Expression across development for most enriched characteristic HIP and 
THAL gene sets. .................................................................................................... 64 
Figure 2.11: Key annotation terms identified from set of significant GO terms with 
significantly smaller HIP characteristic scores. .................................................... 74 
Figure 2.12: Key annotation terms identified from set of significant GO terms with 
significantly smaller THAL characteristic scores. ................................................. 75 
Figure 3.1: Linear regression results testing development stage characteristic scores 
calculated in the BrainSpan RNA-Seq dataset. .................................................... 99 
viii 
 
Figure 3.2: Linear regression results testing development stage characteristic scores 
calculated in Kang microarray dataset. ............................................................. 102 
Figure 3.3: Linear regression results testing development stage characteristic scores 
calculated in Kang microarray dataset, excluding MHC genes. ......................... 103 
Figure 3.4: Linear regression results testing development stage characteristic scores 
calculated in Kang microarray dataset without PMI covariate. ........................ 105 
Figure 3.5: Results from Mann-Whitney tests for genes ranked by single SCZ risk gene 
co-expression model p values calculated in the BrainSpan RNA-Seq dataset. . 110 
Figure 3.6: Median development stage characteristic scores calculated in the 
BrainSpan RNA-Seq dataset for most enriched gene set identified from SCZ risk 
genes co-expression model. .............................................................................. 114 
Figure 3.7: SCZ risk genes comparing microarray and RNA-Seq expression values. . 116 
Figure 3.8: Results from Mann-Whitney tests for genes ranked by single BPD risk 
gene co-expression model p values calculated in the BrainSpan RNA-Seq 
dataset. .............................................................................................................. 118 
Figure 3.9: Median development stage characteristic scores calculated in the 
BrainSpan RNA-Seq dataset for most enriched gene set identified from BPD risk 
genes co-expression model. .............................................................................. 120 
Figure 3.10: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset. ....... 123 
Figure 3.11: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in Kang microarray dataset. .................. 125 
Figure 3.12: Key annotation terms identified from set of significant GO terms with 
smaller SCZ risk genes co-expression model p values. ...................................... 127 
Figure 4.1: Multidimensional scaling plot of individuals in ISC dataset. ................... 148 
Figure 4.2: Violin plots of SE for beta coefficients for SNPs in LD adjusted polygenic 
models. ............................................................................................................... 159 
Figure 7.1: Scatterplots of relationships between global metrics calculated in the 
Johnson dataset and Simes’ gene-wide p values............................................... 236 
Figure 7.2: Scatterplots of relationships between testing global metrics calculated 
within neocortical regions in the Johnson dataset and Simes’ gene-wide p 
values. ................................................................................................................ 237 
ix 
 
Figure 7.3: Scatterplots of relationships between global metrics calculated in the 
Kang dataset and Simes’ gene-wide p values. ................................................... 238 
Figure 7.4: Scatterplots of relationships between testing global metrics calculated 
within neocortical regions in the Kang dataset and Simes’ gene-wide p values.
 ............................................................................................................................ 239 
Figure 7.5: Results from Mann-Whitney tests for genes ranked by global metrics 
calculated in the Johnson and Kang datasets, excluding MHC genes. .............. 240 
Figure 7.6: Results from Mann-Whitney tests for genes ranked by global metrics 
within neocortical regions calculated in the Johnson and Kang datasets, 
excluding MHC genes. ........................................................................................ 241 
Figure 8.1: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the  BrainSpan 
RNA-Seq dataset and Brown’s p values. ............................................................ 266 
Figure 8.2: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the BrainSpan 
RNA-Seq dataset and SCZ Simes’ p values. ........................................................ 266 
Figure 8.3: Results from linear regression of development stage characteristic scores 
calculated in the BrainSpan RNA-Seq dataset, excluding MHC genes. ............. 267 
Figure 8.4: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the BrainSpan 
RNA-Seq dataset and Brown’s p values, excluding MHC genes. ....................... 268 
Figure 8.5: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the BrainSpan 
RNA-Seq dataset and SCZ Simes’ p values, excluding MHC genes. ................... 269 
Figure 8.6: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset and Brown’s p values. ........................................................ 269 
Figure 8.7: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset and Simes’ p values. ........................................................... 270 
x 
 
Figure 8.8: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset and Brown’s p values, excluding MHC genes. .................... 271 
Figure 8.9: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset and Simes’ p values, excluding MHC genes. ...................... 272 
Figure 8.10: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the  Kang 
microarray dataset without PMI covariate  and Brown’s p values. .................. 273 
Figure 8.11: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset without PMI covariate and SCZ Simes’ p values. ............... 273 
Figure 8.12: Results from linear regression of development stage characteristic 
scores calculated in the Kang microarray dataset without PMI covariate, 
excluding MHC genes. ........................................................................................ 274 
Figure 8.13: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset without PMI covariate and SCZ Brown’s p values, excluding 
MHC genes. ........................................................................................................ 275 
Figure 8.14: Results from Mann-Whitney tests to verify significant regression models 
between development stage characteristic scores calculated in the Kang 
microarray dataset without PMI covariate and SCZ Simes’ p values, excluding 
MHC genes. ........................................................................................................ 275 
Figure 8.15: Results from Mann-Whitney tests for genes ranked by SCZ risk genes co-
expression model p values calculated in the BrainSpan RNA-Seq dataset. ...... 276 
Figure 8.16: Results from Mann-Whitney tests for genes ranked by BPD risk genes 
co-expression model p values calculated in the BrainSpan RNA-Seq dataset. . 277 
Figure 8.17: BPD risk genes comparing microarray and RNA-Seq expression values.
 ............................................................................................................................ 278 
Figure 8.18: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in the Kang microarray dataset without 
PMI covariate. .................................................................................................... 279 
xi 
 
List of Tables 
Table 1.1: CNV loci associated with schizophrenia or bipolar disorder. ..................... 19 
Table 1.2: Functional pathways identified from genes differentially expressed 
between schizophrenia or bipolar disorder post-mortem brains and controls. . 23 
Table 2.1: Brain regions included in the Johnson dataset with abbreviations. ........... 34 
Table 2.2: Brain regions included in the Kang dataset with abbreviations and Johnson 
equivalents. .......................................................................................................... 35 
Table 2.3: Counts of CNVs from ISC and MGS studies. ................................................ 38 
Table 2.4: Linear regression results and correlation coefficients testing global metrics 
calculated in the Johnson dataset with gene-wide logP. .................................... 41 
Table 2.5: Linear regression results and correlation coefficients testing global metrics 
calculated within neocortical regions in the Johnson dataset with gene-wide 
logP. ...................................................................................................................... 45 
Table 2.6: Linear regression results and correlation coefficients testing global metrics 
calculated in the Kang dataset with gene-wide logP. .......................................... 48 
Table 2.7: Linear regression results and correlation coefficients testing global metrics 
calculated within neocortical regions in the Kang dataset with gene-wide logP.
 .............................................................................................................................. 50 
Table 2.8: Empirical p values for the number of significant regression models 
between regional characteristic scores and SCZ or BPD Brown’s logP. .............. 54 
Table 2.9: Empirical p values for the number of significant regression models 
between regional characteristic scores and SCZ or BPD Brown’s logP across both 
datasets. ............................................................................................................... 54 
Table 2.10: Linear regression results and correlation coefficients testing regional 
characteristic scores calculated in the Johnson dataset with gene-wide logP. .. 56 
Table 2.11: Linear regression results and correlation coefficients testing regional 
characteristic scores calculated in the Kang dataset with gene-wide logP. ........ 56 
Table 2.12: Linear regression results and correlation coefficients testing regional 
characteristic scores calculated across both the Johnson and Kang datasets with 
gene-wide logP. .................................................................................................... 60 
xii 
 
Table 2.13: Linear regression results testing regional characteristic scores calculated 
across both the Johnson and Kang datasets simultaneously to predict Brown’s 
logP. ...................................................................................................................... 62 
Table 2.14: Logistic regression results testing CNV status on global metrics calculated 
in the Johnson dataset. ........................................................................................ 67 
Table 2.15: Logistic regression results testing CNV status on global metrics calculated 
in Kang dataset. .................................................................................................... 68 
Table 2.16: Linear regression results and correlation coefficients testing global 
splicing logP with gene-wide logP. ....................................................................... 71 
Table 2.17: Logistic regression results testing CNV status on global splicing logP 
calculated in the Johnson dataset. ...................................................................... 72 
Table 2.18: Results of set-based tests for genes found in HIP and THAL enriched sets 
split into those annotated to a significant pathway and those not. ................... 77 
Table 2.19: Results of set-based tests based on pathway groups in Figures 2.11 and 
2.12. ..................................................................................................................... 77 
Table 3.1: Development stages as defined by Kang et al. ........................................... 96 
Table 3.2: Linear regression results testing development stage characteristic scores 
calculated in the BrainSpan RNA-Seq dataset simultaneously predicting SCZ 
Brown’s logP. ..................................................................................................... 107 
Table 3.3: Linear regression results testing development stage characteristic scores 
calculated in Kang microarray dataset simultaneously predicting SCZ Brown’s 
logP. .................................................................................................................... 107 
Table 3.4: Linear regression results testing development stage characteristic scores 
calculated in Kang microarray dataset without PMI covariate simultaneously 
predicting SCZ Brown’s logP. ............................................................................. 107 
Table 3.5: Linear regression results and correlation coefficients testing single SCZ risk 
gene co-expression model logP calculated in the BrainSpan RNA-Seq dataset 
with SCZ Brown’s logP. ....................................................................................... 110 
Table 3.6: Linear regression results and correlation coefficients testing SCZ risk genes 
co-expression model logP across development calculated in the BrainSpan RNA-
Seq dataset with gene-wide logP. ...................................................................... 112 
xiii 
 
Table 3.7: Linear regression results and correlation coefficients testing SCZ risk genes 
co-expression model logP across brain regions calculated in the BrainSpan RNA-
Seq dataset with gene-wide logP. ...................................................................... 112 
Table 3.8: Linear regression results and correlation coefficients testing single SCZ risk 
gene co-expression model logP calculated in Kang microarray dataset with SCZ 
Brown’s logP. ..................................................................................................... 115 
Table 3.9: Linear regression results and correlation coefficients testing BPD risk 
genes co-expression model logP across development calculated in the 
BrainSpan RNA-Seq dataset with gene-wide logP. ............................................ 119 
Table 3.10: Linear regression results and correlation coefficients testing BPD risk 
genes co-expression model logP across brain regions calculated in the 
BrainSpan RNA-Seq dataset with gene-wide logP. ............................................ 119 
Table 3.11: Results of set-based tests for genes found in most enriched gene set 
from SCZ co-expression model and in significantly enriched pathways. .......... 128 
Table 4.1: Logistic regression results testing population weighted polygenic scores.
 ............................................................................................................................ 151 
Table 4.2: Empirical p values for number of SNPs with significant differences in effect 
size across populations in the ISC. ..................................................................... 152 
Table 4.3: Number of SNPs after LD based pruning in sets used to calculate LD 
adjusted polygenic scores. ................................................................................. 153 
Table 4.4: Logistic regression results testing polygenic scores not adjusted for any LD 
SNPs. .................................................................................................................. 154 
Table 4.5: Logistic regression results testing LD adjusted polygenic scores, where all 
SNPs were adjusted for an LD SNP. ................................................................... 154 
Table 4.6: Logistic regression results testing LD adjusted polygenic scores, where 
SNPs where only adjusted for an LD SNP if r2 > 0.25. ........................................ 155 
Table 4.7: Logistic regression results testing LD adjusted polygenic scores, where 
SNPs were adjusted for up to two LD SNPs. ...................................................... 156 
Table 4.8: Logistic regression results testing LD adjusted polygenic scores, where 
SNPS were adjusted for up to three LD SNPs. ................................................... 157 
Table 4.9: Logistic regression results testing polygenic SNP scores and polygenic 
interaction scores separately. ............................................................................ 162 
xiv 
 
Table 4.10: Logistic regression results testing polygenic SNP scores and polygenic 
interaction scores jointly. .................................................................................. 163 
Table 4.11: Logistic regression results testing expression gene set polygenic scores 
using unadjusted and LD adjusted methods. .................................................... 165 
Table 4.12: Logistic regression results jointly testing genome-wide and gene set 
polygenic scores. ................................................................................................ 165 
Table 4.13: Logistic regression results jointly testing genic genome-wide and gene set 
polygenic scores. ................................................................................................ 166 
Table 7.1: Linear regression results and correlation coefficients testing regional 
characteristic scores calculated in the Johnson dataset with gene-wide logP. 213 
Table 7.2: Linear regression results and correlation coefficients testing regional 
characteristic scores calculated in the Kang dataset with gene-wide logP. ...... 215 
Table 7.3: Logistic regression results testing CNV case control status on regional 
characteristic scores calculated in the Johnson dataset. .................................. 217 
Table 7.4: Logistic regression results testing CNV singleton status on regional 
characteristic scores calculated in the Johnson dataset. .................................. 219 
Table 7.5: Logistic regression results testing CNV case control status on regional 
characteristic scores calculated in the Kang dataset. ........................................ 221 
Table 7.6: Logistic regression results testing CNV singleton status on regional 
characteristic scores calculated in the Kang dataset. ........................................ 223 
Table 7.7: Linear regression results and correlation coefficients testing regional 
splicing logP calculated in the Johnson dataset with gene-wide logP............... 225 
Table 7.8: Linear regression results and correlation coefficients testing regional 
splicing logP calculated in the Kang dataset with gene-wide logP. ................... 227 
Table 7.9: Logistic regression results testing CNV case control status on regional 
splicing logP calculated in the Johnson dataset. ............................................... 229 
Table 7.10: Logistic regression results testing CNV singleton status on regional 
splicing logP calculated in the Johnson dataset. ............................................... 231 
Table 7.11: Logistic regression results testing CNV case control status on regional 
splicing logP calculated in the Kang dataset. ..................................................... 233 
Table 7.12: Logistic regression results testing CNV singleton status on regional 
splicing logP calculated in the Kang dataset. ..................................................... 235 
xv 
 
Table 8.1: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset with 
gene-wide logP. .................................................................................................. 243 
Table 8.2: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset with 
gene-wide logP, excluding MHC genes. ............................................................. 245 
Table 8.3: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the Kang microarray dataset with gene-
wide logP. ........................................................................................................... 247 
Table 8.4: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the Kang microarray dataset with gene-
wide logP, excluding MHC genes. ...................................................................... 249 
Table 8.5: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the Kang microarray dataset without 
PMI covariate with gene-wide logP. .................................................................. 251 
Table 8.6: Linear regression results and correlation coefficients testing development 
stage characteristic scores calculated in the Kang microarray dataset without 
PMI covariate with gene-wide logP, excluding MHC genes. ............................. 253 
Table 8.7: Logistic regression results testing CNV case control status on development 
stage characteristic score calculated in the BrainSpan RNA-Seq dataset. ........ 255 
Table 8.8: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset. ....... 257 
Table 8.9: Logistic regression results testing CNV case control status on development 
stage characteristic scores calculated in the Kang microarray dataset............. 259 
Table 8.10: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in the Kang microarray dataset............. 261 
Table 8.11: Logistic regression results testing CNV case control status on 
development stage characteristic scores calculated in the Kang microarray 
dataset without PMI covariate. ......................................................................... 263 
Table 8.12: Logistic regression results testing CNV singleton status on development 
stage characteristic scores calculated in the Kang microarray dataset without 
PMI covariate. .................................................................................................... 265 
xvi 
 
Abbreviations 
ADHD - attention deficit hyperactivity disorder 
ANOVA - analysis of variance 
ARC - activity-regulated cytoskeleton 
BPD - bipolar disorder 
CNS - central nervous system 
CNV - copy number variant 
DNA - deoxyribonucleic acid 
GABA - gamma-aminobutyric acid 
GCTA - genome-wide complex trait analysis 
GEO - Gene Expression Omnibus 
GO - Gene Ontology 
GWAS - genome-wide association study 
ISC - International Schizophrenia Consortium 
LD - linkage disequilibrium 
MAF - minor allele frequency 
Mon - months 
MGS - Molecular Genetics of Schizophrenia 
MHC - major histocompatibility complex 
mRNA - messenger ribonucleic acid 
NCBI - National Center for Biotechnology Information 
NMDAR - N-methyl-D-aspartate receptor 
PCW- post conception weeks 
PGC - Psychiatric Genomics Consortium 
PMI - post-mortem interval 
RIN - RNA integrity number 
RMA - robust multi-array average  
RNA - ribonucleic acid 
SCZ - schizophrenia 
SE - standard error 
xvii 
 
SNP - single nucleotide polymorphism 
SNV - single nucleotide variant 
 
  
xviii 
 
  
xix 
 
Acknowledgments 
Firstly, I would like to thank my supervisors, Dr Andrew Pocklington, Prof. Peter 
Holmans, Dr Richard White and Dr Andrew Jones for giving me the opportunity to 
work towards this PhD. I am proud of the journey I have taken over the last three 
years and appreciate the advice and guidance given to me throughout. This has 
enabled me to develop a skillset, which will equip and serve me well as I continue to 
develop throughout my career in research. I very much enjoyed and benefited from 
the research environment at Cardiff and am grateful to all who have contributed to 
that. In particular, I wish to thank all members of the BBU and the schizophrenia and 
psychosis teams for their day to day contributions, help, and entertainment.  
 
I am eternally grateful to my family, Dad, Holly, Grandma and Granddad you seen me 
through all of my academic achievements so far. Your confidence and belief in me 
pushes me ever forward and I continue to aspire to make you all proud. Phoebe and 
Phil, thank you for your patience, friendship and enthusiasm while we lived together. 
I am grateful for all the trips/nights out, exercise classes and dinners we have done 
together over the years, providing the much needed day to day support and down-
time that allowed me to reach my potential.  Then follows a long list of friends; your 
interest in my studies and confidence in my ability have inspired me to keep going 
and ultimately get to this point. I look forward to celebrating with you all.  
 
1 
 
Chapter 1: Introduction 
1.1 Introduction to disorders 
1.1.1 Schizophrenia  
Schizophrenia (SCZ) is a complex psychiatric disorder with a median lifetime 
prevalence estimate of 0.4% and a median lifetime morbid risk estimate of 0.7% 
(McGrath et al., 2008). The primary diagnostic feature is an episode of psychosis 
characterised by hallucinations, delusions, disorganised thought or speech, with 
additional negative symptoms that affect normal functioning such as affective 
flattening, anhedonia (inability to experience pleasure) or avolition (lack of 
motivation), also required for diagnosis (Andreasen, 1995, Linden, 2011). Deficits in 
motor and cognitive domains (Heinrichs and Zakzanis, 1998, Dickinson et al., 2007) 
are also often part of this heterogeneous disorder. This range of clinical features 
means psychiatrists can see a variety of different presentations, with potentially two 
patients having few common symptoms.  
 
The onset of SCZ typically occurs during adolescence or early adulthood, generally 
occurring later in females (Hafner et al., 1994). Incidence rates are higher in males 
compared to females with a relative risk of approximately 1.4 (Aleman et al., 2003, 
McGrath et al., 2008). Current diagnosis is based on matching observed or reported 
symptoms with descriptions provided by the World Health Organisation in the 
International Classification of Diseases (World Health Organization, 1993) or the 
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders (American Psychiatric Association, 2000, American Psychiatric Association, 
2013), both of which have been revised over the years to reflect research findings.  
 
1.1.2 Bipolar disorder 
Bipolar disorder (BPD) is also a common psychiatric disorder with lifetime prevalence 
estimates ranging from 2-4.4% depending upon the clinical subtypes included 
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(Kessler et al., 2005, Merikangas et al., 2007, Kessler et al., 2012). It is characterised 
by contrasting episodes of depression and mania, sometimes including psychotic 
symptoms (Goodwin and Jamison, 1990), with periods of remission. Similar to SCZ, 
onset generally occurs during early adulthood (Joyce, 1984) and is diagnosed using 
the aforementioned diagnostic manuals.  
 
1.1.3 Schizophrenia and bipolar disorder as separate diagnostic entities 
At the end of the 19th century German psychiatrist Emil Kraepelin first described the 
two diagnostic entities dementia praecox and manic depression (Kraepelin, 1899), 
which are considered the forerunners to SCZ and BPD. This dichotomy has since 
remained, but research findings are challenging such a format (Craddock and Owen, 
2005). 
 
An overlap in clinical features is not uncommon with SCZ patients presenting 
symptoms of depression (Zisook et al., 1999, Majadas et al., 2012) and the first-rank 
symptoms introduced by Schneider (Schneider, 1959), which encompass 
hallucinations and delusions, present in some BPD patients (Rosen et al., 2011). 
Moreover, the idea that these disorders ‘breed true’ has been challenged through 
family and molecular genetic studies providing evidence for a shared genetic 
susceptibility (Lichtenstein et al., 2009, Purcell et al., 2009). The overlap of 
associated risk factors will be discussed further in the following sections. 
 
1.2 Neurodevelopmental hypothesis 
SCZ is classed as a neurodevelopmental disorder (Murray and Lewis, 1987, 
Weinberger, 1987) in which a disruption during the critical period of brain 
development plays a major role in the disease aetiology. This is unlikely to be 
sufficient to cause SCZ and may be combined with genetic predisposition or an 
additional insult during adolescence (Bayer et al., 1999, Keshavan, 1999).  BPD has 
typically been considered an adult disorder, although in light of evidence supporting 
a nosological overlap with SCZ a neurodevelopmental insult has been proposed as 
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part of BPD aetiology (Nasrallah, 1991). Currently, evidence for BPD as a 
neurodevelopmental disorder is inconsistent, with methodological issues limiting the 
ability to draw cohesive conclusions (Sanches et al., 2008). 
 
1.2.1 Human brain development 
Human brain development is a sensitive sequence of processes, coordinated by 
genetic, epigenetic and environmental influences (Tau and Peterson, 2010). By the 
end of the third post conception week (PCW), the earliest neural progenitor cells 
have migrated to the neural plate signalling the start of brain development. The 
neural plate becomes the neural tube, which grows and changes from its cylindrical 
shape to eventually form the cerebral shape of the brain we are familiar with as well 
as the rest of the central nervous system (Stiles and Jernigan, 2010).  
 
The establishment of the regions of the brain happens progressively by a process 
called neural patterning. The first subdivision forms the prosencephalon (forebrain), 
mesencephalon (midbrain) and rhombencephalon (hindbrain). By the end of the 
embryonic period (8th gestational week) both the prosencephalon and 
rhombencephalon further subdivide into the telencephalon and diencephalon and 
the metencephalon and myelencephalon respectively.  Neural patterning, which 
gives rise to the regional organisation of the central nervous system, is coordinated 
by the expression level of signalling molecules (Hoch et al., 2009). These molecules 
prompt neural progenitors to differentiate into neurons appropriate for each region 
(Hebert and Fishell, 2008), a process which continues postnatally. The early stages of 
brain development are characterised by neurogenesis, migration and differentiation 
(Stiles and Jernigan, 2010). 
 
While growth in total brain volume slows after early childhood (Dekaban, 1978, Brain 
Development Cooperative Group, 2012), the human brain still undergoes structural 
changes with maturational processes active up to and during adolescence. Structural 
magnetic resonance imaging has shown that white matter volume continues 
increasing throughout the second and third decade of life (Lenroot et al., 2007, 
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Koolschijn and Crone, 2013). In contrast, grey matter volume reaches its maximum 
during childhood, although the exact time point varies between lobes, before 
decreasing through adolescence (Gogtay et al., 2004, Lenroot et al., 2007, Koolschijn 
and Crone, 2013).  
 
White matter is composed of myelin, a fatty sheath that insulates axons to improve 
the transmission of impulses between neurons; therefore structural brain scans that 
identify changes in the volume of white matter reflect the accumulation and loss of 
myelination (Giedd, 2004). The increases of white matter are consistent with the 
knowledge that myelination continues into adolescence (Benes et al., 1994). 
Moreover, increased white matter volume indicates more efficient communication 
across the brain (Paus, 2005). Myelination is a progressive event that is active during 
the same developmental stages as the regressive mechanism of synaptic pruning, 
both of which may play a role in these structural changes (Sowell et al., 2001). 
Synaptic pruning, which occurs throughout childhood and adolescence 
(Huttenlocher, 1979), will also improve the efficiency of communication within the 
brain.  
 
Given the common onset of SCZ during teenage years and early adulthood there has 
been much interest in this time period. As brain development continues for at least 
two decades, insults early on may have immediate effects or some latency before 
any impacts manifest.  Aetiological hypotheses regarding adolescent 
neurodevelopment have been proposed such as faulty synaptic pruning (Feinberg, 
1982). Further, there has been much focus on the prefrontal cortex as it is one of the 
last brain regions to mature during adolescence (Gogtay et al., 2004) and is related 
to executive functions that are affected in SCZ (Bozikas et al., 2006).  
 
1.2.2 Evidence of neurodevelopmental antecedents for schizophrenia 
Premorbid impairments 
Support for a neurodevelopmental contribution to SCZ aetiology comes from many 
different studies. Birth cohort studies, as well as other study designs, find childhood 
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impairments in motor (Jones et al., 1994, Cannon et al., 2002a, Clarke et al., 2011, 
Dickson et al., 2012), social (Jones et al., 1994, Bearden et al., 2000, Schiffman et al., 
2004) and cognitive (Jones et al., 1994, Cannon et al., 2002a, Dickson et al., 2012) 
domains amongst those who go on to develop the disorder. These could be potential 
indictors of those at higher risk of developing SCZ with aberrant brain development 
leading to both these premorbid features and SCZ symptoms later in life.  
 
As the name may suggest, Kraepelin’s initial descriptions of dementia praecox 
included deterioration of cognitive function (Kraepelin, 1899). In later revisions, 
Kraepelin himself began to recognise that functional recovery did occur in some 
patients (Kraepelin, 1919). This deterioration aspect of SCZ has been a contentious 
issue with the most recent meta-analysis finding no evidence for such a decline 
during disease onset, further supporting a developmental insult giving rise to SCZ 
symptoms (Bora and Murray, 2013). 
 
Pre- and perinatal events 
Complications during pregnancy and delivery are proposed as risk factors for SCZ 
that may have a negative impact on brain development. Studies have found 
increased rates of specific complications in those who go on to develop SCZ including 
low Apgar scores, a scale used immediately after birth to assess the health of 
newborn babies (Cannon et al., 2002a), small for gestational age (Cannon et al., 
2002a), preeclampsia (Cannon et al., 2002b, Byrne et al., 2007), hypoxia or ischaemia 
(Zornberg et al., 2000, Cannon et al., 2002a) and low birth weight (Cannon et al., 
2002b) amongst others. These findings are primarily based on prospective 
population-based samples which, given a lifetime prevalence of 0.4% (McGrath et 
al., 2008) require large cohorts to obtain even a handful of SCZ cases. With a small 
number of cases power is then limited to detect the small effect sizes (odds ratio < 2) 
that are often associated with these risk factors (Cannon et al., 2002b). In addition, 
simultaneously investigating many different individual complications increases the 
multiple testing burden, and therefore the chances of a spurious association if the 
significance level is not adjusted to reflect this. A combination of these issues means 
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that robust replicated findings for specific obstetric complications as yet have not 
been identified but a general increased rate has been reported (Cannon et al., 
2002a). 
 
Exposure in the womb to viruses or infections is one specific insult which may impact 
on brain development that has received much attention. A recent meta-analysis 
supported previous reports of an increased rate of SCZ in offspring whose mothers 
were exposed to infectious agents including Human herpesvirus 2, Toxoplasma 
gondii, Borna disease virus, or Human endogenous retrovirus-W during pregnancy 
(Arias et al., 2012). The association for Borna disease virus was based on the largest 
sample with over 2000 cases and controls, followed by the samples for Human 
herpesvirus 2 and Toxoplasma gondii, the latter of which had evidence of a 
publication bias. However, given that no correction was applied to take into account 
the multiple exposures that were tested, further replication would be required for 
each of these exposures. Additionally, larger samples would allow a more accurate 
estimate of the risk associated with these exposures. 
 
Population-based cohort studies have reported similar increased risk of SCZ in the 
offspring of mothers hospitalised for infection (Nielsen et al., 2013), or diagnosed 
with a bacterial (Sorensen et al., 2009) or respiratory infection (Brown et al., 2000a) 
during pregnancy. As with the obstetric complications these need to have large 
sample sizes to ensure enough SCZ cases, with all of these studies having at least 75 
affected individuals. Studies of the impact of maternal illness have attempted to 
narrow down the period of increased risk, leading to suggestions that the earliest 
stages of pregnancy may be the most vulnerable (Khandaker et al., 2013).  
 
Famine studies look at nutritional deficiency during pregnancy and the impact this 
may have on developing illness later in life.  These are uncommon events but one 
such study showed that those conceived during the lowest point of the Dutch 
Hunger Winter famine during 1945 had an increased risk of developing SCZ (Susser 
et al., 1996, Hoek et al., 1998). A similar study of the Chinese Great Leap Forward 
famine also found that people born during the latter stages, from 1959-1961, and 
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therefore conceived during the famine, also had a greater risk of SCZ (St Clair et al., 
2005).  In both studies risk was estimated from birth rates, death rates and SCZ 
diagnoses from psychiatric hospital records of large geographical regions with 
minimal migration, and therefore had very considerable sample sizes. Famine is a 
broad exposure and can encompass a range of deficiencies, including particular 
nutrients or vitamins, as well as other factors such as maternal stress, which may 
have an impact, making it challenging to identify how exposure to famine may affect 
brain development and ultimately SCZ risk.  
 
One potentially more revealing approach is the study of minor physical anomalies, 
such as cleft palate, low-seated ears or furrowed tongue. As these characteristics are 
established during gestation, they are proposed to be indicative of disruptions during 
the period of early brain development (Lobato et al., 2001). SCZ patients have been 
shown in meta-analyses to have an increased number of minor physical anomalies 
(Weinberg et al., 2007, Xu et al., 2011). Both of these studies obtained total samples 
of over 1000 cases from 11 and 14 studies respectively, which suggest that individual 
studies to date have had quite small sample sizes. Within these, secondary analyses 
of specific anomalies or anomalies affecting a particular area of the body were 
sometimes also tested but the number of studies and hence total sample size for 
these was further reduced. Therefore interpretation of these results requires 
additional caution. 
 
A similar idea is behind the study of dermatoglyphic anomalies, as they are also 
established during foetal development and thought to be markers of insults during 
this timeframe (Lobato et al., 2001).  As with minor physical anomalies 
dermatoglyphic abnormalities are more common in SCZ patients compared to 
controls (Bramon et al., 2005). This includes evidence for two different 
dermatoglyphic abnormalities which implicate different developmental time points, 
suggesting that disruptions potentially causing SCZ could occur at multiple points of 
foetal development (Golembo-Smith et al., 2012). These findings were also based on 
meta-analyses of many small studies producing combined samples of sizes similar to 
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those for the studies of minor physical anomalies and hence further studies should 
look to confirm these findings. 
 
Although lots of studies have been performed investigating the role of pre- and 
perinatal risk factors, the majority of these were based on small samples (< 100 
cases or controls). Meta-analyses look to synthesize the existing evidence but even 
when combined, the samples amount to less than 2000 cases or controls. While 
further evidence is required to strengthen the association for each specific risk factor 
and to accurately quantify the increased risk, as a group they indicate that 
disruptions during foetal brain development play a role in the development of SCZ.  
 
These insults are estimated to have small effect sizes (generally ≤ 2), and therefore 
as the risk to the general population for SCZ is low these will only increase the risk of 
SCZ by an additional few per cent. In addition, there will be many others who 
experience the same complications but do not develop SCZ (Clarke et al., 2006) so 
they have limited predictive power (Lewis and Levitt, 2002). Each factor, therefore, 
contributes to the risk but is not enough to cause it outright; a combination of 
environmental and genetic factors play a part in an individual’s liability. Genetic risk 
factors will be discussed further in Section 1.3. 
 
1.2.3 Evidence of neurodevelopmental antecedents for bipolar disorder 
For BPD the evidence for a neurodevelopment insult is inconsistent. Early studies did 
not find evidence for premorbid impairments in those that went on to develop BPD 
(Zammit et al., 2004, Reichenberg et al., 2005). More recent studies found lower 
cognitive scores in those who went on to develop BPD but these were not 
significantly worse than controls (Osler et al., 2007, Seidman et al., 2012). These 
studies did find a significant difference between SCZ and healthy controls but the 
number of individuals in the SCZ group was greater than that in the BPD group, 
meaning there was reduced power to detect a difference between BPD and controls.  
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Two studies found an association between obstetric complications and BPD although 
both were based on a combined sample of less than 50 (Kinney et al., 1993, Kinney 
et al., 1998), hence a subsequent meta-analysis of eight studies with over 500 
individuals was not significant (Scott et al., 2006). Very little has been reported for 
prenatal exposure to infection for those who go on to develop BPD, with mostly 
negative findings from modest sample sizes that would not have been able to detect 
small effects (Machon et al., 1997, Stober et al., 1997, Mortensen et al., 2011). Rates 
of BPD were found to be higher in those exposed prenatally to the Dutch Hunger 
Winter (Brown et al., 2000b) although this was based on hospitalisation records and 
therefore could reflect a more severely affected subgroup, which may be more 
similar to SCZ.  
 
There is also a paucity of studies looking at the occurrence of minor physical 
anomalies in BPD groups with early studies not finding any association (Green et al., 
1994, Trixler et al., 2001). The most recent reported a significantly higher incidence 
of anomalies affecting the mouth, feet and head, which although the largest to date, 
was based on less than 200 subjects (Akabaliev et al., 2011). In sum, the evidence 
reported so far is inconclusive as to whether BPD can be considered a 
neurodevelopmental disorder, primarily due to a lack of studies with adequate 
sample sizes. Therefore a comparison with SCZ pre- or perinatal risk factors at this 
stage would be inappropriate.  
 
1.3 Genetics of schizophrenia and bipolar disorder 
1.3.1 Heritability and family studies 
Heritability is currently estimated from twin studies at about 80-85% for SCZ (Cardno 
and Gottesman, 2000, Sullivan et al., 2003) and marginally higher at 85-93% for BPD 
(McGuffin et al., 2003, Kieseppa et al., 2004). A large scale study taking advantage of 
the Swedish registry system showed that families where the proband had SCZ had an 
increased risk for both SCZ and BPD, with a similar finding in families where the 
proband had BPD (Lichtenstein et al., 2009). Full siblings had a relative risk of 9.0 for 
SCZ and 3.7 for BPD if their sibling had SCZ, whereas if their sibling had BPD the 
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relative risk was 7.9 for BPD and 3.9 for SCZ. While this supports a shared genetic 
component and discredits the idea that these disorders breed true, they also showed 
that there are unique genetic factors for each disorder.  
 
1.3.2 Association studies 
Earliest genetic studies: linkage and candidate gene studies 
The search for associated genes and variants for SCZ and BPD has followed a similar 
course. Linkage studies were one of the first analysis tools used to identify 
chromosomal regions associated with disease (Teare and Barrett, 2005). Using a 
family pedigree, linkage analysis looks for regions with the same genetic variation 
present in affected family members and not present in unaffected family members. 
The test is based on the probability of loci within these regions segregating together 
to identify regions where this is highly unlikely to have happened by chance.  
 
A limitation of this approach is that it only indicates broad regions of chromosomes 
and not specific genes, with one review summarising that the combined results of 
two meta-analyses for SCZ implicates around 4000 genes (Tandon et al., 2008).  
Another limitation, perhaps the most important for psychiatric disorders, is that it is 
not appropriate to identify variants with small effect sizes (Risch and Merikangas, 
1996). While regions have been identified through this method for both SCZ and BPD 
(Badner and Gershon, 2002, Ng et al., 2009), the replication of these has been 
limited and no specific genes have been identified. 
 
Candidate gene studies were the next step, which looked at variants within genes 
hypothesised as relevant for either SCZ or BPD. These looked at single nucleotide 
polymorphisms (SNPs), which are single deoxyribonucleic acid (DNA) base changes 
that vary between individuals. If these differences occur in coding sequences they 
can alter the resulting amino acid sequence, which may have functional 
consequences. Alternatively, if they are found in non-coding regions they may affect 
regulatory processes such as transcription factor binding and ultimately gene 
expression. Such variants are associated to disease generally through statistical tests 
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that compare the allele frequencies between affected and unaffected individuals 
looking for significant differences. 
 
Most of the candidate genes considered were based on drug mechanisms that were 
successful at reducing symptoms such as dopamine receptor genes, which are the 
targets of antipsychotics. Genes involved in other neurotransmitter systems or brain 
development, based on the neurodevelopmental hypothesis, were also considered 
(Linden, 2011). Serotoninergic genes were amongst the most studied for BPD 
(Seifuddin et al., 2012), in addition to genes involved in the dopaminergic, 
glutamatergic and gamma-aminobutyric acid (GABA) pathways.  However, regardless 
of the biological plausibility of these genes none of these studies were fruitful in 
terms of associating with high levels of confidence specific mutations with SCZ (Allen 
et al., 2008) or BPD (Seifuddin et al., 2012). The limitations of these studies included 
sample size, which meant there was only power to detect variants with large effect 
sizes, and a lack of statistical rigour (Chanock et al., 2007). As a result a large body of 
conflicting studies were reported with limited information about either SCZ or BPD. 
 
Genome-wide association studies: single locus analyses 
As for many areas of medicine, the sequencing of the human genome (Lander et al., 
2001, Venter et al., 2001) was heralded as the start of a new and more productive 
era in psychiatric genetics (Corvin and Gill, 2003). Candidate gene studies had 
introduced a bias to the literature as only genes with a prior hypothesis, based on 
varying types and strength of evidence, were investigated. Genome-wide association 
studies (GWAS) allow the investigation of in excess of a million SNPs at sites across 
the genome in a single study (Beaudet and Belmont, 2008). The main benefit of this 
is that no prior hypotheses are required and potentially novel findings in genes not 
previously considered may be unearthed.   
 
GWAS are designed to identify common (> 1%) variants that are associated with an 
increased risk to complex diseases (Bush and Moore, 2012) and are more powerful 
to detect markers of small effect compared to linkage studies (Risch and Merikangas, 
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1996). They have been made possible not only through the sequencing of the human 
genome but also through the characterisation of linkage disequilibrium (LD) between 
SNPs (International HapMap Consortium, 2005). This knowledge means that only a 
subset of SNPs, called tag SNPs, need to be directly genotyped or tested in order to 
look for association across the genome (Hirschhorn and Daly, 2005). A by-product of 
this is that it is unlikely that any associated SNP identified in a GWAS will be the 
causal marker, more that they tag the true functional variant.  
 
Like candidate gene studies, statistical tests compare the allele frequencies for each 
SNP separately between cases and controls to see if they are significantly different 
(Hirschhorn and Daly, 2005). Power to detect an association of a true disease variant 
is related to both the frequency and effect size of the SNP, being lower for rarer 
alleles and smaller effect sizes (Klein, 2007, Spencer et al., 2009). GWAS are not 
appropriate for looking at very rare SNPs as these cannot be adequately tagged.  
 
While the ability to study hundreds of thousands of variants simultaneously is very 
efficient, it introduces the caveat of multiple testing. Neighbouring loci are known 
not to be independent, so a Bonferroni correction to prevent false positives based 
on the number of SNPs tested would be too severe (Pe'er et al., 2008). Based on a 
UK Caucasian sample, across the autosomes it has been estimated that there are 
effectively 693,138 independent tests equating to a genome-wide significant 
threshold of 7.2 x 10-8 (Dudbridge and Gusnanto, 2008). This is in line with the 
HapMap Consortium’s estimate of 150 effective tests per 500kb of the genome, 
equivalent to 900,000 tests (human genome assumed to be 3000Mb) and a p value 
threshold of 5.5 x 10-8 (International HapMap Consortium, 2005). Generally a p value 
< 5 x 10-8 is accepted as a genome-wide significant result. 
 
Initial GWAS for schizophrenia and bipolar disorder 
Despite much early enthusiasm with many studies, small by today’s standards, being 
performed, it is only in the last few years that robust associations have been 
reported. The first genome-wide significant variants for SCZ were linked to ZNF804A 
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(Williams et al., 2011b), NRGN (Stefansson et al., 2009, Steinberg et al., 2011), TCF4 
(Stefansson et al., 2009, Steinberg et al., 2011), VRK2 (Steinberg et al., 2011) and the 
extensive major histocompatibility complex (MHC) region on chromosome 6 (Purcell 
et al., 2009, Shi et al., 2009, Stefansson et al., 2009). Comparable results were found 
in BPD GWAS for DGKH (Baum et al., 2008), ANK3 (Ferreira et al., 2008), CACNA1C 
(Ferreira et al., 2008) and NCAN (Cichon et al., 2011).  
 
Even in combination these genome-wide significant results only explained a small 
part of the genetic heritability of both disorders, and like many other complex 
diseases the majority was still unaccounted for (Manolio et al., 2009). A susceptibility 
model containing a few common variants of large effect  (genotypic relative risk > 
1.3) was effectively ruled out of SCZ aetiology, as it was demonstrated that there 
was sufficient power in existing studies to identify these if they existed (Shi et al., 
2009). Although alternative genetic models involving rare alleles were also proposed 
(McClellan et al., 2007), GWAS were now focused on identifying many risk alleles, 
implicating many genes, with small effect sizes (~1.1) that only make a small 
contribution to an individual’s risk.  This polygenic architecture of common variants 
was successfully demonstrated using the results of the International Schizophrenia 
Consortium (ISC) GWAS for genetic prediction. In a completely independent dataset, 
scores based on the number of risk alleles identified in the ISC GWAS, including 
those below the threshold for genome-wide significance, were found to be 
significantly higher in cases compared to controls (Purcell et al., 2009). This 
demonstrated that common variants tagged in current studies do play a part in the 
genetics of SCZ (Wray and Visscher, 2010). The majority of these variants have not 
yet reached genome-wide significance due to limited power, but could in principle 
be unearthed in larger sample sizes (Sullivan et al., 2012).  
 
Consortium GWAS 
For both disorders international collaboration through the Psychiatric Genomics 
Consortium (PGC) has brought together samples from across the world, primarily of 
European ancestry, which were analysed in the largest studies at that time. In 2011, 
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results were published from a stage 1 sample of 9394 SCZ cases and 12462 controls 
and an independent stage 2 of 8442 SCZ cases and 21397 controls. Seven loci were 
significant at a genome-wide threshold from a meta-analysis of both stages. Five of 
these were novel associations, located in or nearest to MIR137, PCGEM1, CSMD1, 
MMP16, and CNNM2 or NT5C2, in addition to further support for the MHC region on 
chromosome 6 and a region containing TCF4 and CCDC68 (Ripke et al., 2011). The 
BPD sample comprised of 7481 cases and 9250 controls in stage 1 with 4496 
independent cases and 42422 controls used for replication and identified a novel 
locus in ODZ4 in addition to further support for CACNA1C (Sklar et al., 2011).  
 
Since these publications, meta-analyses of the PGC SCZ study with additional 
samples has identified a further 14 novel loci including SDCCAG8 (Hamshere et al., 
2013), MAD1L1, TSNARE1, AKT, and FONG (Ripke et al., 2013), as well support for 
CACNA1C and the ITIH3/4 region (Hamshere et al., 2013, Ripke et al., 2013). A meta-
analysis of the BPD PGC sample with an independent sample has also obtained 
genome-wide significance for a SNP in TRPC4AP and a region on chromosome 12 
between RHEBL1 and DHH (Green et al., 2012). Genome-wide significance has also 
been reported for SNPs in TRANK1, LMAN2L and PTGFR from a meta-analysis of a 
European BPD sample and a small Asian BPD sample (Chen et al., 2013a). 
 
Estimates of SNP heritability 
Secondary analyses of GWAS data include quantifying how much heritability is 
accounted for by the common SNPs investigated with current microarray 
technology, referred to as the SNP heritability or chip heritability. The ISC found that 
their polygenic genetic prediction procedure using their dataset as the discovery 
sample from which risk alleles were identified, and predicting in the independent 
Molecular Genetics of Schizophrenia (MGS) dataset could explain approximately 3% 
of the variance for SCZ risk. By simulating samples approximately similar to the true 
ISC and MGS data for a range of genetic models they estimated that at least one 
third of the genetic variance could be explained by common variants found on 
genotype chips (Purcell et al., 2009).  
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An alternative methodology which is part of the genome-wide complex trait analysis 
(GCTA) toolkit (Yang et al., 2011), based on a linear mixed model, estimated that 23% 
of the liability variance could be attributed to SNPs using the PGC SCZ data (Lee et 
al., 2012a).  This method has also been applied to BPD PGC data where the SNP 
heritability was calculated to be 25% (Lee et al., 2013). Both of these estimates for 
SNP heritability further imply that common variants play a sizeable role in SCZ and 
BPD aetiology and increasing the sample size for GWAS will help to identify them 
(Lee et al., 2012a).  
 
Approximate Bayesian methods have been developed as an extension to Purcell et 
al.’s polygenic approach to estimate the proportion of variance attributable to 
common variants as well as estimate the number of SNPs involved and the 
distribution of their effect sizes and frequencies (Stahl et al., 2012). This approach 
produced the largest estimate of SNP heritability at 43% (assuming population risk 
estimate of 0.01) and further, predicted that SCZ would have 8300 independent 
SNPs that account for 50% of the variance in liability (Ripke et al., 2013).  
 
Evidence of genetic overlap between schizophrenia and bipolar disorder and 
estimating genetic correlation 
Molecular evidence of overlapping genetic associations for SCZ and BPD is growing, 
particularly for common variants. Prior to the publication of the PGC studies, GWAS 
datasets had been used to show that an overlap did exist and was present among 
SNPs tagged in current studies. The ISC tested their polygenic score approach based 
on SCZ associated alleles in a BPD study and found that BPD cases, like SCZ cases, 
had higher scores compared to controls. Moreover, this was not the case for type 
one or type two diabetes, coronary artery disease, rheumatoid arthritis, Crohn’s 
disease or hypertension sufferers, supporting an overlap in the common variants 
between SCZ and BPD (Purcell et al., 2009). This analysis has been repeated with all 
of the PGC datasets, including attention deficit hyperactivity disorder (ADHD), autism 
and major depressive disorder, for all pairs of the five disorders. Overlap of common 
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variants was found between all disorders, however the most successful pairing used 
SCZ associated alleles to predict BPD status or vice versa (Smoller et al., 2013).  
 
An alternative approach again using the PGC GWAS datasets looked to quantify the 
shared genetic relationships between these five disorders. This methodology (Lee et 
al., 2012b) was similar to the GCTA linear mixed model approach used to calculate 
the SNP based heritability of complex disorders and like the polygenic approach 
found the pairing of SCZ and BPD had the largest genetic correlation, estimated at 
0.68, of all the pairs of PGC disorders (Lee et al., 2013). This estimate of genetic 
correlation was consistent with that estimated from the Swedish national family 
study of 0.6 (Lichtenstein et al., 2009).  
 
Identifying overlapping common variants 
Initial attempts to identify the common genetic variants between BPD and SCZ, took 
risk factors identified in one disorder and investigated them in the second, requiring 
a lower level of significance (one tailed p < 0.05) for evidence of an association. For 
example, rs1006737 found within CACNA1C, identified in a BPD GWAS (Ferreira et 
al., 2008) also showed an association with SCZ (Green et al., 2010). Further, SNPs 
from the MHC region and NRGN identified for SCZ have been shown to be associated 
with BPD, although in the same study variants from TCF4 were not associated with 
BPD and no association was found between ANK3 SNPs and SCZ (Williams et al., 
2011a).  
 
To date, genome-wide significance in separate GWAS for both SCZ and BPD has been 
reported for SNPs in NCAN (Cichon et al., 2011, Ripke et al., 2013), and CACNA1C 
(Ferreira et al., 2008, Sklar et al., 2011, Hamshere et al., 2013, Ripke et al., 2013). 
Combined analyses, where both SCZ and BPD individuals are compared to healthy 
controls, can also be used to identify variants that contribute to the shared genetic 
component while increasing the power to detect those with smaller effect sizes. 
With this approach, genome-wide significance has been obtained for SNPs in 
ZNF804A (O'Donovan et al., 2008), ANK3 (Sklar et al., 2011), and the ITIH3-ITIH4 
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region (Sklar et al., 2011). A GWAS based on a psychosis phenotype including SCZ, 
BPD and related psychoses also found a novel genome-wide significant SNP in the 
16p11.2 region which was associated with gene expression at MAPK3 (Steinberg et 
al., 2012).  
 
The genetic overlap of common variants for SCZ and BPD has been used 
advantageously in conditional false discovery rate analyses which have increased 
power to detect SNPs associated to both disorders (Andreassen et al., 2013). Using 
the PGC data this approach, at a false discovery rate of 0.05, identified 58 SCZ loci 
including 51 novel loci and 35 BPD loci, of which, 30 were novel. Further a 
conjunction p value, taken as the maximum of the two disorder p values, was used 
to identify 14 loci with pleiotropic effects for both disorders including genes 
previously identified such as CACNA1C and ITIH4 as well as novel candidates such as 
PPM1F and IFI44.   
 
Biological pathways associated with GWAS results 
Given few markers have surpassed genome-wide significance it may be a little 
premature to look for common functions but one recurring theme of genes 
identified as top hits in SCZ or BPD GWAS are those relating to calcium channels such 
as CACNA1C or CACNB2 (Ripke et al., 2013). Both of these genes, along with others 
relating to calcium channel activity, have also been implicated in autism, ADHD and 
major depressive disorder through a combined GWAS of psychiatric disorders 
suggesting that this functional process may be disrupted in many disorders (Smoller 
et al., 2013). 
 
Gene-based tests 
For genes to be associated through a GWAS generally they require a SNP located 
within or proximal to them to be significant genome-wide. Although the number is 
steadily increasing, so far few SNPs have been found at the genome-wide 
significance level compared to the large number of genes expected to be associated 
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to either SCZ or BPD. Gene-based tests look to combine SNPs located across a gene 
to see if as a group they confer risk and are likely to be an informative tool (Neale 
and Sham, 2004).  
 
Looking for significant genes as opposed to significant SNPs is a more powerful study 
design as it reduces the multiple testing burden (Li et al., 2011) and multiple 
methods have been tested.  One of the simplest approaches is to identify the 
smallest SNP p value, generally after applying a correction for the number of SNPs 
within that gene. Other methods look at combining SNP association p values such as 
the product of P, or the closely associated truncated product of P (Zaykin et al., 
2002). The presence of LD means that the individual SNP tests are not independent 
and permutations have been used to calculate empirical significance for each gene, 
however this has been found not to be a sufficient correction for the product of P 
approaches (Moskvina et al., 2012).  
 
An alternative methodology made use of Brown’s method (Brown, 1975) for 
combining test statistics that are not independent. By incorporating the correlation 
between markers, permutations are not required to ascertain significance and hence 
this approach is very efficient to run (Moskvina et al., 2011). Thus far the 
performance of each of these methods has rarely been evaluated, and despite being 
applied to real datasets these methods have yet to be used to investigate or identify 
novel genes for SCZ or BPD aetiology.  
 
1.3.3 Copy number variation studies 
Copy number variants (CNVs) are a common class of structural variant where large 
segments of the genome are deleted or duplicated, altering the number of copies of 
any genes within the affected region. The availability of raw genome-wide SNP 
intensity data meant that algorithms could be developed to detect CNVs so that they 
could be investigated in the context of human disease (McCarroll et al., 2006, Redon 
et al., 2006).  
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Copy number variants in schizophrenia 
SCZ patients have been shown to have an increased number or burden of CNVs 
across the genome, which are generally larger and more likely to affect loci that are 
hit rarely in the general population when compared to CNVs found in controls 
(International Schizophrenia Consortium, 2008, Walsh et al., 2008, Kirov et al., 
2009a). The effect sizes of CNVs are typically larger than those found in GWAS for 
SNPs and hence specific loci at which SCZ patients have a significantly increased rate 
of CNVs have been found and are displayed in Table 1.1. There are likely additional 
rarer CNV loci that will be identified as sample sizes increase (Malhotra and Sebat, 
2012). Individuals with SCZ also suffer a higher number of de novo CNVs (Xu et al., 
2008, Malhotra et al., 2011, Kirov et al., 2012), new mutations that have arisen in the 
individuals’ DNA that are not found in their parents, which may explain some non-
familial cases of SCZ.  
 
Deletion CNV loci Schizophrenia Bipolar disorder 
1q21.1 (International Schizophrenia 
Consortium, 2008, Stefansson et 
al., 2008, Kirov et al., 2009a, 
Levinson et al., 2011) 
 
2p16.3 (NRXN) (Kirov et al., 2009b, Levinson et 
al., 2011) 
 
3q29 (Mulle et al., 2010, Levinson et 
al., 2011) 
 
15q11.2 (Stefansson et al., 2008, Kirov et 
al., 2009a) 
 
15q13.3 (International Schizophrenia 
Consortium, 2008, Stefansson et 
al., 2008, Kirov et al., 2009a, 
Levinson et al., 2011, Vacic et al., 
2011) 
 
17q12 (Moreno-De-Luca et al., 2010)  
22q11.2 (International Schizophrenia 
Consortium, 2008, Mulle et al., 
2010, Levinson et al., 2011, Vacic 
et al., 2011) 
 
Duplication CNV loci   
7q36.3 (VIPR2) (Levinson et al., 2011, Vacic et al., 
2011) 
 
16p11.2 (McCarthy et al., 2009, Levinson 
et al., 2011, Vacic et al., 2011) 
(McCarthy et al., 2009) 
16p13.1 (Ingason et al., 2011)  
 Table 1.1: CNV loci associated with schizophrenia or bipolar disorder. 
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Copy number variants in bipolar disorder 
Findings for specific loci for BPD are much less frequent. Table 1.1 shows one locus, 
which has a significantly increased rate, a locus that is also associated with SCZ. 
Further, burden analyses for BPD patients have produced inconsistent results. Some 
report evidence for an increased frequency of rare CNVs compared to controls 
(Zhang et al., 2009, Priebe et al., 2012) whereas others find no difference (Grozeva et 
al., 2010, McQuillin et al., 2011). Similar to SCZ, a higher rate of de novo CNVs have 
been reported in BPD patients (Malhotra et al., 2011). Where increased rates of 
CNVs have been reported for BPD, they were strongest in the subset of individuals 
with an earlier age of onset (Zhang et al., 2009, Malhotra et al., 2011, Priebe et al., 
2012). Therefore CNVs may play a smaller role in BPD aetiology than in SCZ and be 
specific to those with an earlier age of onset which is associated with a more severe 
subtype including more psychotic features, suicide attempts, rapid cycling and worse 
mania symptoms (Schurhoff et al., 2000, Azorin et al., 2013). 
 
Biological pathways associated with CNVs 
One of the early CNV findings was that genes hit by CNVs found in SCZ were 
overrepresented in neurodevelopmental pathways (Walsh et al., 2008), supporting 
the hypothesis that an insult during early development plays a role in SCZ aetiology.  
Although the initial study did not control for the size of the genes hit by each CNV or 
the size of the CNVs themselves, a subsequent investigation controlling for these 
factors has shown that neuronal-activity genes were enriched in this dataset 
(Raychaudhuri et al., 2010).  Pathway analyses for genes hit by de novo CNVs have 
also reported enrichment in brain development categories as well synaptic genes 
(Malhotra et al., 2011) in particular for the N-methyl-D-aspartate receptor (NMDAR) 
and activity-regulated cytoskeleton (ARC) postsynaptic complexes (Kirov et al., 
2012).  
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CNVs have been shown to play a role in other neurodevelopmental disorders 
including autism (Sebat et al., 2007), ADHD (Williams et al., 2010) and intellectual 
disability (Cooper et al., 2011). Moreover, CNV loci have been shown to confer risk of 
multiple developmental disorders, for example 16p11.2 also confers risk for autism 
(Marshall et al., 2008, Weiss et al., 2008) and mental retardation (Ballif et al., 2007, 
Ghebranious et al., 2007). This suggests that CNVs are non-specific risk factors and 
that they may underlie some of the common phenotypes of these disorders such as 
cognitive impairments (Van Den Bossche et al., 2012). 
 
1.3.4 Rare variants: exome and whole genome sequencing 
As discussed in Section 1.3.2, power to detect rare variants in GWAS is reduced 
compared to common variants, meaning that sequencing is the best approach to 
capture variants at the lower end of the frequency spectrum (Eberle et al., 2007).  
Developments in technology and the shift to next-generation sequencing techniques 
have enabled the study of rare or moderately rare variants. Whole genome 
sequencing, which provides the entire sequence of an individual’s DNA, is considered 
the gold standard but current prices make this prohibitive for the large sample sizes 
required to study rare variants (Cirulli and Goldstein, 2010). Although both the cost 
and sequencing time are falling rapidly, exome sequencing, which only looks at ~1% 
of the genome containing protein-coding regions (Teer and Mullikin, 2010), has been 
used as an interim solution.  
 
Currently, no single nucleotide variants (SNVs) have been robustly associated with an 
increased risk for SCZ (Need et al., 2012). Exome sequencing studies of trios 
(proband and both parents) have identified de novo SNVs in SCZ patients and 
reported higher nonsynonymous-to-synonymous (Xu et al., 2012) and nonsense-to-
missense ratios (Girard et al., 2011), as well as an increased likelihood of carrying a 
mutation predicted as damaging (Gulsuner et al., 2013) suggesting these variants are 
involved in the pathogenesis of SCZ.  Although ongoing, no studies of SNVs have 
been published for BPD. 
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1.3.5 Gene expression studies 
After identifying genes implicated in the aetiology of SCZ or BPD through GWAS or 
CNV studies, and likely in the future exome or whole genome sequencing, the 
functions or mechanisms of these genes need to be clarified, particularly in relation 
to disease pathology. Gene expression studies quantify the abundance of gene 
transcripts in a tissue or cell of interest. These studies are an intermediate between 
genotype and phenotype and may provide valuable information in identifying the 
mechanisms relevant to disease aetiology.  
 
Microarray studies of schizophrenia post-mortem brains 
Numerous studies have been undertaken comparing post-mortem SCZ brains to 
control brains. A variety of approaches have been used including real-time 
quantitative polymerase chain reaction (RT-qPCR) and in situ hybridisation (ISH), 
which while more accurate can only be used to look at a handful of genes. 
Microarray technology can be used to assay the whole transcriptome in a hypothesis 
free manner, to identify genes with significantly different expression levels in disease 
brains compared to control brains which may then be taken forward as candidate 
risk genes. Pathway analysis is generally also performed on these sets of candidate 
genes to infer potentially disrupted biological mechanisms for SCZ. 
 
From the studies performed so far, there has been limited replication, particularly at 
the individual gene level, primarily due to methodological differences such as 
microarray platform, age of sample, cause of death, tissue dissected and statistical 
protocols (Sequeira et al., 2012). Sample size is another issue as post-mortem brain 
samples are of limited availability (Mistry et al., 2012) with few studies including 
more than 35 SCZ or control brains. More recent studies have combined data from 
existing studies to obtain sample sizes of over 100 brains (Mistry et al., 2012, Perez-
Santiago et al., 2012), but this is still much smaller than those used for association 
studies and will be limited when trying to detect small changes.  
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Table 1.2: Functional pathways identified from genes differentially expressed between schizophrenia 
or bipolar disorder post-mortem brains and controls.  
In each row first set of studies showed statistical overrepresentation of differentially expressed genes 
in a particular pathway, second set are additional studies that describe genes differentially expressed 
in these pathways. (*Choi et al., 2008) study was based on a psychosis sample. 
 
Another caveat to these studies is the presence and variability of medication 
exposure, both in terms of type and cumulative dosage, within the SCZ samples. 
Antipsychotics have already been shown to affect both proteins and metabolites in 
Pathways implicated Studies comparing schizophrenia 
post-mortem brains to controls 
Studies comparing bipolar 
disorder post-mortem brains to 
controls 
GABA (Mirnics et al., 2000, Glatt et al., 
2005) 
(Hakak et al., 2001, Hashimoto et 
al., 2008) 
 
Glutamate (Mirnics et al., 2000, Maycox et al., 
2009) 
(Bowden et al., 2008) 
 
Immune response (Saetre et al., 2007, Shao and 
Vawter, 2008, Mistry et al., 2012, 
Roussos et al., 2012) 
(Arion et al., 2007, Barnes et al., 
2011) 
(Ryan et al., 2006, Shao and 
Vawter, 2008) 
Mitochondria and 
energy metabolism 
(Mirnics et al., 2000, Prabakaran et 
al., 2004, Glatt et al., 2005, Katsel 
et al., 2005b, Mistry et al., 2012) 
(Middleton et al., 2002, Altar et al., 
2005, Iwamoto et al., 2005, 
Khaitovich et al., 2008) 
(Konradi et al., 2004) 
(Iwamoto et al., 2005, Sun et al., 
2006) 
Myelination and 
oligodendrocytes 
(Katsel et al., 2005b) 
(Hakak et al., 2001, Tkachev et al., 
2003, Aston et al., 2004, Sugai et 
al., 2004) 
(Tkachev et al., 2003) 
Neurogenesis, 
neurodevelopment 
(Shao and Vawter, 2008, Maycox et 
al., 2009) 
(Hakak et al., 2001, Aston et al., 
2004, Bowden et al., 2008) 
(Nakatani et al., 2006, Shao and 
Vawter, 2008) 
Stress response (*Choi et al., 2008) (Iwamoto et al., 2004) 
Synapse and signalling  (Mirnics et al., 2000, Prabakaran et 
al., 2004, Katsel et al., 2005b, 
Maycox et al., 2009, Perez-Santiago 
et al., 2012, Roussos et al., 2012) 
(Hakak et al., 2001, Vawter et al., 
2001, Aston et al., 2004, Altar et 
al., 2005, Barnes et al., 2011) 
(Ryan et al., 2006, Chen et al., 
2013b) 
(Iwamoto et al., 2004) 
Transcription and 
translation 
(*Choi et al., 2008, Roussos et al., 
2012) 
(Vawter et al., 2001, Aston et al., 
2004) 
(Iwamoto et al., 2004) 
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SCZ human post-mortem brains (Guest et al., 2010, Chan et al., 2011) and alter gene 
expression in primate and rat brains (Healy and Meador-Woodruff, 1997, Schmitt et 
al., 2003, O'Connor et al., 2007). The effect of medication on gene expression studies 
could introduce both false positive or false negative results either by creating 
differences not primarily caused by SCZ pathology or by normalising disease-related 
changes so that they are not detected (Mistry et al., 2012). 
 
Despite all these limitations some broadly consistent themes have emerged when 
considering genes in functionally related groups shown in Table 1.2. Genes 
dysregulated between SCZ post-mortem brains and control brains include those 
involved in immune response pathways, mitochondria and energy metabolism, 
myelination and oligodendrocytes, neurogenesis and neurodevelopment, stress 
response, synapse and signalling, and transcription and translation. There is also 
support for disrupted neurotransmitter systems including glutamate and GABA.  
 
The initial focus of gene expression studies for SCZ was on samples from the 
prefrontal cortex, in particular the dorsolateral prefrontal cortex. This was based on 
the rationale that it continues developing through to adolescence (Gogtay et al., 
2004, Lenroot and Giedd, 2006), the time point when SCZ typically presents, and 
impairments in executive functions, which are common in SCZ patients (Bozikas et 
al., 2006) have been attributed to this region (Orellana and Slachevsky, 2013). 
Interestingly though, the number of expression differences found in this region is 
amongst the lowest (Katsel et al., 2005a, Roussos et al., 2012) and in fact the highest 
number of differences were found in the temporal regions (Katsel et al., 2005a).  
 
Microarray studies of bipolar disorder post-mortem brains 
Fewer studies have considered BPD brains including a maximum of 35 post-mortem 
brains. These have found an overlap with SCZ studies in the pathways implicated 
including myelination and oligodendrocyte, mitochondria and energy metabolism, 
synapse and signalling and immune response; see Table 1.2.  
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Gene expression studies directly comparing expression profiles between the two 
disorders are infrequent. Despite one study finding only a few genes differentially 
expressed in SCZ and BPD that overlapped (Iwamoto et al., 2004), a subsequent 
study found more overlapping than expected by chance (Shao and Vawter, 2008). 
While these were enriched for nervous system development, cell death and immune 
categories, only one set of controls was used. 
 
Next-generation sequencing: RNA-Seq 
Technological advances mean there is currently a shift to next-generation expression 
profiling in the form of RNA-Seq. Studies so far have supported the themes identified 
with microarrays such as neural development, mitochondrial function, synapse 
vesicle trafficking (Wu et al., 2012) and inflammatory response (Fillman et al., 2013) 
with genes in these pathways being dysregulated between SCZ and control brains. 
However, these were based on similar sample sizes to the initial microarray studies 
with 9 and 20 matched cases and controls respectively, therefore larger samples will 
be needed in future studies to validate these findings.  
 
Temporal expression profiles of genes associated to schizophrenia  
An alternative approach has considered the expression profiles of SCZ candidate 
genes throughout brain development of healthy individuals (Colantuoni et al., 2008, 
Choi et al., 2009, Harris et al., 2009). All of these studies were before the publication 
of the SCZ PGC GWAS when only a handful of genes were robustly associated, which 
questions any reported findings for SCZ associated genes. There is, however, some 
overlap in the functional classes enriched for genes whose expression was associated 
with age and those enriched for genes differentially expressed between SCZ and 
control brains such as neurodevelopmental processes (Choi et al., 2009, Harris et al., 
2009), synaptic activity (Mistry and Pavlidis, 2010), neurotransmitter systems (Harris 
et al., 2009, Mistry and Pavlidis, 2010) and energy metabolism (Harris et al., 2009). 
One transcriptomics study has found that the expression profiles of genes whose 
expression is associated with age can differentiate SCZ cases from controls 
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(Torkamani et al., 2010). Therefore in light of successful GWAS studies these sorts of 
analyses should be repeated.  Such studies have not been undertaken for BPD genes 
as far as I am aware. 
 
Alternative splicing 
Alternative splicing is a mechanism that produces different gene transcripts by 
including or excluding exons of a gene, affecting the proteins coded for and 
ultimately the gene’s function. These alternatively spliced variants mean that the 
approximately 22,000 genes in the human genome can code for many more 
proteins. This process is estimated to occur in approximately 95% of human genes 
with more than one exon (Pan et al., 2008). In most cases, it is tissue specific and in 
human adults occurs most often in the brain (Yeo et al., 2004).  
 
Splicing is known to be important for many processes during brain development 
including synaptogenesis, as well as affecting ion channel and neurotransmitter 
proteins in mature neurons (Li et al., 2007). Therefore, disruption to this mechanism 
could be relevant to SCZ and BPD, as both calcium channel genes and 
neurotransmitter systems are thought to be involved in the pathogenesis. The vast 
majority of studies have only considered at most a couple of candidate splicing 
genes. Genes including GRIN1 (Le Corre et al., 2000), GRM3 (Sartorius et al., 2008), 
and GABRB2 (Huntsman et al., 1998, Zhao et al., 2009) have been shown to be 
abnormally spliced between either SCZ or BPD and control post-mortem brains. 
Additional aberrantly spliced genes for SCZ include those related to brain 
development (Law et al., 2006, Gibbons et al., 2009).  
 
A genome-wide study looked at two brain regions for SCZ, the prefrontal cortex and 
caudate head, for 20 SCZ samples and 20 control samples and identified 43 and 31 
transcripts as alternatively spliced. Functional analysis found one biological pathway 
overrepresented for the 31 transcripts identified in the caudate head, ‘Agrin in 
Postsynaptic Differentiation’ (Cohen et al., 2012). However due to the paucity of 
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studies in this area, it is hard to assess the reliability of these findings and the impact 
splicing has on psychiatric disorders. 
 
1.3.6 Biological pathway analysis 
Pathway analysis or functional analysis looks to identify the common processes of a 
set of genes related to a trait from association or transcriptome studies. They are 
commonly used as the final step of a genetic study to infer some meaning or 
interpretation of molecular results for the disease of interest. Many genes, but still 
not all, have been functionally characterised and categorised into pathways that 
describe the mechanisms or biological functions they are part of. Resources such as 
the Gene Ontology (GO) database (Ashburner et al., 2000) or Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) (Kanehisa, 1997, Kanehisa and Goto, 2000) provide this 
information so that researchers can integrate it with the results of their genetic 
studies. 
 
The GO Consortium was established to formulate and organise a controlled, 
structured hierarchy of species independent annotation terms separated into 
molecular function, biological process and cellular component ontologies (Ashburner 
et al., 2000) which over time has become the largest such resource (du Plessis et al., 
2011). Terms can be represented by a directed acyclic graph, which demonstrates 
the hierarchical relationships between parent and child terms (Gene Ontology 
Consortium, 2001).  
 
Genes are associated to annotations through existing evidence from the literature or 
other databases. Each association has an evidence code that documents whether it 
was based on experimental evidence and the type of experiment (Gene Ontology 
Consortium, 2001) e.g. introducing a mutation to the gene or affecting the 
expression of the gene, or computational information such as sequence orthology or 
sequence alignment with genes that have highly confident functional information. 
Evidence codes are assigned by expert curators of the database who assess the 
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available evidence and therefore can be used as an indicator of the level of 
confidence in that association.  
 
One evidence code exists for gene annotation associations that have not been 
manually curated and only exist as a result of automated annotation (Rhee et al., 
2008). Even though these constitute the vast majority (> 95%) of annotation terms in 
the database (du Plessis et al., 2011, Khatri et al., 2012) some researchers may wish 
to exclude such associations as the quality of the evidence has not yet be assessed. 
Although these are generally classed as unreliable, comparing successive versions of 
the GO database showed that many of these terms were subsequently verified to 
have experimental evidence, further, this proportion was in line with those manually 
curated and assessed to have computation evidence which were then promoted to 
have experimental evidence (Skunca et al., 2012). 
 
Commonly, gene sets of interest are tested to see if they overlap with a biological 
pathway more than would be expected by chance when compared to a background 
list. The choice of the background or reference list is important as it should reflect 
the genes involved in the experiment, not just all genes in the genome as this will 
introduce errors into the results (Rhee et al., 2008). The limitation of this approach is 
that after selecting only the most significant genes, all members of this set are 
considered equal and assumed to be independent (Khatri et al., 2012). More 
complex methods look to incorporate the effect size associated to each gene, by 
treating each pathway as a gene set for which a summary statistic reflecting the 
combined effect size and empirical significance through permutations can then be 
calculated (Subramanian et al., 2005). 
  
1.3.7 Integrating the ‘omics 
As discussed above many different molecular techniques have been used to 
investigate the biological causes of SCZ and BPD. Despite a lot of different datasets 
being published, there is still a paucity of clear facts for SCZ or BPD. In light of this, 
attempts have been made to integrate data from many different approaches 
29 
 
including GWAS, transcriptomics (including from multiple tissues and organisms), 
linkage, CNVs and animal models. So far this has involved two approaches, the first is 
a gene discovery methodology and the second is a validation exercise (Niculescu, 
2013).  
 
The first approach uses algorithms to combine information from different sources 
generally producing scores to indicate the strength of evidence across each data 
type which can then be used to rank genes (Patel et al., 2010, Ayalew et al., 2012, 
Zhao et al., 2013). Validation of this approach is shown by genotyping SNPs within 
the genes with the strongest evidence across the sources and testing them an 
independent dataset (Patel et al., 2010, Ayalew et al., 2012, Zhao et al., 2013). An 
alternative approach produced a network of genes with a strong likelihood of 
sharing the phenotype of interest (Gilman et al., 2012). These lists of candidate 
genes can then be used to identify functional pathways and so far have found 
enrichment in processes relating to neurodevelopment (Gilman et al., 2012) and 
glutamate receptor signalling (Ayalew et al., 2012) consistent with gene expression 
studies. 
 
This multifaceted approach is also being incorporated into genetic studies as data 
are first published. One such example is a CNV study that used annotations derived 
from proteomics data as the basis of pathway analyses (Kirov et al., 2012) or recent 
sequencing studies that have incorporated expression and proteomics data to 
characterise the potential risk genes identified in order to validate and interpret 
their findings (Xu et al., 2012, Gulsuner et al., 2013).  
 
Obviously the results of these investigations are completely reliant on the quality of 
the contributing data. Generally they will work best when all genes have been 
studied equally, although attempts have been made to avoid this ‘popularity bias’ by 
implementing a maximum score for each contributing factor (Ayalew et al., 2012). 
Therefore as more high-quality data resources are published these combinatorial 
approaches may prove extremely informative in identifying common themes and 
mechanistic targets for treatment.  
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1.4 Aims and objectives of thesis 
The overall aim of this thesis was to integrate analyses of neurodevelopmental gene 
expression data with GWAS and CNV results for SCZ and BPD to identify functional 
pathways. The research question addressed within this was whether genes whose 
expression showed either spatial or temporal variability were associated with SCZ or 
BPD.   
 
1.5 Outline of subsequent chapters  
Chapter 2 investigates spatial gene expression patterns and alternative splicing 
across the mid-foetal brain to identify associations for SCZ or BPD risk genes 
identified through GWAS and CNV studies. Gene expression characteristics 
associated with either disorder were then used to identify pathways from the GO 
database.   
 
Chapter 3 looks at temporal expression profiles identified in an expression dataset 
covering the full scope of human brain development for SCZ and BPD associated 
genes. Similar to Chapter Two, functional analysis was performed for any expression 
profiles associated to SCZ or BPD.  
 
Finally, Chapter 4 develops the framework of the polygenic model described in 
Section 1.3.2 before calculating polygenic scores based on the gene sets associated 
with SCZ from the expression work. These gene set polygenic scores were then 
tested to see if they predicted SCZ status and whether they were a better predictor 
than scores calculated across all SNPs. 
  
31 
 
  
32 
 
Chapter 2: The expression of schizophrenia and bipolar 
disorder risk genes during human foetal brain 
development 
2.1  Introduction 
2.1.1 Background 
The human brain relies on a complex series of molecular mechanisms and 
environmental inputs in order to fully mature. These developmental mechanisms 
start as early as two weeks post gestation (Stiles and Jernigan, 2010) and can be 
extremely vulnerable to disruptions. Such an insult during this period is posited to be 
a factor in the aetiology of both SCZ and BPD (Murray and Lewis, 1987, Weinberger, 
1987, Nasrallah, 1991), and the evidence behind this neurodevelopmental 
hypothesis was discussed in more detail in the Introduction, Section 1.2.  One part of 
this is an increased rate of minor physical anomalies in patients reported in both 
disorders (Akabaliev et al., 2011, Xu et al., 2011), although more consistently so for 
SCZ, which are suggestive of disruptions during foetal brain development (Lobato et 
al., 2001). Insults during this time frame not only lead to the dysmorphogenesis of 
external features but may also predispose the individual to a psychiatric or mood 
disorder in later life (Guy et al., 1983). Therefore this chapter was interested in 
whether expression patterns during foetal brain development are informative to the 
aetiology of SCZ and BPD. 
 
In their study Johnson et al. investigated transcriptional patterns in developing 
human brains. They found that 76% of genes were expressed in at least one brain 
region in mid-foetal brains, of which 33% were differentially expressed and 28% 
showed evidence of alternative splicing across the five major brain structures 
considered: neocortex, cerebellum, hippocampus, striatum and thalamus. The set of 
differentially expressed genes were enriched for human-accelerated conserved 
noncoding sequences, defined as small regions of the genome with more human-
specific substitutions than expected by chance (Prabhakar et al., 2006). This 
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enrichment remained, although to a lesser degree, when excluding genes associated 
with chimpanzee-accelerated conserved noncoding sequences, suggesting that this 
set of genes may be responsible for human-specific attributes (Johnson et al., 2009).  
 
Despite SCZ being associated with reduced fecundity (Power et al., 2013) the 
disorder is still present in today’s society and population prevalence rates appear 
uniform across the globe (Jablensky et al., 1992). As an explanation of these facts, 
SCZ has been proposed to be a consequence of human evolution (Crow, 1997). In 
line with this theory the mutations associated with the ‘speciation events’ that gave 
rise to the appearance of humans would also play a role in the development of the 
disorder. Further, given that the disorder is equally prevalent around the world 
(Jablensky et al., 1992) the associated mutations must have arisen prior to the 
divergence of today’s populations. Therefore, based on this hypothesis and Johnson 
et al.’s findings that genes differentially expressed in the human foetal brain were 
enriched for human-specific noncoding sequences, this chapter looked at risk genes 
for both SCZ and BPD, based on the strongest genetic evidence to date, and 
investigated whether they displayed any characteristic pattern of expression in the 
human foetal brain. 
 
2.1.2 Outline 
Aim 
The research question considered in this chapter was whether genes associated with 
either SCZ or BPD had common expression profiles, either consistent or variable, in 
the human foetal brain.  
 
Datasets 
The primary dataset used in this chapter was that of the Johnson study (Johnson et 
al., 2009) which contained expression data sampled from four human mid-foetal 
brains (18-23 weeks gestation). For each brain, samples were taken from thirteen 
different brain regions, listed in Table 2.1 with their abbreviations, from both 
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hemispheres. These data, referred to as the Johnson dataset, were obtained with 
the Affymetrix Human Exon 1.0 ST chip, which provides expression values at both 
the gene and exon level. Further details on data processing can be found at the end 
of this chapter in the Methods section. Unless referred to otherwise all analyses 
used the gene level expression values. In Johnson et al.’s original study they 
controlled for individual and hybridisation date differences, hence these variables 
were also included in this work. 
 
 Full name Abbreviation 
Neocortex: prefrontal cortex 
Dorsolateral prefrontal cortex DLPFC 
Medial prefrontal cortex MPFC 
Orbital prefrontal cortex OPFC 
Ventrolateral prefrontal cortex VLPFC 
Neocortex: non-frontal regions 
Motor-somatosensory cortex MS 
Parietal association cortex PAS 
Temporal auditory cortex TAU 
Temporal association cortex TAS 
Occipital visual neocortex OCC 
Hippocampus HIP 
Striatum STR 
Mediodorsal thalamus THAL 
Cerebellum CBL 
Table 2.1: Brain regions included in the Johnson dataset with abbreviations. 
 
A second publically available microarray dataset from a study by Kang et al. was used 
for replication, where gene expression values were obtained for human brains 
covering the full range of development (Kang et al., 2011). Like the Johnson dataset, 
multiple regions from both hemispheres were available and the same microarray 
chip was used to derive the expression values. Twelve regions overlapped with the 
Johnson dataset and these are identified in Table 2.2. Throughout the text the 
Johnson abbreviations will be used for common regions but readers can refer to 
Table 2.2 for the nomenclature used in the Kang manuscript.  
 
Five independent individuals that fell in the same gestational period (18-23 weeks) 
as the Johnson dataset were extracted to form a replication dataset, referred to as 
the Kang dataset. The dataset downloaded for this work was already normalised, 
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Kang et al. having used the same software package as the Johnson study. In their 
study Kang et al. included covariates to adjust for sample RNA integrity (RIN) and 
post-mortem interval (PMI), therefore these were taken into account in this work 
also. In order to keep the analyses across the two datasets consistent, ideally the 
same covariates would have been used for both the Johnson and Kang dataset. This 
was not possible as the additional sample information provided with the datasets did 
not contain the relevant data. Johnson et al. included a covariate to control for 
individual differences based on the observation that after brain region, this factor 
contributed the next highest proportion of the variation in the expression data. This 
covariate could have been included in the analyses of the Kang dataset and will 
capture a variety of differences between the samples, including lifestyle differences 
which are hard to measure and factors relating to the post-mortem brain such as 
PMI. However, including it in the initial analyses may remove some the general 
variation we were interested in detecting. 
 
 Full name Abbreviation 
Johnson 
equivalent 
Neocortex: prefrontal 
cortex 
Dorsolateral prefrontal cortex DLPFC DLPFC 
Medial prefrontal cortex MPFC MPFC 
Orbital prefrontal cortex OPFC OPFC 
Ventrolateral prefrontal cortex VLPFC VLPFC 
Neocortex: non-frontal 
regions 
Primary motor cortex M1C  
Primary sensory cortex S1C  
Primary auditory cortex A1C TAU 
Primary visual cortex V1C OCC 
Posterior inferior parietal 
cortex 
IPC PAR 
Superior temporal cortex STC TAS 
Inferior temporal cortex ITC  
Hippocampus HIP HIP 
Amygdala AMY  
Striatum STR STR 
Mediodorsal thalamus THAL THAL 
Cerebellum CBL CBL 
Table 2.2: Brain regions included in the Kang dataset with abbreviations and Johnson equivalents. 
 
Analyses reported in this thesis were based on two different types of genetic 
variants. SNP association results were taken from the PGC studies, the largest GWAS 
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available for both SCZ (Ripke et al., 2011) and BPD (Sklar et al., 2011). The SNP p 
values for each PGC study were combined into two summary statistics for each gene. 
Firstly, gene-wide p values based on Brown’s formula (Brown, 1975) which allows for 
correlations between SNPs were calculated and provided by V. Escott-Price 
(Moskvina et al., 2011). Secondly, the p values of all SNPs within a gene were 
corrected for multiple testing using Simes’ procedure (Simes, 1986) and the most 
significant one taken. Simes’ method was developed to be less conservative than the 
Bonferroni method and was promoted for situations comprising of many highly 
correlated test statistics.  
 
 
Figure 2.1: QQ plot to demonstrate distribution of gene-wide logP. 
Panels A and B are QQ plots plotted with SCZ gene-wide logP; panels C and D are BPD gene-wide logP. 
Panels A and C are Brown’ logP; panels B and D are Simes' logP. 
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Brown’s p values are designed to take into account multiple independent SNP signals 
within a gene, whereas Simes’ p values would be better if a gene has a single highly 
significant SNP result. While consistent enrichment across both types of p value was 
desirable, as they should both be capturing true association signal, stronger 
enrichments with Brown’s p values might suggest that many of the genes harbour 
multiple semi-independent associated variants consistent with a polygenic model. 
Neither type of p value was biased by gene size, important for this study as brain 
genes are generally large (Raychaudhuri et al., 2010). Including p values based on 
these two methods allows an assessment of the performance of each as well as an 
opportunity to establish the robustness of the results reported. All gene-wide p 
values were –log10 transformed and will be referred to as Brown’s logP or Simes’ 
logP. Figure 2.1 presents QQ plots for all four sets of gene-wide p values. These 
figures show that all four sets are inflated and pull away from the null line quite early 
on. It can also be seen that there is greater inflation in the SCZ logP compared to the 
BPD logP, compare panels A and C with B and D respectively, likely reflecting the 
larger sample size and greater power to detect small effects. In addition, the Brown’s 
logP (panels A and B) show less inflation than the Simes’ logP (panels C and D).   
 
The genetic overlap of SCZ and BPD, particularly for common variants, is well 
documented and was discussed in the Introduction Section 1.3.2. The inclusion of 
BPD gene-wide p values in addition to SCZ gene-wide p values provides a level of 
genetic replication; however the PGC samples contained overlapping controls and 
hence were not entirely independent.  
 
CNV data, solely for SCZ, from both the ISC (International Schizophrenia Consortium, 
2008) and MGS (Levinson et al., 2011) collaborations were also included. CNVs found 
in SCZ individuals were compared to see if they overlapped with any control CNV, 
those that did not were classed as singletons. Table 2.3 displays the counts of CNVs 
found in cases and controls as well as the number of deletions, duplications and 
singleton CNVs for both datasets. The ISC study was performed on two different 
chips, Affymetrix 5.0 and Affymetrix 6.0, whereas the MGS was done solely on 
Affymetrix 6.0, therefore chip differences were controlled for in addition to study 
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differences in all analyses. The numbers presented in Table 2.3 do not match those 
in the corresponding manuscripts, as the raw data were available in-house the size 
filter was relaxed by E. Rees to include all CNVs larger than 15kb. These CNVs were 
then annotated with the genes hit by A. Pocklington. 
 
 
All CNVs CNVs that hit at least 1 gene 
Cases Controls Cases Controls 
ISC 7288 7397 3499 3351 
ISC: deletion 3693 3843 1372 1270 
ISC: duplications 3595 3554 2127 2081 
ISC: singletons 1081 n/a 601 n/a 
ISC: singletons & 
deletions 
524 n/a 234 n/a 
ISC: singletons & 
duplications 
557 n/a 367 n/a 
MGS 4847 5366 2353 2549 
MGS: deletion 2738 2964 1086 1111 
MGS: 
duplications 
2109 2402 1267 1438 
MGS: singletons 969 n/a 513 n/a 
MGS: singletons 
& deletions 
516 n/a 235 n/a 
MGS: singletons 
& duplications 
453 n/a 278 n/a 
Table 2.3: Counts of CNVs from ISC and MGS studies. 
 
Outline of analysis 
Various different expression profiles were identified in the Johnson and Kang 
datasets. Sets of genes with generally consistent or variable expression profiles 
across the mid-foetal brain were identified based on summary statistics for each 
gene and tested for an enrichment of SCZ and BPD associated variants. More specific 
variable profiles of genes characteristic of each brain region were also identified and 
tested in a similar manner. Each set of genes was tested for an enrichment of gene-
wide p values based on common variants in the largest GWAS studies. In addition, 
genes with these expression profiles were tested to see if they were hit more 
frequently by CNVs found in SCZ individuals compared to those found in healthy 
controls, and within SCZ CNVs comparing genes hit by singleton CNVs to all 
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remaining case CNVs. This methodology was repeated in a second expression 
dataset for replication and permutations were performed to ascertain if significant 
findings across the datasets were unlikely to have occurred by chance. 
 
P values reflecting evidence of alternative splicing were derived for each gene to 
reflect both global and region specific splicing. Alternatively spliced genes were then 
tested for enrichment with SCZ and BPD common risk variants and SCZ CNVs.  Finally, 
sets of genes that were enriched for SCZ or BPD associated variants were used to 
identify GO pathways relevant for disease aetiology.  
 
2.2  Results 
2.2.1 Global pattern of gene expression and common risk variants 
In order to characterise global expression patterns across the mid-foetal brain, three 
summary scores were calculated for each gene: the mean, scaled mean and 
coefficient of variation. In their work, Johnson et al. showed that many genes were 
co-expressed across the nine neocortical regions they included. To prevent the 
neocortex from being over-represented in the summary statistics the median value 
across all neocortical samples, for all individual and hemisphere pairings, was taken 
for each gene. The mean was then computed across the neocortical medians and all 
non-neocortical samples for each gene, to identify those highly expressed. Alongside 
this a scaled version of the mean was calculated, where it was divided by the 
maximum expression value for that gene. This restricts all values for this metric to 
fall between 0 and 1, with larger values representing more consistent expression 
relative to the maximum value for a given gene. Ultimately this will identify highly 
consistent but not necessarily highly expressed genes.  In addition the coefficient of 
variation was also calculated. This measure was included to identify more variable 
expression profiles and hence, is inversely correlated to the scaled mean. It would be 
expected, therefore, that their results would be correlated also. The scaled mean is 
looking for consistency with its maximum expression value whereas the coefficient 
of variation is just looking for general consistency or variation. For genes where the 
expression values are either highly consistent or highly variable, the ranks from these 
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metrics should be negatively correlated. However, this may not be the case for genes 
in between these two extremes and agreement between these two metrics would 
present a more robust finding.  These three measures will be referred to as global 
metrics. 
 
A regression approach was used to test for correlations between the gene 
expression global metrics and SCZ or BPD gene-wide p values. The linear model took 
each global metric in turn as the independent variable and either Brown’s or Simes’ 
logP as the dependent variable for SCZ and BPD separately. These results are 
displayed in Table 2.4. 
 
Strongly significant positive relationships were found between mean expression and 
SCZ Brown’s logP (p = 1.07 x 10-10) and BPD Brown’s logP (p = 4.89 x 10-6) indicating 
that genes with high means and therefore highly expressed have smaller association 
p values. An even more significant positive relationship was observed between the 
scaled mean and both SCZ (p = 4.58 x 10-14) and BPD (p = 3.06 x 10-8). Conversely, 
highly significant negative relationships were found when testing the coefficient of 
variation (SCZ p = 3.03 x 10-13; BPD p = 1.99 x 10-7), implying genes not variably 
expressed were associated to these disorders. By definition if a gene is not variably 
expressed it must be consistently expressed. Therefore, all three global metrics have 
identified an enrichment of SCZ and BPD common variants in genes with high 
consistent expression across the foetal brain.  The same pattern of results was seen 
with the Simes’ logP, again with strong levels of significance, although less significant 
than with Brown’s logP.  
 
Despite the high significance of the regression models between the global metrics 
calculated in the mid-foetal brain and gene-wide p values for SCZ and BPD, the 
correlation coefficients were small with absolute values between 0.03 and 0.07. 
Table 2.4 shows that these were marginally higher for SCZ compared to BPD, and 
generally also slightly higher for Brown’s logP compared to Simes’ logP. 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Mean 
P value 1.07 x 10-10 6.25 x 10-8 4.89 x 10-6 2.29 x 10-6 
Correlation 
Coeff. 
0.0562 0.0502 0.0390 0.0438 
+ + + + 
Scaled 
mean 
P value 4.58 x 10-14 1.47 x 10-7 3.06 x 10-8 2.10 x 10-5 
Correlation 
Coeff. 
0.0657 0.0488 0.0473 0.0395 
+ + + + 
Coeff. of 
variation 
P value 3.03 x 10-13 2.98 x 10-6 1.99 x 10-7 6.24 x 10-5 
Correlation 
Coeff. 
-0.0635 -0.0433 -0.0444 -0.0371 
- - - - 
Excluding genes in MHC region 
Mean 
P value 2.69 x 10-15 7.47 x 10-13 3.46 x 10-6 3.66 x 10-6 
Correlation 
Coeff. 
0.0692 0.0670 0.0399 0.0433 
+ + + + 
Scaled 
mean 
P value 4.31 x 10-16 1.05 x 10-9 1.73 x 10-8 1.04 x 10-5 
Correlation 
Coeff. 
0.0711 0.0570 0.0484 0.0412 
+ + + + 
Coeff. of 
variation 
P value 5.27 x 10-15 1.23 x 10-7 5.27 x 10-7 3.49 x 10-5 
Correlation 
Coeff. 
-0.0684 -0.0494 -0.0456 -0.0387 
- - - - 
Table 2.4: Linear regression results and correlation coefficients testing global metrics calculated in the 
Johnson dataset with gene-wide logP. 
Figure 2.2 presents scatterplots of the six relationships between the global metrics 
and Brown’s logP. These associations do not look as convincingly linear as the 
regression p values may suggest, showing a large degree of noise. This is consistent 
with the small correlation coefficients reported in Table 2.4, indicating that although 
these results were highly significant, there are SCZ or BPD risk genes for which this 
relationship is not apparent. Corresponding scatterplots for Simes’ logP can be seen 
in Appendix Figure 7.1 and show similar relationships.  
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Figure 2.2: Scatterplots of relationships between global metrics calculated in the Johnson dataset and 
Brown’s gene-wide p values. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Brown’s 
logP against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and 
D plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
These analyses were repeated removing genes found in the MHC region which is 
strongly associated to SCZ. Due to the strong LD within this region many genes are 
likely to have highly significant gene-wide p values and may cause spurious results if 
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these genes are also highly co-expressed. Even without the MHC genes the same 
pattern of significance remained, shown in Table 2.4. While the BPD results were not 
greatly altered, the linear relationships with SCZ logP were a couple of orders of 
magnitude more significant and the correlation coefficients slightly stronger. The 
association between SNPs in this region is predominantly with SCZ rather than BPD 
(Bergen et al., 2012) and therefore a greater effect on the SCZ regression models 
would be expected. Interestingly though these results suggest that the MHC region 
was not causing false positive results, in fact it was having an effect in the opposite 
direction and suppressing the signal.  
 
Linear regression assumes that the errors have a normal distribution; despite linear 
regression being fairly robust, the possibility remains that the results from a 
parametric approach with this assumption may be biased. This problem is irrelevant 
in a nonparametric test such as the Mann-Whitney test, as no extra weight is given 
to highly significant p values, just a higher ranking. Therefore a rank-based approach 
was used to validate the results found with the parametric methods. Genes were 
ranked separately by each of the three global metrics before the top n% (5, 10…50%) 
was selected and tested for more significant p values against the bottom 50%.  
 
In Figure 2.3 panel A, a clear enrichment of more significant SCZ Brown’s p values 
can be seen in the sets of highest ranked genes by either the mean or scaled mean, 
i.e. those highly and consistently expressed. The most significant enrichments 
occurred when testing the top 20-50%. For example the strongest enrichment was 
found in the top 45% of genes ranked by mean expression (p = 5.27 x 10-13) and in 
the top 25% of genes ranked by their scaled mean expression (p = 1.70 x 10-15) 
showing that the regression results were not due to outliers. Panel C of Figure 2.3 
shows that enrichments for BPD signals were also present in gene sets other than 
just the top 5 or 10% when ranked by either the mean or scaled mean; therefore 
these regression results were not due to extreme values either. No significant results 
were found for genes with high coefficients of variation, validating the regression 
findings that genes consistently expressed across the foetal brain regions were 
enriched for SCZ and BPD risk variants.  
44 
 
 
Figure 2.3: Results from Mann-Whitney tests for genes ranked by global metrics calculated in the 
Johnson and Kang datasets.  
Panels A & B are results testing top n% of genes ranked by each global metric in turn against the 
bottom 50% for smaller SCZ p values; panels C & D are results testing for smaller BPD p values. Panels 
A & C global metrics were calculated in the Johnson dataset; panels B & D were calculated in Kang 
dataset. Black dashed line is p = 0.05. 
 
The same pattern of results was seen with Simes’ p values, also shown in Figure 2.3, 
although less significantly compared to results with Brown’s p values.  Results were 
generally more significant when testing SCZ p values compared to BPD p values. 
Removing genes in the MHC region had minimal effects on the results of the Mann-
Whitney tests; hence these results are not presented here but can be found in 
Appendix Figure 7.5. 
 
In the analyses presented so far, expression values for all neocortical regions have 
been combined into a single measure. To see if the findings reported above held 
45 
 
within the neocortex, the global metrics were calculated across the nine neocortical 
brain regions. Highly significant positive relationships were again found between the 
gene-wide logP and the mean or scaled mean expression, and highly significant 
negative relationships were found with the coefficient of variation.  The correlation 
coefficients associated with these relationships were of a similar strength to those 
presented in Table 2.4 for global metrics calculated across the mid-foetal brain. This 
pattern of results, shown in Table 2.5, was found with both Brown’s and Simes’ p 
values. As with the global metrics calculated across the five major brain structures, 
Figure 2.4 and Appendix Figure 7.2 show that there was a fair amount of noise 
present in the significant relationships presented in Table 2.5. 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Mean 
P value 2.07 x 10-11 8.36 x 10-12 1.38 x 10-6 1.14 x 10-6 
Correlation 
Coeff. 
0.0583 0.0617 0.0412 0.0424 
+ + + + 
Scaled 
mean 
P value 6.92 x 10-16 5.01 x 10-11 9.62 x 10-7 2.54 x 10-5 
Correlation 
Coeff. 
0.0702 0.0594 0.0419 0.0399 
+ + + + 
Coeff. of 
variation 
P value 1.25 x 10-14 2.22 x 10-11 1.17 x 10-6 6.53 x 10-5 
Correlation 
Coeff. 
-0.0671 -0.0605 -0.0415 -0.0380 
- - - - 
Excluding genes in MHC region 
Mean 
P value 5.86 x 10-16 7.95 x 10-19 9.49 x 10-7 2.80 x 10-6 
Correlation 
Coeff. 
0.0708 0.0806 0.0421 0.0427 
+ + + + 
Scaled 
mean 
P value 1.29 x 10-20 5.92 x 10-17 3.93 x 10-7 7.50 x 10-6 
Correlation 
Coeff. 
0.0813 0.0761 0.0436 0.0408 
+ + + + 
Coeff. of 
variation 
P value 6.68 x 10-18 5.20 x 10-16 5.75 x 10-7 1.85 x 10-5 
Correlation 
Coeff. 
-0.0754 -0.0738 -0.0430 -0.0390 
- - - - 
Table 2.5: Linear regression results and correlation coefficients testing global metrics calculated 
within neocortical regions in the Johnson dataset with gene-wide logP. 
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Figure 2.4: Scatterplots of relationships between testing global metrics calculated within neocortical 
regions in the Johnson dataset and Brown’s gene-wide logP.  
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Brown’s 
logP against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and 
D plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
 
Nonparametric tests, presented in Figure 2.5, showed these results were not due to 
extreme values as enrichments were found in the top 20-50% with both sets of p 
values, supportive of the general pattern of results. All analyses remained significant 
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after excluding the MHC genes, shown in Table 2.5 and Appendix Figure 7.5. 
Therefore the results presented so far show that genes consistently expressed across 
the neocortex and wider brain structures are enriched for SCZ and BPD common risk 
variants.  
 
Figure 2.5: Results from Mann-Whitney tests for genes ranked by global metrics within neocortical 
regions calculated in the Johnson and Kang datasets. 
Panels A & B are results testing top n% against the bottom 50% for smaller SCZ p values; panels C & D 
are results testing for smaller BPD p values. Panels A & C global metrics were calculated in the 
Johnson dataset; panels B & D were calculated in Kang dataset. Black dashed line is p = 0.05. 
 
Validation in an independent expression dataset 
All analyses were repeated in the Kang dataset to look for replications. Table 2.6 
presents the results of the linear regression analyses for the global metrics 
calculated using the median neocortex values. Significant positive relationships were 
found when testing the mean (SCZ p = 9.87 x 10-8; BPD p = 3.13 x 10-5) and the scaled 
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mean (SCZ p = 1.57 x 10-6; BPD p = 1.59 x 10-5). As in the Johnson dataset a significant 
negative relationship was found with the coefficient of variation, although this was 
only nominally significant with Brown’s BPD logP (SCZ p = 0.000149; BPD p = 0.0108).  
Results with Simes’ logP were consistent with those for Brown’s logP, although the 
negative relationship between the coefficient of variation and BPD Simes’ logP was 
not significant. The correlation coefficients reported in Table 2.6 were of a similar 
magnitude to those reported in Table 2.4 for the Johnson dataset. Figure 2.6 and 
Appendix Figure 7.3 both show that these linear relationships were subject to a lot of 
noise and do not hold for all SCZ and BPD risk genes. 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Mean 
P value 9.87 x 10-8 1.47 x 10-8 3.13 x 10-5 4.97 x 10-6 
Correlation 
Coeff. 
0.0462 0.0510 0.0354 0.042 
+ + + + 
Scaled mean 
P value 1.57 x 10-6 2.84 x 10-5 1.59 x 10-5 0.000949 
Correlation 
Coeff. 
0.0416 0.0377 0.0367 0.0297 
+ + + + 
Coeff. of 
variation 
P value 0.000149 0.00822 0.0108 0.102 
Correlation 
Coeff. 
-0.0329 -0.0238 -0.0217 -0.0147 
- - - - 
Excluding genes in MHC region 
Mean 
P value 1.22 x 10-11 8.18 x 10-15 1.87 x 10-5 3.83 x 10-6 
Correlation 
Coeff. 
0.0591 0.0703 0.0366 0.0419 
+ + + + 
Scaled mean 
P value 9.12 x 10-8 2.53 x 10-7 9.15 x 10-6 4.49 x 10-4 
Correlation 
Coeff. 
0.0466 0.0467 0.0379 0.0318 
+ + + + 
Coeff. of 
variation 
P value 0.000145 0.00705 0.00885 0.090 
Correlation 
Coeff. 
-0.0331 -0.0244 -0.0224 -0.0154 
- - - - 
Table 2.6: Linear regression results and correlation coefficients testing global metrics calculated in the 
Kang dataset with gene-wide logP. 
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Figure 2.6: Scatterplots of relationships between global metrics calculated in the Kang dataset and 
Brown’s gene-wide logP. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Brown’s 
logP against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and 
D plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
 
Removing genes from the MHC region caused the SCZ regression models to become 
more significant and had a minimal effect on the BPD regression models, see Table 
2.6. As in the Johnson dataset this showed that these associations were not driven 
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by the highly correlated p values of these genes. Mann-Whitney tests verified the 
regression associations with Brown’s logP and SCZ Simes’ logP, shown in Figure 2.3 
panels B and D. An enrichment of BPD Simes’ p values was found in gene sets ranked 
by their scaled mean, but only a trend for enrichment was found for genes ranked in 
the top 10% by their mean expression value. Removing the MHC genes from the 
Mann-Whitney results had minimal impact, shown in Appendix Figure 7.5. 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Mean 
P value 9.90 x 10-9 6.58 x 10-10 1.98 x 10-6 1.01 x 10-6 
Correlation 
Coeff. 
0.0497 0.0556 0.0404 0.0440 
+ + + + 
Scaled mean 
P value 8.80 x 10-6 3.66 x 10-5 1.33 x 10-6 6.76 x 10-6 
Correlation 
Coeff. 
0.0385 0.0372 0.411 0.0405 
+ + + + 
Coeff. of 
variation 
P value 6.69 x 10-6 0.00151 4.79 x 10-6 0.000187 
Correlation 
Coeff. 
-0.0390 -0.0286 -0.0389 -0.0336 
- - - - 
Excluding genes in MHC region 
Mean 
P value 9.68 x 10-13 8.63 x 10-17 8.77 x 10-7 4.73 x 10-7 
Correlation 
Coeff. 
0.0622 0.0754 0.0420 0.0456 
+ + + + 
Scaled mean 
P value 1.49 x 10-7 2.42 x 10-8 4.84 x 10-7 2.08 x 10-6 
Correlation 
Coeff. 
0.0458 0.0506 0.0430 0.0430 
+ + + + 
Coeff. of 
variation 
P value 5.13 x 10-8 3.72 x 10-6 1.42 x 10-6 5.17 x 10-5 
Correlation 
Coeff. 
-0.0475 -0.0419 -0.0412 -0.0367 
- - - - 
Table 2.7: Linear regression results and correlation coefficients testing global metrics calculated 
within neocortical regions in the Kang dataset with gene-wide logP. 
Analyses were repeated in the Kang dataset within the neocortical samples and are 
presented in Table 2.7. Significant linear models were found for both disorders, with 
both sets of gene-wide p values for all three global metrics, consistent with the 
results in the Johnson dataset shown in Table 2.5. The results of the rank-based tests 
with Brown’s p values, see Figure 2.5, verified these regression results. Generally 
results testing Simes’ p values showed that the regression associations were not due 
to extreme values although only nominal enrichments were found for BPD in the top 
10, 30 and 50% of genes ranked by their mean expression. Again, scatterplots of 
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these associations, Figure 2.7 and Appendix Figure 7.4, showed that these signals 
were particularly noisy. Rerunning these analyses without the MHC genes did not 
change the pattern of results; see Table 2.7 and Appendix Figure 7.6. 
 
Figure 2.7 Scatterplots of relationships testing global metrics calculated within neocortical regions in 
the Kang dataset and Brown’s gene-wide logP. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Brown’s 
logP against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and 
D plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
 
52 
 
Summary 
The analyses presented from two independent expression datasets showed that 
genes consistently and highly expressed across the human mid-foetal brain were 
enriched for both SCZ and BPD risk variants. This was found to be the case for gene 
expression across non-neocortex structures as well as across neocortical regions. 
Although no formal correction for multiple testing has been applied to these p values 
they were generally sufficiently small to remain significant even after a conservative 
Bonferroni correction. Adjusting the significance threshold of p < 0.05 for the 12 
tests in the top half of Tables 2.4-7 would require a p value of less than 0.00417 to 
report the tests as significant. Despite these associations being highly significant, 
they were found to be particularly noisy, meaning that this relationship does not 
hold for all SCZ and BPD associated genes. 
 
The initial associations found with a parametric regression model were validated 
with rank-based tests showing that these results were not due to extreme values, 
neither were the associations due to genes in the MHC region. Testing both Brown’s 
and Simes’ gene-wide p values obtained broadly the same results pattern, however 
more significantly and consistently across SCZ and BPD with Brown’s p values.  
 
2.2.2 Regional characteristic gene expression and common risk variants 
So far the variation in expression levels across the mid-foetal brain captured through 
the global metrics has been fairly general. This section investigates genes that exhibit 
specific patterns of variation, looking for those upregulated or downregulated in an 
individual brain region. Such genes were referred to as characteristic genes for that 
region. 
 
Initially a characteristic score was defined based on fold changes between brain 
region expression values (taking the mean expression across individuals and 
hemispheres) to calculate a relative enrichment score for each gene in each region 
(Doyle et al., 2008). Regional characteristic scores were then regressed against the 
gene-wide logP to identify any region(s) where relative expression levels were 
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correlated with disease risk. On closer inspection of the results it was found that 
correlations were typically driven by extreme scores in one or occasionally two 
individuals.  
 
To properly control for inter-individual variation, along with other sample 
differences, a linear model was constructed in which these appeared as covariates 
alongside a binary brain region term that was used to compare the expression values 
of one region to all others. By fitting this model separately for each brain region, 
characteristic scores for each gene were derived from the p value and coefficient 
estimates of this binary term. The magnitude or absolute value of this score 
indicated how strongly characteristic the gene was of that region and the sign of the 
score specified whether there was an increase or decrease in expression relative to 
the average expression across all other brain regions. This formed a scale where 
large positive values of the characteristic score indicated genes with a highly 
characteristic increase of expression in that brain region relative to all other brain 
regions, and large negative values indicated genes with a highly characteristic 
decrease of expression (further detail in the Methods). 
 
Significant number of associated regions across both microarray datasets 
The characteristic scores for each region were tested for a linear relationship with 
the dependent variable Brown’s logP. Significant results with positive coefficients 
signified that upregulated genes in that brain region were associated with more 
significant gene-wide p values, whereas significant results with a negative coefficient 
indicated that downregulated genes in that brain region were associated with more 
significant gene-wide p values. Before considering the results for each brain region, 
the true results were compared to permutations to see whether the number of 
significant models, limited to the 12 brain regions present in both datasets, was 
greater than that expected by chance.  
 
Briefly, in each dataset the sample labels (containing individual, hemisphere and 
region information) were permuted before the characteristic scores were 
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recalculated and tested with SCZ and BPD Brown’s logP. Based on 1000 
permutations, empirical p values were calculated for the number of significant SCZ 
or BPD regression models (p < 0.01) for both expression datasets, shown in Table 
2.8. Empirical p values were also calculated for the number of regions significant 
across both datasets, and in the same direction, for all pairs of permutations, 106 in 
total, presented in Table 2.9.  
 
Johnson 
Number of 
brain regions 
Empirical p 
value 
Brain regions 
Schizophrenia p < 0.01 5 0.553 
CBL, DLPFC, HIP, MPFC, 
THAL 
Bipolar disorder p < 0.01 3 0.521 HIP, MPFC, THAL 
Kang    
Schizophrenia p < 0.01 6 0.533 
CBL, HIP, TAS, THAL, PAS, 
OCC 
Bipolar disorder p < 0.01 5 0.458 
HIP, THAL, MPFC, PAS, 
OCC 
Table 2.8: Empirical p values for the number of significant regression models between regional 
characteristic scores and SCZ or BPD Brown’s logP. 
Based on 12 regions overlapping both datasets and 1000 permutations. 
Across both Johnson and Kang 
Number of 
brain regions 
Empirical p 
value 
Brain regions 
Schizophrenia p < 0.01 3 0.376 CBL, HIP,THAL 
Schizophrenia p < 0.01, in same 
direction 
3 0.096 CBL, HIP,THAL 
Bipolar disorder p < 0.01 3 0.075 MPFC, HIP, THAL 
Bipolar disorder p < 0.01, in same 
direction 
3 0.013 MPFC, HIP, THAL 
Schizophrenia & bipolar disorder p 
< 0.01 
2 0.083 HIP, THAL 
Schizophrenia & bipolar disorder p 
< 0.01, in same direction 
2 0.025 HIP, THAL 
Table 2.9: Empirical p values for the number of significant regression models between regional 
characteristic scores and SCZ or BPD Brown’s logP across both datasets. 
Based on 12 regions overlapping both datasets and 106 permutations. 
The first observation from these results was that events expected to be quite rare, 
for example Table 2.8 shows 5 of 12 regions having a SCZ regression model p value 
less than 0.01, had quite a high empirical p value (p = 0.553).  Expression across 
neocortical regions has previously been shown to be co-expressed (Johnson et al., 
2009), which could reduce the independence of the observations, particularly if the 
associations indicate differential expression between neocortical regions and non-
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neocortical regions.   The second observation was that each dataset taken 
individually did not show more significant associations between brain region 
characteristic genes and disease p values than expected by chance (all empirical p > 
0.05).  
 
When looking for consistent results across datasets, two results were greater than 
expected by chance. BPD Brown’s logP were associated with three regional 
characteristic scores with the same sign of the coefficient: HIP, THAL and MPFC (p = 
0.013). The second significant result was across both disorders where two regions, 
HIP and THAL, were significant in the same direction across both datasets (p = 
0.025). 
 
Table 2.10 shows the results of the regression analyses for the HIP, THAL and MPFC 
in the Johnson dataset adjusted for testing 13 brain regions by Bonferroni’s 
procedure. This shows that genes with decreased expression or downregulated in 
the HIP were enriched for SCZ (corrected p = 1.76 x 10-6) and BPD (corrected p = 
0.0186) Brown’s logP. The THAL characteristic scores were also negatively correlated 
with the SCZ (corrected p = 0.0178) and BPD (corrected p = 0.000534) Brown’s logP 
and hence it was genes downregulated in this brain region that were associated with 
more significant gene-wide p values. Conversely, genes with increased expression or 
upregulated in the MPFC were associated with BPD common variants (corrected p = 
0.0384), although in this dataset the enrichment was stronger with SCZ Brown’s logP 
(corrected p = 2.63 x 10-5). Table 2.10 also shows that characteristic scores for these 
three regions were significant when tested with SCZ Simes’ logP. Nominal evidence 
was found with the BPD Simes’ logP, which did not remain significant after 
correction for 13 brain regions, but was importantly in the same direction. The full 
results for this dataset including all other brain regions can be found in Appendix 
Table 7.1. 
 
The correlation coefficients for these relationships, also presented in Table 2.10, 
were small and of a similar magnitude to those reported with the global metrics in 
Section 2.2.1. The strongest correlation was found between the HIP characteristic 
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scores and SCZ Brown’s logP (r = -0.0459). Generally the correlations were stronger 
for associations with SCZ logP, as was observed with the global metrics in Section 
2.1.1. 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
MPFC 
P value 
2.02 x 10-6 
(2.63 x 10-5) 
3.52 x 10-5 
(0.000458) 
0.00295 
(0.0384) 
0.0341 
(0.443) 
Correlation 
Coeff. 
0.0414 0.0374 0.0254 0.0192 
+ + + + 
HIP 
P value 
1.35 x 10-7 
(1.76 x 10-6) 
1.78 x 10-6 
(2.32 x 10-5) 
0.00143 
(0.0186) 
0.0283 
(0.368) 
Correlation 
Coeff. 
-0.0459 -0.0432 -0.0272 -0.0198 
- - - - 
THAL 
P value 
0.00137 
(0.0178) 
2.37 x 10-5 
(0.000308) 
4.10 x 10-5 
(0.000534) 
0.00668 
(0.0868) 
Correlation 
Coeff. 
-0.0279 -0.0382 -0.0350 -0.0245 
- - - - 
Table 2.10: Linear regression results and correlation coefficients testing regional characteristic scores 
calculated in the Johnson dataset with gene-wide logP. 
P values in brackets have been corrected for 13 brain regions using Bonferroni’s method. 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
MPFC 
P value 0.997 0.324 
0.00195 
(0.0312) 
0.0203 
(0.324) 
Correlation 
Coeff. 
-3.17 x 10-5 0.00888 0.0133 0.0209 
- + + + 
HIP 
P value 
8.28 x 10-10 
(1.32 x 10-8) 
8.78 x 10-8 
(1.40 x 10-6) 
3.35 x 10-6 
(5.36 x 10-5) 
9.23 x 10-6 
(0.000148) 
Correlation 
Coeff. 
-0.0532 -0.0481 -0.00743 -0.0399 
- - - - 
THAL 
P value 
2.66 x 10-5 
(0.000425) 
6.69 x 10-7 
(1.07 x 10-5) 
4.55 x 10-6 
(7.28 x 10-5) 
0.00293 
(0.0469) 
Correlation 
Coeff. 
-0.0364 -0.0447 -0.00390 -0.0268 
- - - - 
Table 2.11: Linear regression results and correlation coefficients testing regional characteristic scores 
calculated in the Kang dataset with gene-wide logP. 
P values in brackets have been corrected for 16 brain regions using Bonferroni’s method, where 
missing corrected p value was 1. 
Table 2.11 presents the results from the same analyses but for the Kang dataset, 
where the p values were corrected for 16 brain regions. Strong negative correlations 
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were found between the HIP and THAL characteristic scores and both the BPD and 
SCZ Brown’s logP.  It can also be seen that there was a positive correlation between 
the MPFC characteristic scores and the BPD logP only. Results with the Simes’ logP 
supported these associations. Compared to Table 2.10 the results were more 
significant in the Kang dataset. The correlation coefficients are again small, 
suggesting these results do not explain the totality of risk genes for SCZ and BPD. The 
full results for this dataset can be found in Appendix Table 7.2. 
 
Validation with nonparametric tests 
For the same reasons outlined in the global metrics analyses (Section 2.2.1) 
nonparametric tests were used to verify the regression results. In order to test for an 
enrichment in either the upregulated or downregulated set of characteristic genes, 
tests were run as follows. Genes were ranked by the absolute value of their 
characteristic score i.e. the p value for differential expression of that gene in the 
region in question, and the top n% (5, 10…50%) selected. These sets were then split 
into two subgroups, genes with positive characteristic scores indicating increased 
characteristic expression, and genes with negative characteristic scores indicating 
decreased characteristic expression. The relevant subset consistent with the 
coefficient of the significant regression model was then tested against the bottom 
50% of genes i.e. those that were not characteristic of that region in either direction, 
for more significant gene-wide p values. 
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Figure 2.8: Results from Mann-Whitney tests to verify significant regression models with regional 
characteristic scores calculated in the Johnson and Kang datasets. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative 
subsets. The subset consistent with the direction of the significant regression model in Tables 2.10 
and 2.11 was tested in a one-sided Mann-Whitney test against the bottom 50%. Panels A - D tested 
the negative subset i.e. genes with decreased expression; panels E & F tested the positive subset i.e. 
genes with increased expression. Panels A & B tested for smaller SCZ p values; panels C - F tested for 
smaller BPD p values. Panels A, C & E characteristic scores were calculated in the Johnson dataset; 
panels B, D & F were calculated in Kang dataset. Black dashed line is p = 0.05. 
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Mann-Whitney tests found significantly smaller SCZ or BPD Brown’s p values in genes 
with decreased expression in either the HIP or THAL in the top 15-50% in both the 
Johnson and Kang datasets; see Figure 2.8 panels A-D. This verifies that the 
regression results reported for these regions were not due to outliers. Across both 
datasets enrichments were also found for smaller BPD Brown’s p values in genes 
with increased expression in the MPFC, panels E-F in Figure 2.8. As this was the case 
for genes in the top 20-50% of characteristic genes for this region, this result was 
also not caused by outliers.  
 
Simes’ p values produced less significant results in the rank-based tests compared to 
Brown’s p values, an observation that was broadly the case in the regression results. 
Mann-Whitney tests with SCZ Simes’ p values were significant for genes with 
decreased expression in the HIP and THAL in the top 30-50% for both datasets. 
Results from testing BPD Simes’ p values were less significant, with a trend for 
enrichment in genes with increased expression in the MPFC found only in the Kang 
dataset. In the top 35-50% of genes ranked by HIP characteristic score in the Kang 
dataset nominal enrichments were found for BPD Simes’ p values, whereas only a 
trend for significance was found in the top 45% in the Johnson dataset. Enrichments 
were found in both datasets for genes with decreased expression in the THAL in the 
top 10-40%. 
 
For the regional characteristic scores showing consistent associations across both 
datasets, combined scores were calculated using expression data from both the 
Johnson and Kang studies.  This was done to reduce the noise present in either 
dataset, as genes detected across both studies were more likely to be true signals. 
All subsequent analyses in this section were performed with these combined 
characteristic scores. Initially these were used to check that the associations were 
not driven by genes in the MHC region. 
 
As expected Table 2.12 shows significant linear relationships between the Brown’s 
logP and combined dataset characteristic scores for the HIP, THAL and MPFC. 
Running the analyses without the MHC genes broadly did not affect the results but 
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did reduce the significance of several models, such as MPFC in BPD and THAL in SCZ. 
Generally the same results pattern was found with Simes’ logP, however for BPD the 
associations were only nominally significant, and after removing the MHC genes the 
MPFC model was no longer significant. While all correlation coefficients were small, 
the strongest correlation coefficient was for the association between HIP 
characteristic scores and SCZ Brown’s logP. 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
MPFC 
P value   0.000995 0.0362 
Correlation 
Coeff. 
  0.0282 0.0190 
  + + 
HIP 
P value 2.39 x 10-7 5.92 x 10-6 0.000539 0.00285 
Correlation 
Coeff. 
-0.0450 -0.0410 -0.0296 -0.0270 
- - - - 
THAL 
P value 0.000167 7.00 x 10-6 2.91 x 10-5 0.0205 
Correlation 
Coeff. 
-0.0328 -0.0407 -0.0358 -0.0210 
- - - - 
Removing MHC genes 
MPFC 
P value   0.00269 0.0596 
Correlation 
Coeff. 
  0.0258 0.0172 
  + + 
HIP 
P value 5.10 x 10-7 4.40 x 10-6 0.000505 0.00186 
Correlation 
Coeff. 
-0.0440 -0.0419 -0.0299 -0.0284 
- - - - 
THAL 
P value 0.00148 0.000124 3.29 x 10-5 0.0166 
Correlation 
Coeff. 
-0.0279 -0.0350 -0.0357 -0.0219 
- - - - 
Table 2.12: Linear regression results and correlation coefficients testing regional characteristic scores 
calculated across both the Johnson and Kang datasets with gene-wide logP. 
 
The results of nonparametric tests, presented in Figure 2.9, supported the regression 
results with Brown’s p values presented in Table 2.12. Genes with decreased 
expression in the HIP were enriched for more significant SCZ (best p = 1.30 x 10-5 top 
35%) and BPD p values (best p = 0.000903 top 20%). Similar results were found for 
genes with decreased expression in the THAL (SCZ best p = 6.07 x 10-6 top 35%; BPD 
best p = 2.11 x 10-5 top 30%). The top 25-50% of MPFC characteristic genes with 
increased expression were enriched for BPD Brown’s p values (best p = 0.00181 top 
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25%). 
 
Figure 2.9: Results from Mann-Whitney tests to verify significant regression models with regional 
characteristic scores calculated across Johnson and Kang datasets.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative 
subsets. The subset consistent with the direction of the significant regression model in Table 2.12 was 
tested in a one-sided Mann-Whitney test against the bottom 50%. Panels A - D tested the negative 
subset i.e. genes with decreased expression; panels E-F tested the positive subset i.e. genes with 
increased expression. In all panels results are based on characteristic scores calculated across Johnson 
and Kang datasets. Panels A & B tested for smaller SCZ p values; panels C - F tested for smaller BPD p 
values. Panels A, C & E included all genes, panels B, D & F excluded genes in MHC region from 
analysis. Black dashed line is p = 0.05. 
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Results from testing SCZ Simes’ p values showed only nominal significance when 
testing genes with decreased expression in either the HIP or THAL. A trend for 
significance or nominal significance was found with BPD Simes’ p values in HIP or 
THAL characteristic genes and no significance was found in genes with increased 
expression in the MPFC. Almost identical results were found when removing the 
MHC genes from the nonparametric analyses; see Figure 2.9 panels B, D & F. 
 
Test for independent associations 
Using the combined dataset characteristic scores, the associations for each set were 
tested simultaneously to see if they were independent. The results of linear 
regression models for each pair of scores predicting Brown’s logP only, as this set of 
p values had the most consistent enrichments, are presented in Table 2.13.  
 
Dependent 
variable (Brown’s 
logP) 
Independent variables included in regression model 
HIP characteristic score THAL characteristic 
score 
MPFC characteristic 
score 
P value Coeff. P value Coeff. P value Coeff. 
Schizophrenia 1.11 x 10
-5 - 0.00915 -   
Bipolar disorder 0.0112 - 0.000553 -   
Bipolar disorder 0.00307 -   0.00574 + 
Bipolar disorder   0.000555 - 0.0215 + 
Bipolar disorder 0.0216 - 0.00369 - 0.0420 + 
Table 2.13: Linear regression results testing regional characteristic scores calculated across both the 
Johnson and Kang datasets simultaneously to predict Brown’s logP. 
Each row represents a separate regression model. 
 
In each pair of characteristic scores, both remained significant although to a lesser 
degree than when tested individually; compare Table 2.13 to Table 2.12. This 
indicates that the associations of the characteristic scores were not completely 
independent.  A model was also fitted predicting BPD Brown’s logP with all three 
characteristic scores; this showed that the MPFC score explained little of the signal 
when including both the THAL and HIP. Therefore as the HIP and THAL were 
consistent across the two disorders, and largely explain the MPFC signal only these 
will be considered further. 
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Expression of enriched gene sets across brain development 
In order to compare the results of this Section with that found in Section 2.2.1 for 
genes consistently expressed across the mid-foetal brain, the expression of the most 
enriched HIP and THAL characteristic genes was plotted. Based on the results from 
the Mann-Whitney tests those with negative characteristic scores in the top 35% of 
genes ranked by their absolute HIP characteristic score were taken as the most 
enriched set. Figure 2.9 panel A shows that the most significant result with SCZ 
Brown’s gene-wide p values came in the top 35% and panel C shows that the most 
significant results with BPD Brown’s gene-wide p values came in the top 20%, hence 
the top 35% was chosen as this encompassed the top enrichments for both 
disorders. Similarly, the genes with negative characteristic scores in the top 35% of 
absolute THAL characteristic scores were taken as that most enriched set, as the top 
35% was most enriched for smaller SCZ Brown’s gene-wide p values and the top 30% 
for smaller BPD Brown’s gene-wide p values, also shown in Figure 2.9 panels A and C. 
 
Thus far, only a small part of mid-foetal development has been considered, between 
18 and 23 weeks gestation. The Kang replication dataset was taken from a larger 
transcriptome study covering a much wider range of human brain development and 
can be used to look at expression profiles over a longer period of development. For 
each brain region, at each time point, the median expression for the set of enriched 
genes was plotted from embryonic through to adolescence. For comparison a 
corresponding value was calculated based on all remaining genes in the dataset that 
were not in the enriched gene set.  
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Figure 2.10: Expression across development for most enriched characteristic HIP and THAL gene sets.  
The sets of genes with decreased expression in either the HIP or THAL most enriched for smaller SCZ 
Brown’s gene-wide p values and BPD Brown’s p values were identified from Mann-Whitney tests of 
characteristic scores calculated across both the Johnson and Kang datasets; panel A top 35% HIP 
decreased, panel B top 35% THAL decreased.  Median expression values for each time point were 
calculated in more extensive version of Kang dataset, in addition median expression values were also 
calculated for all remaining genes not part of the enriched gene sets labelled as ‘Rest’ in figure. PCW – 
post conception weeks, Mon – months, Y-years, NCTX – neocortex. 
Figure 2.10 shows that the set of enriched characteristic HIP genes do have lower 
expression in the HIP compared to all other regions however, these genes are still 
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relatively highly expressed in this region, consistent with the results of Section 2.2.1. 
In fact the decreased expression in the HIP occurs across all foetal samples up to 22 
PCW. In this set of genes all brain regions had a peak of expression during foetal 
development that dropped off before birth, followed by lower expression in 
postnatal samples. In contrast, genes not part of this enriched set showed a 
relatively consistent profile across development. A similar pattern was seen when 
taking the most enriched set of THAL decreased genes. Despite an obvious decrease 
in expression relative to the neocortical regions in the THAL, these genes were still 
highly expressed in this region. The decrease in expression for the THAL compared to 
other samples was greater than seen in the HIP and remained throughout early 
years.  
 
The expression plots of these two sets of enriched genes corroborates the pairwise 
regression analyses by suggesting there was an underlying common set of genes 
with the same development expression profile. Further, it was evident from these 
graphs that these genes would have higher means than the remaining set of genes 
and suggests some overlap in these results with those in the Section 2.2.1. 
 
Summary 
In summary, two sets of characteristic genes showed enrichment for SCZ common 
variants: genes downregulated in the HIP and genes downregulated in the THAL. 
Both of these gene sets, as well as genes upregulated in the MPFC, were enriched for 
BPD common variants. The association of two sets of characteristic scores (HIP and 
THAL) with SCZ and BPD, in the same direction across both datasets, was significantly 
greater than expected when compared to random permutations. The significant 
enrichment of the MPFC characteristic scores with BPD, in the same direction across 
both datasets, in addition to the HIP and THAL associations was also more than 
expected by chance. All three of these relationships were associated with small 
correlation coefficients, indicating that they do not explain all of SCZ or BPD risk. 
These results were most consistent with the Brown’s p values using both regression 
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and rank-based tests. Simes’ gene-wide p values showed associations in the same 
direction but not always significantly nor consistently across disorders or tests. 
 
The associations of the HIP, THAL, MPFC characteristic genes with BPD variants were 
found to be partly overlapping, with the HIP and THAL associations capturing most of 
the MPFC signal. The SCZ signals in the HIP and THAL characteristic genes were also 
shown to be overlapping. A common variable profile of expression across 
development was identified for the enriched sets of genes characteristic of the HIP 
and THAL, further supporting the idea that they have captured an overlapping set of 
co-regulated genes. The profile was characterised by a peak of expression during 
foetal development followed by a relative decrease in postnatal stages and suggests 
these are developmentally regulated genes, which may be particularly important 
during foetal brain development. 
 
2.2.3 Global pattern of gene expression and schizophrenia structural variants 
In this section CNVs identified in SCZ case control studies were tested to see if they 
hit genes with common expression profiles. For each CNV the global metrics, 
introduced in Section 2.2.1, were collated for each gene hit and the minimum, 
median and maximum calculated. A series of logistic regression models were fitted 
to compare these metrics between CNVs found in SCZ patients and those found in 
controls (formulae for these can be found in the Methods). CNV data from the MGS 
and ISC studies were combined for this analysis, so extra covariates were included to 
control for study and chip differences. In addition a term for the number of genes hit 
by that CNV (limited to those found in the expression dataset) was included to 
control for any CNV size bias, as CNVs that hit more genes are more likely to have an 
extreme score. Each model was fitted for the full set of CNVs, and the deletions and 
duplications separately. 
 
No significant differences were found for any of the global metrics (mean, scaled 
mean or coefficient of variation) when taking the minimum, median or maximum 
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score of the genes hit by each CNV, see Table 2.14. This was also the case when 
testing the deletions and duplications separately. 
 
 Compare genes hit by 
schizophrenia CNVs to control 
CNVs 
Compare singleton 
schizophrenia CNVs to non-
singleton schizophrenia CNVs 
All CNVs Min. Med. Max. Min. Med. Max. 
Mean P value 0.594 0.492 0.431 0.320 0.0852 0.0305 
Coeff. - - - + + + 
Scaled mean P value 0.319 0.523 0.771 0.236 0.182 0.0401 
Coeff. - - - + + + 
Coeff. of 
variation 
P value 0.745 0.453 0.131 0.0700 0.179 0.527 
Coeff. + + + - - - 
Deletion CNVs 
Mean P value 0.644 0.877 0.762 0.205 0.129 0.150 
Coeff. - + + + + + 
Scaled mean P value 0.170 0.573 0.832 0.111 0.0339 0.0198 
Coeff. - - - + + + 
Coeff. of 
variation 
P value 0.931 0.740 0.240 0.0585 0.0928 0.299 
Coeff. + + + - - - 
Duplication CNVs 
Mean P value 0.643 0.377 0.443 0.885 0.364 0.106 
Coeff. - - - + + + 
Scaled mean P value 0.973 0.899 0.562 0.902 0.852 0.511 
Coeff. + + + + - + 
Coeff. of 
variation 
P value 0.745 0.773 0.413 0.480 0.816 0.895 
Coeff. - + + - - + 
Table 2.14: Logistic regression results testing CNV status on global metrics calculated in the Johnson 
dataset. 
 
Studies have shown that not only do SCZ patients have an increased number of 
CNVs, but also that those found in SCZ patients are rare in the general population 
(International Schizophrenia Consortium, 2008, Walsh et al., 2008).  Hence, the 
global metrics for each case CNV, calculated as above, were tested to see if singleton 
CNVs, defined as those that did not overlap with any control CNV, hit genes with 
common expression characteristics. Similar to above, a logistic regression framework 
was used for this analysis, to compare singleton case CNVs to the remaining case 
CNVs.  
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Nominal p values for the maximum mean values (p = 0.0305) and maximum scaled 
mean (p = 0.0401) suggest that singleton SCZ CNVs hit genes more highly and 
consistently expressed compared to more common SCZ CNVs, see Table 2.14. 
Analyses run separately showed that this was not specific to either deletions or 
duplications when testing the mean metric. The median (p = 0.0339) and maximum 
(p = 0.0198) scaled means were significantly higher in singleton deletions compared 
to non-singleton deletions but not when comparing duplications. However these 
results were only nominally significant and would not survive multiple testing. 
 
 Compare genes hit by 
schizophrenia CNVs to control 
CNVs 
Compare singleton 
schizophrenia CNVs to non-
singleton schizophrenia CNVs 
All CNVs Min. Med. Max. Min. Med. Max. 
Mean P value 0.620 0.594 0.589 0.679 0.197 0.0203 
Coeff. - - - + + + 
Scaled mean P value 0.377 0.497 0.473 0.133 0.0430 0.00338 
Coeff. - - - + + + 
Coeff. of 
variation 
P value 0.503 0.457 0.407 0.155 0.332 0.603 
Coeff. + + + - - - 
Deletion CNVs 
Mean P value 0.652 0.333 0.190 0.890 0.617 0.512 
Coeff. + + + + + + 
Scaled mean P value 0.572 0.655 0.660 0.334 0.195 0.0566 
Coeff. - + + + + + 
Coeff. of 
variation 
P value 0.599 0.562 0.699 0.130 0.151 0.269 
Coeff. - - - - - - 
Duplication CNVs 
Mean P value 0.116 0.0829 0.127 0.717 0.221 0.0149 
Coeff. - - - + + + 
Scaled mean P value 0.456 0.284 0.436 0.308 0.128 0.0289 
Coeff. - - - + + + 
Coeff. of 
variation 
P value 0.401 0.221 0.196 0.635 0.911 0.708 
Coeff. + + + - + + 
Table 2.15: Logistic regression results testing CNV status on global metrics calculated in Kang dataset. 
Validation in independent expression dataset 
Repeating these analyses in the Kang dataset, presented in Table 2.15, found no 
significant differences in the global metrics of genes hit when comparing case CNVs 
to control CNVs.  Singleton SCZ CNVs were found to hit genes with higher mean 
expression, testing the maximum (p = 0.0203), and higher scaled mean expression, 
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when testing the median (p = 0.0430) and maximum (p = 0.00338). None of these 
remained significant when limiting the analysis to deletions but when testing the 
duplications both the maximum mean (p = 0.0149) and maximum scaled mean (p = 
0.0289) of the genes hit were significantly higher in the singleton CNVs. 
 
Summary  
No significant differences were found in either dataset when comparing SCZ CNVs to 
those found in healthy controls for the mean, scaled mean or coefficient of variation 
of the genes hit by each CNV. Both datasets provided nominal evidence that 
singleton SCZ CNVs hit genes with increased means and scaled means, which after 
correction for multiple testing would be unlikely to remain significant. Therefore 
further replication of these results would be needed. 
 
2.2.4 Regional characteristic gene expression and schizophrenia structural variants 
Next, SCZ CNVs were compared to control CNVs to see if the genes they hit were 
more characteristic of particular brain regions. For each brain region, the 
characteristic scores for each gene hit by each CNV were collated and the minimum, 
median and maximum were taken. As positive characteristic scores indicated an 
increase of expression in that region and negative scores indicated a decrease of 
expression in that region, for any significant model the sign of the coefficient 
informed which type of characteristic genes were associated. The same regression 
framework from the previous section was used, controlling for study, chip and the 
number of genes hit by each CNV. No significant differences (p < 0.01) were found 
between genes hit by SCZ CNVs compared to control CNVs for any brain region’s 
characteristic scores. Further, no significant results were found when separately 
analysing the deletions and duplications. This was also the case in the Kang dataset 
results; these results can be found in Appendix Tables 7.3 and 7.5. 
 
Singleton CNVs were compared to all remaining case CNVs for each brain region’s 
characteristic scores. After correcting the analyses in both the Johnson and Kang 
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datasets for the number of brain regions tested no regression model was significant 
across both datasets. Hence these results will be discussed no further but can be 
found in the Appendix Tables 7.4, 7.6. 
 
2.2.5 Alternative splicing and common risk variants 
So far the methods used in this chapter for identifying variable expression in the 
foetal brain would not capture whether multiple isoforms of a gene were being 
expressed. The previous analyses of variably expressed genes, in Sections 2.2.1 and 
2.2.2 were based on a composite value of expression taken from multiple transcripts 
for each gene, so it is possible that consistently expressed genes were present as 
alternative isoforms.  
 
The availability of expression data at the exon level from the Affymetrix Human Exon 
chip enabled methods to be employed to detect for alternative splicing events. The 
FIRMA (finding isoforms using robust multichip analysis) algorithm (Purdom et al., 
2008) was used to identify alternative splicing. FIRMA calculates a score for each 
exon-sample pairing based on the residual from the estimation step of the robust 
multichip average (RMA) normalisation procedure to characterise differences 
between the observed and estimated expression values. The benefit of using this 
method was that it enabled comparisons between groups, so both global alternative 
splicing and splicing specific to each brain region could be investigated.  
 
This method was applied separately to each individual in the dataset before being 
combined. Initially, to look at global splicing across the foetal brain, the FIRMA 
scores were summarised into a single value for each exon.  This was achieved by 
fitting a linear model for each exon to see if any brain region had a non-zero 
coefficient. To give each gene an overall splicing p value, all p values from all exons 
and individuals were collated and the best Simes’ corrected one taken. 
 
In order to minimize the number of false positives it has been suggested to remove 
lowly expressed genes prior to detecting alternative splicing (Affymetrix, 2008). The 
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FIRMA method was applied to the raw CEL files, which prevented pre-filtering steps 
from being applied prior to the algorithm itself.  Instead genes with only one exon 
and genes filtered out of the previous analyses as lowly expressed in the foetal brain 
were removed after calculating FIRMA p values before any further analyses. One 
caveat of using the FIRMA method was that potential confounders, such as individual 
and hybridisation date could not be included.  
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Johnson 
P value 0.787 0.419 0.536 0.241 
Correlation  
Coeff. 
0.00236 0.00734 0.00228 0.0107 
+ + + + 
Kang 
P value 0.354 0.637 0.847 0.167 
Correlation 
Coeff. 
-0.00806 0.00426 -0.00165 0.0125 
- + - + 
Table 2.16: Linear regression results and correlation coefficients testing global splicing logP with gene-
wide logP. 
 
The global splicing logP were tested in a regression framework with the Brown’s logP 
to assess if genes with evidence of alterative splicing were enriched for association 
signal. No significant relationship with either SCZ (p = 0.787) or BPD (p = 0.536) 
Brown’s logP was found, shown in Table 2.16. In the Kang dataset none of the 
regression models with either the Brown’s or Simes’ logP were significant.  
 
Brain region splicing p values were also calculated from the FIRMA scores using a 
linear model to compare the scores from one region to all other regions and deriving 
a p value for each exon for each brain region. These were combined into gene level 
brain region splicing p values by selecting the best p value after Simes' correction. 
Each set of brain region splicing logP were then tested in a linear model with the 
Brown’s logP. Across the Johnson and Kang dataset, no set of region splicing p values 
were consistently associated with either SCZ or BPD. Therefore these results will not 
be presented here but can be found in Appendix Tables 7.7 and 7.8. 
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2.2.6 Alternative splicing and schizophrenia structural variants 
The minimum, median and maximum global splicing logP were calculated from the 
genes hit by each CNV to test if they were significantly different between case and 
control CNVs. This was not the case, neither were they significantly different 
between singleton case CNVs and all other case CNVs, Table 2.17.   
 
 
Comparing schizophrenia CNVs to 
control CNVs 
Comparing rare schizophrenia CNVs to 
common schizophrenia CNVs 
All CNVs Minimum Median Maximum Minimum Median Maximum 
P value 0.795 0.643 0.460 0.423 0.477 0.737 
Coeff. - - - - - - 
Deletion CNVs 
P value 0.409 0.520 0.363 0.400 0.419 0.469 
Coeff. - - - + + + 
Duplication CNVs 
P value 0.962 0.932 0.902 0.105 0.140 0.349 
Coeff. + - + - - - 
Table 2.17: Logistic regression results testing CNV status on global splicing logP calculated in the 
Johnson dataset. 
None of the twelve overlapping regions between the two expression datasets had 
significantly different brain region splicing p values between case and control CNVs 
across both datasets; results presented in Appendix Tables 7.9 and 7.11. Significant 
models were found when comparing singleton SCZ CNVs to all other SCZ CNVs, 
although after correction for testing multiple brain regions there were no consistent 
enrichments across the Johnson and Kang datasets. These results will not be 
presented here but can be found in Appendix Tables 7.10 and 7.12. 
 
2.2.7 Functional analysis of genes with enriched expression profiles 
Significant associations were found between SCZ and BPD common variants and 
genes with decreased expression in the HIP or THAL, therefore characteristic scores 
for both of these regions were used to identify functional terms. Annotation terms 
were taken from the GO database (Ashburner et al., 2000) to identify those that 
were enriched for genes with decreased expression in either the HIP or THAL, 
consistent with the direction of the association reported in Section 2.2.2. The GO 
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terms are the largest resource of pathways (du Plessis et al., 2011) with a wide range 
of terms and therefore were used here for a hypothesis free analysis. 
 
The GO terms were filtered to those with between 20 and 2000 genes, leaving 3204 
unique terms that were tested.  A Mann-Whitney test was used for each GO term to 
compare the HIP and THAL characteristic scores for genes annotated to that term 
against all remaining genes, to see if they had smaller characteristic scores. In other 
words these tests looked to identify GO terms with genes that had decreased 
expression in these regions in line the enrichments reported for SCZ and BPD 
variants in Section 2.2.2.  
 
A Bonferroni corrected significance threshold of 1.56 x 10-5 was used to identify 
significant GO terms for the HIP and THAL separately. Many of the GO terms within 
each set are known to be overlapping and therefore the significance of many of the 
pathways was not independent. Within each set the pathways were clustered into 
related groups by identifying the smallest term that captured the signal of any larger 
terms. Genes in the smallest pathway were removed from all larger pathways and 
the enrichment analysis was repeated on the remaining genes in each larger 
pathway. If the larger pathway was no longer significantly enriched for characteristic 
genes, the smaller pathway was said to explain it. Any pathways explained were 
combined with the smaller pathway into a merged pathway, and the process 
repeated until no more pathways could be explained.  
 
The set of terms enriched for lower THAL characteristic scores was the largest with 
134 terms compared to 105 with lower HIP characteristic scores. In each set 32 
terms were found to explain at least one other term, shown in Figures 2.6 and 2.7, 
with seventeen terms common to the two figures, highlighted in yellow. Within each 
panel the terms and clusters have been manually grouped into broad themes, with 
the same themes appearing in both sets. These themes were ‘Chromosome: 
structural modification & repair’, ‘Transcription’ and ‘Post-transcriptional RNA 
processing & transport’. 
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Figure 2.11: Key annotation terms identified from set of significant GO terms with significantly smaller HIP characteristic scores.  
Figure shows set of 32 GO terms that explained at least one other term in the set of significant pathways. Terms that did not explain any other term were not included in 
the Figure. Arrows point from explaining term to the merged pathway it explains i.e. the term pointed to, merged with all other terms it explains. Terms in yellow ovals are 
also present in Figure 2.12; terms in black boxes were grouped into common themes. 
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Figure 2.12: Key annotation terms identified from set of significant GO terms with significantly smaller THAL characteristic scores.  
Figure shows set of 32 GO terms that explained at least one other term in the set of significant pathways. Terms that did not explain any other term were not included in 
the Figure. Arrows point from explaining term to the merged pathway it explains i.e. the term pointed to, merged with all other terms it explains. Terms in yellow ovals are 
also present in Figure 2.11; terms in black boxes were grouped into common themes. *Means merged term explains pathway pointed to. 
76 
 
 
Having found characteristic gene sets that were associated with SCZ and BPD and 
identified pathways enriched in these gene sets, the final step was to test whether 
these pathways captured the association signal of each gene set. The set of genes 
with the strongest enrichment for SCZ and BPD gene-wide p values identified from 
the Mann-Whitney tests, the top 35% for the HIP and the top 35 % for THAL, were 
used as the basis for set-based tests. The HIP decreased genes and the THAL 
decreased genes were then spilt into two groups, those that were annotated to one 
of the significant pathways for that region, and those that were not annotated to any 
of the significant pathways. A set-based test was then performed on each subset to 
look for an association with SCZ or BPD. This set-based test was equivalent to 
Brown’s method for combining non-independent test statistics and in this case 
collapses the SNP p values from a GWAS into a single p value to demonstrate the 
sets’ overall association with a phenotype.  
 
The SNP association p values were taken from the PGC GWAS for SCZ and BPD and 
SNP correlations were calculated from the HapMap data 
(http://hapmap.ncbi.nlm.nih.gov/). At a gene set level, where SNPs from multiple 
genes were combined, it was noticed that sets with more SNPs had more significant 
p values. In order to correct for this, 10000 simulations were performed (see 
Methods for details) and an adjustment made for the number of SNPs in each set.   
 
Genes with decreased expression in the HIP and in pathways enriched for HIP 
decreased genes showed evidence for association with both SCZ (adjusted p = 
0.00611) and BPD (adjusted p = 0.0290) compared to genes not in significant 
pathways, results in Table 2.18. This was also the case for genes with decreased 
expression in the THAL, where genes in significant pathways were associated to both 
disorders (SCZ adjusted p = 0.000804; BPD adjusted p = 0.000463) whereas genes 
with decreased expression in the THAL but not in significant pathways were not. This 
result would not have been expected if either the SCZ or BPD associations or 
functional gene set enrichments with the HIP or THAL characteristic scores were 
spurious, and therefore validates these findings.  
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Schizophrenia Bipolar disorder 
Number of SNPs 
in set 
Adjusted p 
value 
Number of 
SNPs in set 
Adjusted p 
value 
Top 35% HIP 
decreased 
genes 
In 
pathways 
40164 0.00611 76007 0.0290 
Not in 
pathways 
44160 0.145 83138 0.0975 
Top 35% THAL 
decreased 
genes 
In 
pathways 
37620 0.000804 69560 0.000463 
Not in 
pathways 
35932 0.134 68408 0.722 
Table 2.18: Results of set-based tests for genes found in HIP and THAL enriched sets split into those 
annotated to a significant pathway and those not. 
Set p values were adjusted for number of SNPs in each set. 
 
Further set-based tests were then used to ascertain which of the pathway groups in 
Figures 2.6 and 2.7 were the most enriched for association signal. For each pathway 
group a set was formed based on the genes in either the top 35% of HIP decreased, 
or the top 35% of THAL decreased, and in any of the pathways within that group. 
After adjusting for the number of SNPs in each set, all pathway groups had a 
significant association with SCZ, with the most significant p value for the 
‘Chromosome: structural modification & repair’ group (adjusted p = 0.000599). For 
BPD, two of the three pathway groups were associated with the ‘Transcription’ 
group being the exception. The most significant group for BPD was the ‘Post-
transcriptional RNA processing & transport’ group (adjusted p = 3.40 x 10-6). 
 
 
Schizophrenia Bipolar disorder 
Number of 
SNPs in set 
Adjusted p 
value 
Number of 
SNPs in set 
Adjusted p 
value 
Chromosome: structural modification 
& repair 
13063 0.000599 24190 0.00475 
Transcription 11390 0.0124 20922 0.381 
Post-transcriptional RNA processing & 
transport 
18032 0.00983 33032 3.40 x 10-6 
Table 2.19: Results of set-based tests based on pathway groups in Figures 2.11 and 2.12. 
Set p values were adjusted for number of SNPs in each set. 
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2.3 Discussion 
2.3.1 Identification of common spatial expression profiles 
This chapter presents the first brain-wide and genome-wide study in the human 
foetal brain for either SCZ or BPD associated genes. In particular, expression profiles 
across multiple regions of the mid-foetal human brain were investigated to identify 
sets of genes associated with SCZ or BPD. The first reported association in Section 
2.2.1 was between genes consistently highly expressed across the mid-foetal brain, 
and both SCZ and BPD common risk variants. This finding was then replicated in an 
independent expression dataset covering the same period of gestation.  
 
While general variation was not enriched for SCZ or BPD common variants, 
enrichments were found in gene sets identified with specific variable expression 
profiles in Section 2.2.2. Genes with decreased expression in the HIP or THAL were 
found to be associated with risk genes for both disorders. In addition, genes with 
increased expression in the MPFC during this period of foetal development were 
associated with BPD. These results were also replicated in an independent 
expression dataset and across the two datasets the probability of these results 
occurring by chance was nominal, hence these appear to be robust results.  
 
The associations of these three sets of characteristic genes were not independent. 
The HIP and THAL enriched genes were shown to have the same variable 
development profile from foetal through to adolescence supporting the idea that 
there was a common underlying gene set driving the associations. This common 
profile, shown in Figure 2.10, had high expression during foetal development and 
lower levels of expression during postnatal stages. The peak of expression of these 
gene sets was observed to occur during the second trimester suggesting these genes 
play a role in development processes active during this time frame, before dropping 
off in the third trimester. The second trimester is an important period of 
neurogenesis. Neurons are produced at a very high rate and even a minor insult can 
significantly affect the maturation of these cells influencing the structure and 
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function of the brain, making this period of brain development particularly 
vulnerable (Miranda, 2012).  
 
Two recently published studies also made use of the BrainSpan publically available 
expression datasets to investigate the spatial and temporal patterns of autism risk 
genes (Parikshak et al., 2013, Willsey et al., 2013). Both used a network-based 
approach to identify genes that showed common expression profiles in the 
developing brain. Willsey et al. looked at co-expression between nine autism risk 
genes, selected as having the strongest evidence for association, and all other genes 
in the dataset. Resulting networks based on co-expression during mid-foetal 
development (10-24 PCW) and in prefrontal regions were enriched for a second set 
of autism risk genes, termed probable risk genes as they were based on weaker 
evidence than the initial high confidence set. This work and the work presented this 
chapter highlights the importance of gene expression in the human mid-foetal brain 
for both SCZ and autism. 
 
In contrast, Parikshak et al. created a weighted gene co-expression network using 
correlations between all pairs of genes in the dataset, and identified distinct 
modules enriched for autism candidate genes that had common developmental 
expression trajectories. Their module M2, and to some degree M3, showed a 
temporal expression profile consistent with that in Figure 2.10. Further, both of 
these modules were enriched for GO pathways relating to the regulation of 
expression including specific terms identified in Figures 2.11 and 2.12 such as ‘zinc 
ion binding’ and ‘histone modification’. The similarity of these findings and those 
presented in this thesis suggest that the developmental trajectory described is not 
specific to SCZ but may be the case for a number of neurodevelopmental disorders 
including both SCZ and autism. 
 
This finding is consistent with an early developmental model for SCZ with 
widespread effects. Prenatal insults associated with SCZ risk are thought to occur 
during this period of gestation. Minor physical anomalies are presumed to be 
markers of aberrant brain development during the first or second trimester as they 
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are formed from the same primordial tissue (Lobato et al., 2001). In particular 
anomalies of the craniofacial region, for which there is evidence of in SCZ (Ismail et 
al., 1998, Weinberg et al., 2007), are posited to be the result of an insult during the 
critical period of 9-16 weeks gestation (Waddington et al., 1998). Differences in 
fingertip ridge count, observed in SCZ, are also thought to be caused by second 
trimester insults (Bracha et al., 1992).  
 
The identification of variable profiles across brain regions and genes highly 
consistently expressed appears contradictory. However, Figure 2.10 shows genes 
identified with variable expression across brain regions still have higher expression 
across the mid-foetal brain compared to all other genes in the dataset. These genes 
would have a higher mean expression value than the remaining genes. The mean 
was one of the global metrics used to identify consistently expressed genes and was 
part of the calculation of both the scaled mean and coefficient of variation. 
Therefore in the mid-foetal brain SCZ and BPD genes in general have higher 
expression that is relatively lower in the HIP and THAL compared to other brain 
regions. Moreover, disruptions in the expression of these genes could have fairly 
global, rather than specific effects on foetal neurodevelopment. Although higher 
gene expression was observed in neocortical regions when compared to other 
regions, in particular the HIP and THAL, there was no support for any particular 
neocortical region being involved in SCZ or BPD pathogenesis.  
 
These associations were found by looking for a correlation between a summary 
expression metric and gene-level summarised p values calculated from GWAS 
results. These gene-wide p values which by definition are found in the interval [0, 1] 
were –log10 transformed to the interval [0, ∞) which emphasises the most 
significant genes, giving them more weight in the regression model used to test for 
associations. This transformation creates an unsymmetrical distribution of the gene-
wide p values which may cause the assumptions of the regression model to no 
longer be satisfied, and can introduce outliers that may cause highly significant but 
noisy associations. In order to minimise the possibility of reporting false positive 
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results, additional nonparametric tests were used to validate any significant 
regression results reported in this chapter.   
 
No consistent results were found for any analyses with SCZ CNVs, this may be 
surprising given CNVs have been shown not only to increase the risk of SCZ but also 
the risk of other developmental disorders. The results here should not be 
interpreted to mean that CNVs do not have an impact in the foetal brain; rather they 
do not appear to have a specific impact. Further, no associations were found 
between genes with evidence of alternative splicing in the foetal brain and either 
SCZ or BPD.  
 
2.3.2 Identification of functional pathways from enriched expression gene sets 
Pathway analysis in Section 2.2.7 identified three groups of terms associated with 
genes with decreased expression in the HIP or THAL: ‘Chromosome: structural 
modification & repair’, ‘Transcription’ and ‘Post-transcriptional RNA processing & 
transport’. All three of these groups imply that these genes are involved in the 
regulation or control of gene expression particularly during the process of 
transcription. Genes with characteristic expression of the HIP and THAL within these 
pathways were found to be associated with SCZ and BPD, therefore this suggests 
that SCZ and BPD risk genes are involved in the regulation of gene expression. The 
cascade of brain development mechanisms is controlled by gene expression 
concentrations, therefore given the temporal profile described above for genes 
enriched for SCZ and BPD common variants, these genes may be involved in the 
control of expression throughout brain development. Furthermore, a disruption 
early on could have consequences later in life. The temporal profile of SCZ and BPD 
genes will be investigated further in the next chapter. 
 
The coherence of the functional results was somewhat noteworthy. Given that GO is 
incomplete, as not all genes have been fully characterised (Khatri et al., 2012), it 
would be expected that some true overlaps would be missing and therefore the 
groupings in Figures 2.6 and 2.7 would not be complete. While the HIP and THAL 
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scores were shown not to be entirely independent, there will be some variation 
between them which may lead to the identification of some spurious terms. 
Considering this, the concordance of the results across both sets increases the 
confidence of these results. Further the fact that the subset of genes with these 
characteristic expression profiles also present in the associated pathway groups 
were enriched for SCZ, and to some extent BPD GWAS signal supports the relevance 
of these categories for SCZ aetiology.  
 
2.3.3 Comparison of results with schizophrenia and bipolar disorder variants 
Given the genetic overlap of common variants discussed in the Introduction Section 
1.3.2 it was not surprising that results were consistent for both disorders, and in fact 
the reason for including both was for genetic replication. Generally there was 
stronger evidence for enrichment of the association signal with the SCZ gene-wide p 
values compared to BPD gene-wide p values. In all likelihood this was due to the 
larger sample size in the SCZ PGC GWAS (approximately 9,400 SCZ cases and 12,500 
controls compared to 7,500 BPD cases and 9,300 controls) giving the study more 
power to detect small effect sizes, which in turn meant there was more power in this 
study to detect associations.  
 
2.3.4 Comparison of results with Brown’s and Simes’ gene-wide p values 
Two sets of gene-wide p values were used in this chapter, based on Simes’ multiple 
correction procedure (Simes, 1986) and Brown’s method for combining correlated 
test statistics (Brown, 1975). Generally the results were more significant and more 
consistent with Brown’s gene-wide p values compared to Simes’ p values. This is 
supportive of a polygenic model for common variants as this suggests that 
recognizing and incorporating multiple, semi-independent association signals within 
genes leads to more significant associations, compared to just using the single best p 
value. 
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2.3.5 Summary of chapter findings 
The original premise of this study was based on the fact that SCZ has been 
postulated as a human specific disorder (Crow, 1997) and sequences associated with 
human evolution were found to be enriched in genes differentially expressed in the 
foetal brain (Johnson et al., 2009).  While enrichments for SCZ risk genes were found 
in specific variable expression patterns, they were not found for general variation. 
Regions identified with human-specific evolutionary signatures have been 
investigated in another study with the PGC data, and no enrichment for SCZ or BPD 
common variants was found (Bigdeli et al., 2013). The authors conjectured that using 
common variants limits the power to investigate this theory, and rarer variants 
identified from sequencing studies may be more appropriate, which may also be the 
case here.  
 
In sum, the findings reported in this chapter suggest that SCZ risk genes play a role in 
the regulation of brain development particularly during foetal stages. Therefore in 
the next chapter, gene expression across the full range of brain development will be 
investigated to see if genes associated to SCZ or BPD have a common temporal 
profile. 
 
2.4  Methods 
All methods described below were completed with the R statistical language unless 
otherwise stated. 
 
Preliminary data processing: Johnson 
A previously published microarray dataset was downloaded as CEL files from the 
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO), accession number GSE13344. In total 95 samples from up to thirteen brain 
regions for four individuals, from both hemispheres, were hybridised to the 
Affymetrix Human Exon 1.0 chip to obtain genome-wide expression values, these 
data are referred to as the Johnson dataset. Further details on the quality control, 
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assessment of the tissue samples and microarray procedure can be found in the 
original manuscript (Johnson et al., 2009).  
 
Partek Genomics Suite software (Partek GS) was used to process the CEL files into 
expression values.  The RMA algorithm with its default settings was used to 
transform intensity values into exon transcript values. Principal component analysis 
reduced the data into 3 dimensions to detect for outliers. By visual inspection no 
outliers were identified, so all samples were included in the analysis. The Tukey 
biweight one-step algorithm, with default settings, was then used to calculate gene 
transcript scores from the exon transcript values. At this stage the data were 
exported out of Partek GS.  
 
All gene transcripts denoted as core and unique were annotated using messenger 
ribonucleic acid (mRNA) information of the corresponding exon probesets extracted 
from the annotation files provided online by Affymetrix 
(http://www.affymetrix.com/support/technical/annotationfilesmain.affx). These 
were then mapped to Entrez ids in the latest build of the genome (37.3), checking 
they matched the accompanying gene symbol, by a series of python scripts. Any 
Entrez ID annotated to a gene by more than 90% of the possible probesets was kept. 
Genes with multiple or non-unique Entrez IDs were removed, so that each Entrez ID 
was unique in the final dataset. From here gene transcripts will be referred to as 
genes. The gene expression values were filtered on a gene by gene basis to remove 
any genes that were lowly expressed, specifically anything with a median less than 3 
or a maximum less than 5 done by another python script. The final dataset 
comprised of 16,212 genes. 
 
Preliminary data processing: Kang 
The Kang replication microarray dataset, accession number GSE25219, was also 
downloaded from GEO. This dataset contained post-mortem brains from individuals 
throughout development, but only those that fell between 18 and 23 weeks 
gestation were extracted to form the replication dataset. The Kang dataset and 
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Johnson dataset were known to have overlapping individuals; therefore any 
individual in the Kang dataset that matched an individual in the Johnson dataset 
based on age, gender and available brain regions was removed to leave five 
independent individuals. These data were downloaded already normalised, Kang et 
al. having also used Partek GS with the same default settings. The same annotation 
and filtering procedures were applied as described for the Johnson microarray 
dataset. 
Calculating Brown’s gene-wide p values from GWAS results 
Brown’s gene-wide p values were provided by V. Escott-Price having been calculated 
as described in (Moskvina et al., 2011). Briefly, after excluding monomorphic SNPs, 
GWAS p values for all SNPs located within the start and stop position of each gene 
were combined into a single p value using Brown’s method for combining dependent 
tests (Brown, 1975). 
 
Calculating Simes’ gene-wide p values from GWAS results 
Gene locations were downloaded from the NCBI website for build 36.3. SNPs were 
filtered by minor allele frequency (MAF > 0.01) and INFO score (> 0.8) before all SNPs 
located within each gene’s start and stop position along with their association p 
values for SCZ and BPD from the PGC GWAS were collated. Simes’ procedure (Simes, 
1986) for multiple comparisions was applied to all SNP p values and the most 
significant one after correction was taken as the Simes’ p value.  
 
Global metrics across the foetal brain 
In their initial work Johnson et al. included covariates to control for differences 
between individuals and date of hybridisation between samples. For this analysis the 
first step was to regress out the effects of these variables. This was done using a 
linear regression model with the expression value for each gene taken as the 
dependent variable with individual and scan date the independent variables. As the 
residuals are standardised to have a mean of 0 they are unrelated to the original 
expression values, and therefore ranking genes by these values would be effectively 
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random. Hence for each sample the residuals were added to the intercept of the 
model for each gene. A similar procedure was applied to all Kang expression values 
to regress out the effects of RIN and PMI variables, consistent with the covariates 
used in their analysis.  
 
Based on Johnson et al.’s findings explained in the main text, all samples from 
neocortical regions were combined by taking the median expression value for each 
individual, separately for each hemisphere, to replace the individual neocortical 
sample values. For each gene, across all individuals, the mean and scaled mean 
(mean divided by the maximum expression value) were calculated across the 
neocortical medians and non-neocortical samples. The coefficient of variation 
(standard deviation divided by the mean) was calculated separately for each 
individual and then averaged into a single value for each gene, to remove any effects 
of individual variation. In addition, the mean, scaled mean and coefficient of 
variation were calculated as described here but for the subset of neocortical 
samples. 
 
Brain region characteristic scores 
Brain region characteristic scores were derived from a linear model controlling for 
individual, hemisphere as well as the additional confounders specific to each dataset, 
shown in Equation 2.1.  
 
expijk =  individuali +  hemispherek +  confounderijk + brainregionjl 
Equation 2.1 Regression model used to calculate characteristic scores for brain region l, where exp ijk is 
the gene expression value for individual i, in brain region j and hemisphere k, and brainregionjl is a 
binary variable denoting whether that sample came from the brain region l or not i.e. are brain 
regions j and l the same. 
 
In the Johnson dataset an additional covariate was included for hybridisation date, 
whereas for the Kang microarray data the additional covariates included were RIN 
and PMI. The model was fitted separately for each brain region, for each gene across 
all samples. The brain region term was a binary variable indicating whether the 
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expression value was taken from the brain region in question or not. Three samples 
from three individuals were excluded from the model fitting as the hemisphere was 
denoted NA. The characteristic p value was taken as the p value for the binary brain 
region term in the model. A characteristic score was defined for each gene as the –
log10(characteristic p value) for the brain region term multiplied by the sign of the 
coefficient associated with the same term.  
 
For regional characteristic scores found to be associated with either SCZ or BPD 
gene-wide p values, combined characteristic scores were calculated across the 
Johnson and Kang datasets. This used the model in Equation 2.1 and included 
hemisphere and individual covariates. There was no need to include a study 
covariate, as the individual term absorbed these differences.  In addition the extra 
confounders were excluded, as these were not the same across the two datasets. 
 
Alternative splicing - FIRMA 
The FIRMA algorithm was used to identify alternative splicing (Purdom et al., 2008). 
This method was implemented in R as part of the aroma.affymetrix package 
(Bengtsson et al., 2008), following an online vignette provided by the authors 
(http://www.aroma-project.org/vignettes/FIRMA-HumanExonArrayAnalysis), to each 
individual separately as there was no option to include potential confounders.  
 
After generating the FIRMA scores, the authors have proposed using the limma 
package (Smyth, 2005) in R, to fit a linear model and consider F–statistics to see if 
any tissue type, in this case brain region, has a non-zero coefficient. The p values for 
each exon and individual were combined into an overall global splicing p value by 
selecting the best one after Simes’ correction. To calculate brain region splicing p 
values, the FIRMA scores from each brain region were compared to all others with a 
linear model and combined as described for the global splicing p values. Genes with 
only one exon were removed, as were genes lowly expressed prior to testing for 
associations with either SCZ or BPD variants. 
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Testing for enrichment with gene-wide p values 
Mean expression, scaled mean expression, coefficient of variation, brain region 
characteristic scores and FIRMA gene level logP were tested in separate models with 
the PGC gene-wide logP. This was done for all four combinations of disease (SCZ and 
BPD) and summarised p value (Brown’s and Simes’). Some of the SCZ Brown’s p 
values had a value of 0 and could not be log transformed so were excluded from this 
analysis. 
 
Nonparametric Mann-Whitney tests were used for validation of any significant 
regression results. Genes were ranked by mean expression, scaled mean expression, 
coefficient of variation and splicing p values separately and the top 5, 10,…, 50% was 
tested against the bottom 50% in a one-tailed test for smaller gene-wide p values. 
For regional characteristic scores found to be associated with either SCZ or BPD 
across both datasets, genes were ranked by the absolute values of the score and the 
top 5,10,…,50% taken. Each set of genes was then separated based on the sign of the 
characteristic score into two subgroups. If the characteristic score was positive, the 
genes detected had increased expression in that brain region relative to the average 
of all other brain regions. Alternatively if the score was negative the genes had 
decreased expression relative to the other brain regions. Depending on the 
coefficient of the significant regression model the appropriate subset was tested 
with a one sided Mann-Whitney test for smaller gene-wide p values against genes 
ranked in the bottom 50% by absolute characteristic score. 
 
Overlap of significantly associated regions across datasets 
Brain regions not present in both the Johnson and Kang datasets were removed for 
this analysis leaving 12: DLPFC, MPFC, OPFC, VLPFC, TAU, TAS, PAS, OCC, HIP, THAL, 
CBL and STR. Separately for each dataset the sample labels, containing region, 
individual and hemisphere information, were permuted 1000 times and the 
characteristic regression model in Equation 2.1 fitted for each region. Characteristic 
scores were calculated as for the true data and tested with a linear regression model 
predicting SCZ and BPD Brown’s logP for each brain region.  
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Empirical p values were calculated for each dataset by counting how many times in 
the 1000 permuted datasets, the same number or more, significant models occurred 
(p < 0.01). All pairs of permutations (106 in total) were then considered and the 
number of regions significant in both datasets and in the same direction was 
counted so that empirical p values could be calculated. In addition, the number of 
regions significant for both SCZ and BPD, in the same direction across both datasets, 
was also counted. 
 
CNV logistic regression 
CNVs from the ISC (International Schizophrenia Consortium, 2008) and MGS 
(Levinson et al., 2011) study were provided annotated with the genes hit by each by 
A. Pocklington based on builds 35.1 and 36.3 respectively. For each CNV the 
corresponding global metrics, characteristic scores and –log 10 FIRMA gene-level 
splicing p values for each gene hit were taken, and the minimum, median and 
maximum identified. Only CNVs that hit genes found in the expression datasets were 
used for these analyses. In order to test for a significant difference in each of these 
metrics the following logistic regression model was fitted across the combined set of 
CNVs from the ISC and MGS. The p value was taken from the M(genes hit) term and 
the coefficient considered to identify the direction of any associations. Separate 
models were fitted for all CNVs in addition to the deletions and duplications subsets.  
 
 
case CNV = M(genes hit) +  N + study + chip 
Equation 2.2 Logistic regression model to test if genes hit by SCZ CNVs have common characteristic 
profile, where case CNV is the case status of the individual the CNV was found in, M(genes hit) is 
either the minimum, median or maximum metric of the genes hit and N is the number of genes in the 
expression dataset hit by the CNV. 
Each SCZ CNV was compared to all control CNVs in the ISC and MGS datasets to see if 
there was any overlap with any control CNV or was unique to SCZ cases. Those that 
did not overlap with any control CNV were classed as singletons. These singleton 
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CNVs were then compared to all remaining SCZ CNVs with a logistic regression model 
defined as follows. 
 
singleton CNV = M(genes hit) +  N + study + chip 
Equation 2.3 Logistic regression model to test if genes hit by singleton SCZ CNVs have common 
characteristic profile, where singleton CNV denotes whether the CNV was singleton or not, M(genes 
hit) is either the minimum, median or maximum metric of the genes hit and N is the number of genes 
in the expression dataset hit by the CNV. 
 
As with the previous CNV logistic regression model, the p value was taken from the 
M(genes hit) term and the coefficient considered to identify the direction of any 
associations. This model was fitted for all CNVs, as well as deletions and duplications 
separately. 
 
Functional analysis 
Using the HIP and THAL combined characteristic scores (those calculated across both 
the Kang and Johnson datasets) functional pathways from the GO database were 
tested to identify those with genes with decreased expression in either the HIP or 
THAL. A file containing annotation categories and their associated genes was 
provided by P. Holmans. Each annotation term was tested with a one-sided Mann-
Whitney test to see if genes within that category had lower HIP or THAL 
characteristic scores than genes not in the category. Only genes annotated to at least 
one GO term and terms with between 20 and 2000 genes were considered in these 
Mann-Whitney tests. 
 
Significant terms identified from a Bonferroni corrected p value of 1.56 x 10-5 were 
combined into groups of related terms, to identify the predominant functions 
represented. In each set the smallest pathway was selected and all other pathways 
with any overlapping genes identified. The Mann-Whitney test was rerun for each of 
the larger pathways, removing any genes that overlapped with the smaller pathway 
to see if it remained significant (p < 0.01). If it did not, the smaller pathway was said 
to explain the larger pathway. All explained larger pathways were combined with the 
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smaller pathway they were explained by into a merged pathway and the process was 
repeated until no more pathways could be explained.  
 
Set-based tests 
Genes with decreased expression in the top 35% of HIP and THAL characteristic 
genes were identified as the most significantly enriched sets from the Mann-Whitney 
tests in Figure 2.9 for both SCZ and BPD Brown’s p values. Each set was split into two 
groups, those that overlapped with a significant GO pathway found with that 
characteristic score and those that did not. For both subsets, in pathways and not in 
pathways, set-based p values were calculated. In addition each group of terms in 
Figures 2.6 and 2.7 had a set-based p value calculated for genes that intersected 
with either the top HIP or THAL enriched sets. 
 
GWAS results from PGC SCZ and BPD were filtered to remove SNPs with MAF less 
than 0.01, INFO score less than 0.8 and all SNPs in the MHC region (chr6:25000000-
35000000). All remaining genic SNP p values were corrected for genomic inflation. 
Set-based p values were calculated from these corrected p values using the 
undocumented –set-screen command in PLINK (Brown, 1975, Purcell et al., 2007, 
Moskvina et al., 2011). HapMap genotype data release 23 for Europeans only were 
downloaded (http://hapmap.ncbi.nlm.nih.gov/) and used for the LD statistics 
involved in the calculation.  
 
Simulations for set-based tests 
After observing a correlation between set p value and the number of SNPs in each 
set, simulations were used to adjust the set p values. Simulated sets with between 
20 and 3000 random genes were created and a set-based p value calculated for 
each. A regression model was then fitted to predict the set log p value from the 
number of SNPs. Using this relationship, for each true set the predicted log p value 
was calculated and subtracted from the true log p value. If the residual was positive 
i.e. the true p value was more significant than the predicted p value then the residual 
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was unlogged to derive the adjusted p value.  A separate set of simulations and 
adjustment formula was performed for the PGC SCZ and the PGC BPD. 
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Chapter 3: Expression patterns of schizophrenia and 
bipolar disorder risk genes throughout human brain 
development 
3.1 Introduction 
3.1.1 Background 
The human brain continues to develop throughout postnatal life (Stiles and Jernigan, 
2010). During early years the brain rapidly increases in volume (Dobbing and Sands, 
1973, Matsuzawa et al., 2001, Knickmeyer et al., 2008), while synaptogenesis and 
pruning modify connectivity throughout the first two decades of life (Glantz et al., 
2007). Therefore, as the brain is still developing through the period of onset for SCZ 
and BPD in adolescence or early adulthood it is reasonable to look at expression 
across these stages in addition to the earliest stages of brain development.   
 
Kang et al. conducted a study covering the full range of brain development including 
foetal post-mortem brains and found 86% of genes surveyed were expressed in at 
least one region in one of their defined development stages (Kang et al., 2011). 
Almost 90% of these expressed genes were differentially expressed across 
development stages with the major differences occurring between foetal stages and 
either postnatal or adult stages. An accompanying study, based on more individuals 
but with just one prefrontal cortex sample per individual, showed that the highest 
rates of change in expression occurred during foetal development (Colantuoni et al., 
2011).  
 
Results from Chapter 2 found that genes enriched for either SCZ or BPD common 
variants were highly expressed in the mid-foetal brain. Visual inspection of the 
median expression of these genes across development showed a variable profile 
with peak expression values during the second trimester and a drop in expression 
during the third trimester. In this chapter a more formal analysis was conducted to 
see if genes associated with either SCZ or BPD were enriched in sets of genes with 
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common developmental expression profiles. The findings in the previous chapter 
suggest that SNPs contribute to prenatal expression, however in this chapter all 
stages across the full range of human life were considered to see if they also 
contributed to the expression patterns in other stages of development such as 
adolescence. 
 
3.1.2 Outline 
Aim 
In this chapter, genes with variable profiles across the full range of human brain 
development were tested for enrichment of SCZ or BPD risk genes, in order to 
characterise a developmental expression profile. Results from Chapter 2 suggest that 
expression patterns during prenatal stages will be important for SCZ and BPD. Both 
SCZ and BPD present symptoms around adolescence coinciding with the maturation 
of brain structures, such as the prefrontal cortex, associated with the executive 
functions that are commonly impaired in SCZ (Orellana and Slachevsky, 2013) 
therefore differences at this time point would also be of interest.  
 
Datasets 
BrainSpan: Atlas of Developing Human Brain (http://www.brainspan.org) is a 
publically available internet resource providing RNA-Seq expression data to enable 
studies of the developing brain transcriptome. This resource contains gene 
expression data on 41 individuals from 8 PCW to 41 years with up to 16 different 
brain regions for each individual. Microarray expression data taken from the Kang et 
al. study introduced in the previous chapter were also used. This dataset provided 
expression values for multiple brain regions, from both hemispheres, for 57 
individuals from embryonic to late adulthood (Kang et al., 2011). Almost all of the 
BrainSpan individuals were also present in the Kang dataset; therefore this was used 
for technical not biological replication.  
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RNA-Seq data are generated through the direct sequencing of transcripts. The 
resulting data are more reliable and accurate than that of microarrays, which suffer 
from cross hybridisation and are limited to detecting the transcripts represented on 
the chip (Wang et al., 2009). In both datasets individuals were classified into 15 
development stages from embryonic to late adulthood as defined in the original 
Kang et al. manuscript, shown in Table 3.1. No individuals in the BrainSpan data were 
part of the embryonic, middle adulthood or late adulthood stages.  
 
Development stage Time period Development stage Time period 
Embryonic [4 pcw, 8 pcw) 
Neonatal and early 
infancy 
[birth, 6 mon) 
Early foetal A [8 pcw, 10 pcw) Late infancy [6 mon, 12 mon) 
Early foetal B [10 pcw, 13 pcw) Early childhood [12 mon, 6 yr) 
Early mid-foetal A [13 pcw, 16 pcw) 
Middle and late 
childhood 
[6 yr, 12 yr) 
Early mid-foetal B [16 pcw, 19 pcw) Adolescence [12 yr, 20 yr) 
Late mid-foetal [19 pcw, 24 pcw) Young adulthood [20 yr, 40 yr) 
Late foetal [24 pcw, 38 pcw) Middle adulthood [40 yr, 60 yr) 
  Late adulthood [60 yr, ] 
Table 3.1: Development stages as defined by Kang et al. 
pcw – post conception weeks, mon – months, yr- years. 
 
GWAS data from the SCZ and BPD PGC studies (Ripke et al., 2011, Sklar et al., 2011), 
summarised as described in Chapter 2 into Brown’s and Simes’ gene-wide p values, 
were also used in this chapter to test for associations. In addition, GWAS data from 
similar large studies for Alzheimer’s disease (Harold et al., 2009), and Parkinson’s 
disease (UK sample from (Nalls et al., 2011)) were combined into gene-wide p values 
using Brown’s method by V.Escott-Price and permission given for use. All 
summarised p values were -log10 transformed and shall be referred to as logP. CNV 
data from the ISC (International Schizophrenia Consortium, 2008) and MGS 
(Levinson et al., 2011) studies were also included as an alternative type of variant, to 
test for enrichment in a manner similar to that of the previous chapter.  
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Outline of analysis 
Temporal expression patterns were quantified using regression in a similar fashion to 
the brain region analysis of Chapter 2. Characteristic scores for each gene in each 
development stage were derived from linear models, to indicate whether genes 
were upregulated or downregulated during each period. These were tested for 
relationships with SCZ and BPD gene-wide logP and genes hit by SCZ CNVs. 
 
One unifying explanation of the polygenic nature of SCZ or BPD whereby many 
variants that only slightly increase an individual’s risk of SCZ or BPD are distributed 
across both genes and the genome, is that these variants work in combination and 
affect common pathways or mechanisms (Sullivan, 2012). In order, therefore, to 
have a noticeable influence it would be expected that risk genes would be co-
expressed. This was tested by taking genes highly co-expressed with risk genes 
identified from the PGC GWAS, the most powerful study and therefore most likely to 
be true associations, to investigate if they were enriched for association signal. If 
enrichment was found in the co-expressed gene sets their developmental profile 
could be looked at and results compared with that of the previous analysis of 
development stage characteristic genes, ideally looking for a convergent profile. 
 
All these methods were performed initially in the BrainSpan RNA-Seq dataset and 
followed up in the Kang microarray dataset. Both parametric and nonparametric 
tests were used to validate results. Functional analysis was then performed on genes 
enriched for SCZ or BPD variants to elucidate potential mechanisms and interpret 
these results. 
 
3.2 Results 
3.2.1 Development stage characteristic gene expression and common risk variants 
In Chapter 2, genes with expression characteristic of each brain region in the foetal 
brain were identified. In this chapter a very similar approach was used in the 
BrainSpan RNA-Seq dataset to identify genes with an increase or decrease of 
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expression during each development stage described in Table 3.1, relative to all 
other time points. Here characteristic scores, defined in the same way as the 
previous chapter, were taken from a linear model with a binary development stage 
term and an additional covariate controlling for brain region differences.  
 
For each development stage, a linear regression model was used to test for a 
significant association between its characteristic scores and Brown’s logP. Figure 3.1 
panel A shows these results, where positive relationships indicating upregulation are 
represented by bars above the origin and negative relationships indicating 
downregulation are represented by bars below the origin. There was a clear pattern 
to these results, which broadly suggests that SCZ risk genes are upregulated in early 
and mid-foetal stages after which their expression levels decrease until early 
childhood during which they are downregulated. Nine of the twelve stages had 
significant linear relationships with SCZ Brown’s logP after correcting for testing 
twelve models. In particular the most significant enrichments were found in genes 
characteristic of early childhood (corrected p = 1.55 x 10-15) and early mid-foetal A 
(corrected p = 9.36 x 10-9). When testing BPD Brown’s logP, the directions of effect 
were consistent with the results for SCZ for ten stages, overall showing a parallel 
pattern of results, although less significantly. Only two stages were significant after 
correcting the number of development stages tested, both of which were also 
significantly associated with smaller SCZ p values.  As in Chapter 2, the correlation 
coefficients associated with these significant relationships were small, all absolute 
values < 0.07; see Appendix Table 8.1. Generally these were larger for SCZ logP than 
BPD logP consistent with the higher number of significant developmental stages. 
 
The same pattern of enrichment was seen across all stages when testing SCZ Simes’ 
logP instead of Brown’s logP, see Figure 3.1 panel B. For SCZ seven stages had 
significant regression models, all of which were significant with the Brown’s logP in 
the same direction. Early childhood (corrected p = 1.49 x 10-7) and early mid-foetal A 
(corrected p = 1.36 x 10-7) were again the most significant stages. For BPD although 
no regression models were significant after correcting for twelve development 
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stages, the directions of effect were consistent with the SCZ results and supported 
the pattern described.  
 
Figure 3.1: Linear regression results testing development stage characteristic scores calculated in the 
BrainSpan RNA-Seq dataset. 
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above 
the origin indicate positive regression coefficients; bars below the origin indicate negative regression 
coefficients. Panel A tested Brown’s logP; panel B tested Simes’ logP. All p values were corrected for 
12 development stages using Bonferroni’s method. Black dashed line is p = 0.05. 
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As in Chapter 2 rank-based tests were used to verify the associations reported 
between characteristic scores and gene-wide p values with a regression approach. 
Mann-Whitney tests showed that genes with increased expression during foetal 
development and genes with decreased expression in postnatal stages were 
enriched for smaller gene-wide p values; see Appendix Figures 8.1 and 8.2. All 
significant regression models in Figure 3.1 were verified and shown not to be due to 
extreme values, supporting the results profile already described.  
 
As in the previous chapter these analyses were repeated removing genes located in 
the MHC. While this reduced the significance of some of the linear regression 
models, the overall results profile remained. The impact on the Mann-Whitney tests 
was minimal and hence it can be concluded that this results pattern was not due to 
the correlated association of genes in the MHC, results presented in Appendix 
Figures 8.3-8.5. 
 
Comparison with other disorders 
The above analyses suggest that SCZ risk genes have a variable profile across brain 
development with increased expression during mid-foetal stages and decreased 
expression from birth. Findings with BPD p values were only nominally significant but 
consistent with this profile. In this section other psychiatric disorders were tested to 
assess whether the association of a developmental expression profile was specific to 
SCZ and BPD. Parkinson’s disease and Alzheimer’s disease are adult 
neurodegenerative disorders with onset much later than SCZ and BPD, rarely 
occurring before 50 for Parkinson’s (de Lau and Breteler, 2006) or 65 for Alzheimer’s 
disease (Reitz et al., 2011), therefore Brown’s p values for these diseases were used 
as negative controls.  
 
No significant results were observed for Parkinson’s Brown’s logP, shown in Figure 
3.1 panel A. Initially Alzheimer’s disease Brown’s logP were associated with genes 
with increased expression during early childhood (corrected p = 6.93 x 10-7), 
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although this was not validated with the Mann-Whitney tests. Further investigation 
found that the regression signal was biased by two highly significant Brown’s logP for 
APOE and APOC1. When these genes were removed from the analysis there were no 
significant enrichments for Alzheimer’s disease logP. This advocates the use of both 
parametric and nonparametric approaches to verify that associations were not due 
to extreme values.  
 
Technical validation with microarray data 
Characteristic scores were also calculated for each development stage in the Kang 
microarray dataset from linear models that included extra covariates for 
hemisphere, PMI and RIN. Figure 3.2 presents the results of testing for enrichment 
with these characteristic scores. These results showed that genes with smaller SCZ 
Brown’s p values were upregulated in early foetal development and downregulated 
during early childhood, consistent with the results in the RNA-Seq dataset. Results 
with BPD Brown’s p values were consistent with risk genes being downregulated 
during middle and late childhood. In contrast to Figure 3.1, genes upregulated during 
adolescence and young adulthood were enriched for more significant SCZ p values 
which was opposite to the direction of effect reported in the RNA-Seq dataset. 
Therefore, although the microarray data during early foetal B and childhood was 
coherent with the results described in the RNA-Seq dataset, the results profile across 
the development stages was not technically validated across the two datasets. 
 
Results testing Simes’ p values in Figure 3.2 panel B were broadly consistent with 
downregulation during early childhood for SCZ risk genes. Interestingly, early mid-
foetal B characteristic scores were positively associated with Simes’ SCZ logP rather 
than early foetal B which were associated with Brown’s SCZ p values. Although there 
was no association with young adulthood scores, there was an enrichment in genes 
with decreased expression during late adulthood.  BPD Simes’ p values were also 
associated with genes downregulated during late childhood consistent with that 
found with Brown’s p values. Mann-Whitney tests with both Brown’s and Simes’ p 
values verified most of these findings; see Appendix Figures 8.6 and 8.7.  
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Figure 3.2: Linear regression results testing development stage characteristic scores calculated in 
Kang microarray dataset.  
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above 
the origin indicate positive regression coefficients; bars below the origin indicate negative regression 
coefficients.  Panel A tested Brown’s logP; panel B tested Simes’ logP. All p values were corrected for 
15 development stages using Bonferroni’s method. Black dashed line is p = 0.05. 
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Figure 3.3: Linear regression results testing development stage characteristic scores calculated in 
Kang microarray dataset, excluding MHC genes.  
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above 
the origin indicate positive regression coefficients; bars below the origin indicate negative regression 
coefficients. Analysis was run excluding MHC genes. Panel A tested Brown’s logP; panel B tested 
Simes’ logP. All p values were corrected for 15 development stages using Bonferroni’s method. Black 
dashed line is p = 0.05. 
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Removing genes from the MHC region produced a similar profile of results, however 
genes with increased expression in foetal development or decreased expression 
during early postnatal years were no longer significantly enriched for SCZ Brown’s 
logP, see panel A of Figure 3.3. There was, however, still enrichment for BPD Brown’s 
logP in genes with decreased expression during late childhood. Further, there was 
still an enrichment for more significant SCZ Simes’ p values in genes with increased 
expression during mid-foetal development, see panel B of Figure 3.3. Mann-Whitney 
tests broadly supported the significant associations in Figure 3.3; see Appendix 
Figures 8.8 and 8.9. Therefore in this dataset, the MHC genes appear to be having a 
greater effect on the results. 
 
Effect of post-mortem interval covariate 
Two potential confounders associated with the quality of the post-mortem brain 
samples were included when calculating the characteristic scores. One of these, PMI 
was observed to correlate with the age of the sample, and therefore may have been 
removing some of the temporal effects the characteristic scores were designed to 
capture. To examine the impact of this, characteristic scores were recalculated 
omitting this variable and tested as previously described. 
 
Excluding the PMI variable produced a results profile more in line with that found in 
the RNA-Seq dataset, see Figure 3.4. Genes upregulated during early and mid-foetal 
development and genes downregulated in early postnatal years were enriched for 
smaller SCZ Brown’s p values. The results testing BPD p values were consistent with 
this profile, as were results testing Simes’ logP. Again, the correlation coefficients, 
shown in Appendix Table 8.5 were small, all absolute values < 0.05, suggesting that 
these expression patterns are not true for all risk genes. Rank-based tests verified all 
significant regression models; Appendix Figures 8.10 and 8.11. Therefore, the PMI 
covariate does appear to absorbing some of the temporal expression profile. 
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Figure 3.4: Linear regression results testing development stage characteristic scores calculated in 
Kang microarray dataset without PMI covariate. 
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above 
the origin indicate positive regression coefficients; bars below the origin indicate negative regression 
coefficients. Panel A tested Brown’s logP; panel B tested Simes’ logP. All p values were corrected for 
15 development stages using Bonferroni’s method. Black dashed line is p = 0.05. 
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Removing genes located in the MHC region did reduce the significance of some of 
the regression models, but the same broad pattern was present indicating that 
genes outside of the MHC region associated to SCZ had increased expression in mid-
foetal stages and decreased expression after birth, presented in Appendix Figure 
8.12. These associations without the MHC genes were also verified with Mann-
Whitney tests, see Appendix Figures 8.13 and 8.14. 
 
These results do suggest that the PMI covariate was removing some of the temporal 
effects, however it was not possible to disentangle whether the temporal expression 
profiles enriched for SCZ variants were genuine or due to the differences in PMI 
between the samples.  
 
Test for independent associations 
So far each characteristic profile has been considered separately and a general 
pattern of results has been found, where genes with increased expression during 
early and mid-foetal development, and genes with decreased expression in postnatal 
stages were associated with SCZ common variants. As characteristic scores were 
calculated relative to the expression in all other stages, they were to some degree 
correlated; therefore the reported associations may be correlated also. In the RNA-
Seq dataset the strongest enrichment was found with early childhood scores 
(uncorrected p = 1.29 x 10-16). The eight other significant stages were tested in a 
pairwise manner alongside the early childhood scores to see whether both scores 
remained significant and the associations were independent. 
 
Table 3.2 shows that in almost all models (each one represented by a row) the early 
childhood scores remained highly significant whereas the paired characteristic scores 
did not. The exception was late foetal, which also remained significant. This showed 
that the associations demonstrated in Figure 3.1 generally were not independent, 
and were detecting enrichment in similar sets of genes which had increased 
expression through foetal development followed by a decrease through birth and 
early postnatal years to the lowest expression values in early childhood. 
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Development stage 
Development stage Early childhood  
P value Coeff. P value Coeff. 
Early foetal B 0.569 - 1.66 x 10-13 - 
Early mid-foetal A 0.179 + 1.22 x 10-8 - 
Early mid-foetal B 0.359 + 3.56 x 10-10 - 
Late mid-foetal 0.329 + 3.79 x 10-13 - 
Late foetal 0.00206 - 7. 36 x 10-16 - 
Late infancy 0.189 + 1.90 x 10-13 - 
Late childhood 0.114 - 6.57 x 10-12 - 
Adolescence 0.749 - 8.82 x 10-13 - 
Table 3.2: Linear regression results testing development stage characteristic scores calculated in the 
BrainSpan RNA-Seq dataset simultaneously predicting SCZ Brown’s logP.  
Each row represents a separate regression model. 
 
In the Kang microarray dataset, the most significant stage was young adulthood 
(uncorrected p = 6.13 x 10-5) so all other significant stages were tested 
simultaneously with this stage to predict SCZ Brown’s logP. Interestingly, and in 
contrast to the RNA-Seq results, all stages remained significant implying that these 
were independent associations, Table 3.3. 
 
 
Development stage Young adulthood 
P value Coeff. P value Coeff. 
Early foetal B 7.08 x 10-5 + 9.81 x 10-6 + 
Early childhood 0.000347 - 5.57 x 10-5 + 
Late adulthood 2.05 x 10-6 - 3.12 x 10-7 + 
Table 3.3: Linear regression results testing development stage characteristic scores calculated in Kang 
microarray dataset simultaneously predicting SCZ Brown’s logP.  
Each row represents a separate regression model. 
 
 
Development stage Early mid-foetal B 
P value Coeff. P value Coeff. 
Early foetal B 0.117 + 0.000385 + 
Early mid-foetal A 0.183 + 0.000527 + 
Early infancy 0.0763 - 9.55 x 10-6 + 
Late infancy 0.0328 - 0.00286 + 
Early childhood 0.00205 - 6.77 x 10-7 + 
Middle adulthood 0.368 - 0.00234 + 
Table 3.4: Linear regression results testing development stage characteristic scores calculated in Kang 
microarray dataset without PMI covariate simultaneously predicting SCZ Brown’s logP.  
Each row represents a separate regression model. 
108 
 
These pairwise analyses were also done with the microarray characteristic scores 
calculated without the PMI covariate, where the most significantly associated stage 
was early mid-foetal B (uncorrected p = 2.39 x 10-7). Most stages, see Table 3.4, were 
not significant after controlling for the early mid-foetal association implying that 
many of these associations were not entirely independent.  
 
Summary 
Genes with increased expression during mid-foetal development and decreased 
expression around birth and in postnatal stages were shown to be enriched for 
common SCZ risk variants.  This was primarily found in the RNA-Seq dataset and 
verified with both parametric and nonparametric tests. When these analyses were 
repeated in a microarray dataset containing overlapping individuals, although the 
number of significant stages was less, those that were significant were consistent 
with the results profile for SCZ risk genes described in the RNA-Seq dataset. The lack 
of complete coherence between the RNA-Seq and microarray datasets was in part 
due to the inclusion of the PMI covariate, which was observed to correlate with the 
age of the sample. Removing this covariate produced a results profile more similar to 
that found with the RNA-Seq data. In addition, microarray data have reduced 
sensitivity and are not able to detect the small differences that RNA-Seq data can, 
which may also have contributed to the more significant results in the RNA-Seq 
dataset. 
 
The association of each set of characteristic scores in the RNA-Seq dataset or 
microarray dataset without the PMI covariate was not completely independent and 
suggests that a common set of genes underlie the significant results pattern. 
Generally only nominally significant results were found when testing BPD p values 
but these were consistent with the pattern seen with SCZ p values, whereas no 
significant associations were found for either Alzheimer’s disease or Parkinson’s 
disease. Therefore, SCZ risk genes have been shown to have a common variable 
expression profile across brain development.  
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3.2.2 Schizophrenia risk genes co-expression models 
So far specific expression profiles across brain development have been identified and 
enrichments found for SCZ associated genes. In this section genes co-expressed with 
known SCZ risk genes were identified to see if they were enriched for disease risk.  
 
Ten independent genome-wide significant SNPs were reported in the PGC 
manuscript across the two stages of the study, with the nearest gene for each 
identified (Ripke et al., 2011). These genes were chosen as having the strongest 
current evidence as they were identified in the largest published GWAS for SCZ to 
date. Of these TRIM26 is located in the MHC region and was excluded from 
consideration (and eventual analyses) as it is unclear where the true association in 
this region is. Two genes, PCGEM1 and MIR137, were not present in the BrainSpan 
dataset leaving seven genes to be considered: CSMD1, CNNM2, NT5C2, TCF4, 
CCDC68, MMP16 and STT3A. 
 
Genes co-expressed with schizophrenia risk genes 
Taking the expression profile for each of these genes across brain development, a 
linear regression framework was used to compare the expression of all remaining 
genes in the dataset. P values were calculated for all genes in the dataset, excluding 
those considered for the co-expression model, indicating how closely their 
expression profile correlated across development with the expression of each risk 
gene, further details in the Methods. These co-expression p values, referred to as 
model p values, were then used to test for association with the Brown’s logP. 
 
Genes whose expression correlated with either CNNM2 (p = 1.27 x 10-6), NT5C2 (p = 
1.58 x 10-6), MMP16 (p = 0.0104) or TCF4 (p = 5.71 x 10-5) were enriched for SCZ 
associated common variants, while the CSMD1 model logP showed a trend for 
significance (p = 0.0643), results in Table 3.5. Only CCDC68 had a negative 
coefficient. Similar to all previous analyses with gene-wide logP the correlation 
coefficients were small. Nonparametric tests were then used to verify these 
associations, see Figure 3.4. CNNM2, CSMD1, TCF4, NT5C2 and MMP16 all showed 
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evidence of enrichment with this approach that was not driven by extreme values, 
while STT3A did not. In sum, five of the seven genes considered at this stage were 
enriched for SCZ risk supportive of the idea that genes harbouring associated 
variants are co-expressed. 
 
Gene Model CSMD1 CNNM2 NT5C2 CCDC68 
P value 0.0643 1.27 x 10-6 1.58 x 10-6 0.139 
Correlation 
Coeff. 
0.0164 0.0430 0.0426 -0.0132 
+ + + - 
Gene Model MMP16 TCF4 STT3A 
P value 0.0104 5.71 x 10-5 0.276 
Correlation 
Coeff. 
0.0227 0.0357 0.00968 
+ + + 
Table 3.5: Linear regression results and correlation coefficients testing single SCZ risk gene co-
expression model logP calculated in the BrainSpan RNA-Seq dataset with SCZ Brown’s logP.  
 
Figure 3.5: Results from Mann-Whitney tests for genes ranked by single SCZ risk gene co-expression 
model p values calculated in the BrainSpan RNA-Seq dataset. 
Genes ranked by SCZ single risk gene co-expression model p values and top n% tested for smaller SCZ 
Brown’s p values against bottom 50%. Black dashed line is p = 0.05. 
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Identifying alternative genes 
Typically, the gene located closest to each associated SNP is assumed to be the most 
functionally relevant, however this may not always be the case. Taking the two 
genes for which co-expression did not index disease association (CCDC68 and 
STT3A), additional proximal genes to the SNP associated in PGC study were tested to 
see if they showed evidence for a correlation between co-expression and SCZ 
association. SNPs in strong LD with those reported in the PGC paper were identified 
using the data from HapMap phases 1, 2 & 3. 
 
For CCDC68, a region was taken ~350 kb either side of rs12966547 to include the two 
neighbouring genes RAB27B and TCF4. Five SNPs were found to be in perfect LD (r2 = 
1, D’ = 1) with the genome-wide significant SNP. Three of these were found closest 
to CCDC68 (rs4131791, rs4309482, rs12969453) and the other two approximately 
halfway (>100 kb) between CCDC68 and TCF4 (rs11874716, rs4891131) for which co-
expression had already been shown to index SCZ association, see Table 3.4. If risk 
enrichment of co-expressed genes was used as a measure of SCZ relevance, then it 
would predict that the association at rs12966547 is most likely through TCF4. 
 
For STT3A, a region of 100kb on chromosome 11 containing EI24 and CHEK1 around 
rs548181 was taken. In this region five SNPs were found in perfect LD, three of which 
were closest to or within STT3A (rs503288, rs513209, rs540723), and the remaining 
two found in CHEK1 (rs540436, rs569766). Genes co-expressed with CHEK1 were 
identified using the method described but these were not associated with SCZ 
association (p = 0.916; r = -0.000942). 
 
Co-expression with multiple schizophrenia risk genes 
In this section the co-expression model was extended to investigate if identifying co-
expression with multiple risk genes was a more significant predictor of association 
signal. A combined model based on the genes whose expression pattern successfully 
predicted SCZ association should reduce any noise present assuming there is a 
consistent expression pattern amongst these risk genes.  
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P values were obtained for all genes as a measure of their co-expression with 
CNNM2, CSMD1, MMP16, NT5C2 and TCF4. A significant positive relationship (p = 
1.06 x 10-7) between SCZ Brown’s logP and model logP was found that was more 
significant and had a larger correlation coefficient than identifying co-expressed 
genes using any gene individually (compare Table 3.6 with Table 3.5). Similarly the 
nonparametric test results were all highly significant with the best p-value when 
testing the top 25% (p = 9.30 x 10-13) see Appendix Figure 8.15 panel A.  
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
P value 1.06 x 10-7 3.92 x 10-5 0.00522 0.00104 
Correlation Coeff. 
0.0472 0.0378 0.0243 0.0302 
+ + + + 
Excluding MHC genes 
P value 7.41 x 10-9 2.82 x 10-7 0.00252 0.000512 
Correlation Coeff. 
0.0516 0.0476 0.0264 0.0322 
+ + + + 
Table 3.6: Linear regression results and correlation coefficients testing SCZ risk genes co-expression 
model logP across development calculated in the BrainSpan RNA-Seq dataset with gene-wide logP. 
Based on co-expression model with CNNM2, CSDM1, MMP16, NT5C2 and TCF4. 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
P value 1.29 x 10-6 0.000126 0.00922 0.00273 
Correlation Coeff. 
0.0430 0.0353 0.0226 0.0276 
+ + + + 
Excluding MHC genes 
P value 1.23 x 10-7 1.89 x 10-6 0.00458 0.0014 
Correlation Coeff. 
0.0472 0.0441 0.0248 0.0296 
+ + + + 
Table 3.7: Linear regression results and correlation coefficients testing SCZ risk genes co-expression 
model logP across brain regions calculated in the BrainSpan RNA-Seq dataset with gene-wide logP. 
Based on co-expression model with CNNM2, CSDM1, MMP16, NT5C2 and TCF4. 
This association test was also rerun removing genes in the MHC, Table 3.6 and 
Appendix Figure 8.15. The associations were marginally stronger (regression p = 7.41 
x 10-9; Mann-Whitney p = 9.33 x 10-14 top 25%), so genes within this region were not 
driving this result. An association was also found between BPD Brown’s logP and the 
SCZ model logP. This was both with (p = 0.00522) and without the MHC genes (p = 
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0.00252). The SCZ model p values were also correlated with the Simes’ logP for SCZ 
and BPD, a result that withstood removing the MHC genes. 
 
Variation across brain regions 
The models used so far have looked at temporal co-expression but due to the nature 
of this dataset spatial co-expression could also be investigated, using a similar 
regression framework to try to identify which is most relevant for capturing SCZ 
association. Regression analysis found a slightly weaker enrichment (p = 1.29 x 10-6) 
with a smaller correlation coefficient than when correlating across development, 
results presented in Table 3.7, that was verified with rank-based tests shown in 
Appendix Figure 8.15. This model was also enriched for BPD p values (p = 0.00922), 
and was also significant with Simes’ logP (SCZ p = 0.000126; BPD p = 0.00273). 
Further, all models remained significant after removing genes from the MHC.   
 
When fitting a regression model to predict SCZ Brown’s logP with the model logP 
measuring co-expression across development and co-expression across brain regions 
simultaneously, both terms were a lot less significant but the model across 
development remained just significant (p = 0.0201), whereas the model across brain 
regions did not (p = 0.445). Both models appear to be capturing very similar sets of 
genes that were co-regulated across development stages and brain regions. 
Therefore, only variation across development will be considered further in this 
section. 
 
Comparison of results with Section 3.2.1 
In order to see if these results converged with those in Section 3.2.1 where 
development stage characteristic scores were tested for association with gene-wide 
p values, the characteristic scores of genes identified from the SCZ co-expression 
model were examined.  The set of genes most enriched for SCZ association was 
identified as the top 25% from Appendix Figure 8.15 panel A and the median 
development stage characteristic scores for this set of genes were plotted in Figure 
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3.6. An identical pattern to that seen in Figure 3.1 showed that the results from this 
section converged with the results in Section 3.2.1. Both sections found enrichment 
for SCZ and BPD common variants in genes with increased expression during early 
and mid-foetal development that dropped off prior to birth and had decreased 
values through late infancy and childhood before increasing through adolescence 
and young adulthood. 
 
 
Figure 3.6: Median development stage characteristic scores calculated in the BrainSpan RNA-Seq 
dataset for most enriched gene set identified from SCZ risk genes co-expression model. 
Based on the top 25% of genes ranked by SCZ risk genes co-expression model p values identified as 
most enriched gene set from the Mann-Whitney tests. For each development stage, the median 
characteristic score of this set of genes was calculated. 
 
MIR137 targets 
One particularly interesting top hit in the SCZ PGC GWAS was MIR137, as prior 
evidence suggests this gene plays a role in brain development, in particular 
regulating adult neurogenesis (Szulwach et al., 2010) and neuron maturation (Smrt 
et al., 2010). Therefore, disruptions to this gene may form part of the 
neurodevelopmental hypothesis of SCZ’s aetiology. The PGC authors found that SNPs 
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in or near predicted targets of MIR137 were enriched for association (Ripke et al., 
2011), a finding that was validated with results from a subsequent meta-analysis of 
SCZ GWAS (Ripke et al., 2013). MIR137 could not be included in the SCZ co-
expression model as it was not present in the expression dataset.  
 
A list of 301 genes predicted as targets for MIR137, obtained from TargetScan (Lewis 
et al., 2005), were tested with a Mann-Whitney test to see if they were more closely 
co-expressed across development with the top hits in the PGC GWAS compared to all 
other genes. This was found to be the case (p = 5.54 x 10-22) demonstrating that 
these target genes more closely resemble the developmental profile of the SCZ 
genes than the genes not predicted as targets.  
 
Technical validation in microarray dataset 
The same approach was applied using the microarray data, although only six genes 
(CCDC68, CNNM2, CSMD1, NT5C2, STT3A, and TCF4) were considered, as MMP16 
was not present in the final dataset. Co-expression model logP were not associated 
with SCZ Brown’s logP (all p > 0.05) for any of the six genes considered, shown in 
Table 3.8.  
Table 3.8: Linear regression results and correlation coefficients testing single SCZ risk gene co-
expression model logP calculated in Kang microarray dataset with SCZ Brown’s logP. 
 
 
CCDC68 CNNM2 CSMD1 NT5C2 STT3A TCF4 
P-value 0.0866 0.598 0.190 0.288 0.434 0.977 
Correlation 
Coeff 
-0.0149 0.00460 -0.0114 0.00927 0.00682 0.000257 
- + - + + + 
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Figure 3.7: SCZ risk genes comparing microarray and RNA-Seq expression values.   
Risk genes selected from PGC GWAS whose co-expression indexed association in the RNA-Seq dataset 
and were also present in the microarray dataset. Median expression values calculated for each 
development stage in each dataset, scale on left for RNA-Seq data, scale on right for microarray data. 
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In order to compare these results to those found in the RNA-Seq dataset, the 
microarray and RNA-Seq expression values for common genes were plotted on the 
same graph but with scales appropriate to each type, see Figure 3.7. The red lines 
that represent the RNA-Seq values show much more variability in expression values 
across development compared to the microarray values in blue. RNA-Seq expression 
values are known to have a much larger dynamic range than microarray expression 
values (Wang et al., 2009), which is partly why they are more accurate. For some 
genes however, such as NT5C2 or TCF4, the microarray expression values appear to 
be slightly higher in foetal stages compared to postnatal stages. The reduced 
sensitivity of microarrays meant that the linear model was unable to detect these 
subtle expression differences that could be picked up when using data from next-
generation sequencing technologies. Therefore these results could not be technically 
validated in the Kang dataset. 
 
Summary 
Genes identified as having an expression profile that follows the same trajectory 
across development as CNNM2, CSMD1, MMP16, NT5C2 and TCF4, through the SCZ 
co-expression model, were enriched for SCZ gene-wide p values. These five genes 
were identified as genome-wide significant in the largest GWAS to date and are 
presumed most likely to be true associations. Initially genes co-expressed with each 
gene separately were shown to be enriched for SCZ variants, but the association with 
SCZ gene-wide p values was more significant when considering these five genes 
together. These results were validated with both parametric and nonparametric 
approaches. Further, genes predicted as targets for MIR137, another genome-wide 
significant hit for SCZ, were also enriched for genes co-expressed with these SCZ risk 
genes. The results in this section for co-expressed genes were not validated in the 
microarray data, although this was likely due to technical differences in the 
expression values each method obtains. 
 
Genes identified as co-expressed with these genes were shown to have a profile of 
development stage characteristic scores consistent with the results in Section 3.2.1. 
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Therefore the two different approaches in Sections 3.2.1 and 3.2.2 have identified 
the same expression profile for SCZ risk genes, characterised by highest expression 
values during foetal development, followed by a drop in expression around birth to 
the lowest values around late infancy and early childhood before increasing again.  
 
3.2.3 Bipolar disorder risk genes co-expression models 
An equivalent approach was performed considering BPD risk genes identified from 
the PGC study. Four genome-wide significant SNPs were associated in either the 
primary analysis or the combined primary and replication meta-analysis (Sklar et al., 
2011). These were located closest to ANK3, SYNE1, ODZ4, and CACNA1C, all of which 
were present and expressed in the RNA-Seq data. To begin with separate models 
were fitted for each gene and all remaining genes in the expression dataset were 
given a p value for how highly co-expressed they were with each risk gene.  
 
Figure 3.8: Results from Mann-Whitney tests for genes ranked by single BPD risk gene co-expression 
model p values calculated in the BrainSpan RNA-Seq dataset. 
Genes ranked by BPD single risk gene co-expression model p values and top n% tested for smaller BPD 
Brown’s p values against bottom 50%. Black dashed line is p = 0.05. 
Significant positive correlations were found between the co-expression model logP 
and BPD Brown’s logP for all four genes (ANK3 p = 0.0199, r = 0.0202; CACNA1C p = 
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3.63 x 10-6, r = 0.0402; ODZ4 p = 3.30 x 10-5, r = 0.0361; SYNE1 p = 2.05 x 10-5, r = 
0.0370). Nonparametric tests verified the associations for each gene model logP, for 
all top proportions of genes tested, see Figure 3.8. Therefore co-expression with any 
of the four genes identified from the PGC study was associated with more significant 
BPD associations, adding further confidence that these risk genes are true.  
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
P value 1.97 x 10-5 1.23 x 10-5 3.68 x 10-5 2.35 x 10
-6 
Correlation Coeff. 
0.0379 0.0402 0.0358 0.0434 
+ + + + 
Excluding MHC genes 
P value 5.27 x 10-7 7.49 x 10-8 1.89 x 10-5 1.15 x 10
-6 
Correlation Coeff. 
0.0448 0.0498 0.0374 0.0451 
+ + + + 
Table 3.9: Linear regression results and correlation coefficients testing BPD risk genes co-expression 
model logP across development calculated in the BrainSpan RNA-Seq dataset with gene-wide logP. 
Based on co-expression model with ANK3, CACNA1C, ODZ4, and SYNE1. 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
P value 0.00289 0.000154 7.05 x 10-5 1.96 x 10
-5 
Correlation Coeff. 
0.0265 0.0348 0.0304 0.0393 
+ + + + 
Excluding MHC genes 
P value 0.000111 8.31 x 10-6 4.08 x 10-5 1.16 x 10
-5 
Correlation Coeff. 
0.0345 0.0413 0.0358 0.0406 
+ + + + 
Table 3.10: Linear regression results and correlation coefficients testing BPD risk genes co-expression 
model logP across brain regions calculated in the BrainSpan RNA-Seq dataset with gene-wide logP. 
Based on co-expression model with ANK3, CACNA1C, ODZ4, and SYNE1. 
Two further models were fitted including all four of these genes, one measuring 
temporal co-expression and the other spatial co-expression, results in Tables 3.9 and 
3.10. A marginally stronger association was found with BPD Brown’s logP and 
temporal co-expression logP (p = 3.68 x 10-5) rather than spatial co-expression logP 
(p = 7.05 x 10-5). The results of the Mann-Whitney tests verified these enrichments, 
see Appendix Figure 8.16, and showed that they were not due to extreme values. 
 
120 
 
Genes identified with each model were also associated with SCZ Brown’s logP with 
both parametric and nonparametric tests. A more significant result was found when 
considering variation across development (p = 1.97 x 10-5) compared to development 
across brain regions (p = 0.00289), see Tables 3.9 and 3.10. Enrichments for both SCZ 
and BPD were also found with Simes’ logP, and all enrichments remained after 
removing genes located in the MHC. All significant regression models were validated 
with nonparametric tests and shown not to be due to extreme values, see Appendix 
Figures 8.16. 
 
 
Figure 3.9: Median development stage characteristic scores calculated in the BrainSpan RNA-Seq 
dataset for most enriched gene set identified from BPD risk genes co-expression model. 
Based on the top 40% of genes ranked by BPD risk genes co-expression model p values identified as 
most enriched gene set from the Mann-Whitney tests. For each development stage, the median 
characteristic score of this set of genes was calculated. 
 
As with the SCZ co-expression model the most enriched set of genes identified 
through the BPD co-expression model were taken and their median characteristic 
scores were plotted, see Figure 3.9. The graph looked very similar to that of Figure 
3.1 and Figure 3.6 showing that these genes had very similar expression 
characteristics to those found to be enriched in Sections 3.2.1 and 3.2.2. Therefore 
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the results of the BPD co-expression model also converged with those reported in 
Sections 3.2.1 and 3.2.2. This would imply that both the SCZ and BPD co-expression 
models were selecting fairly similar sets of genes. The median characteristic scores in 
Figure 3.9 were not as extreme as in those in Figure 3.6 in Section 3.2.2 perhaps 
suggesting that BPD risk genes do not have as an extreme temporal expression 
profile compared to SCZ risk genes.  
 
When the logP from the SCZ co-expression model and BPD co-expression model 
were tested simultaneously to predict BPD Brown’s logP, both terms were 
considerably less significant than when tested separately with the BPD model logP 
remaining significant (SCZ model logP p = 0.490; BPD model logP p = 0.00139). A 
similar result was found when predicting SCZ Brown’s logP with the SCZ co-
expression model logP remaining significant (SCZ model logP p = 0.000412; BPD 
model logP p = 0.491).  
 
This follows what was observed in Figures 3.6 and 3.9 that both models were 
capturing an overlapping set of genes. Interestingly, despite this high degree of 
overlap, the BPD model was most enriched for BPD signal whereas the SCZ model 
was most enriched for SCZ signal. This perhaps suggests that the models were 
picking up slightly different temporal expression characteristics for each disorder 
although this was not evident from Figures 3.6 and 3.9. The only notable difference 
was that the median expression characteristic scores for the BPD co-expressed genes 
were not as extreme as those for the SCZ co-expressed genes. 
 
Validation with microarray data 
This approach was repeated in the microarray dataset, although only two genes 
ANK3, SYNE1 were present. Neither regression result with SYNE1 model logP (p = 
0.597, r = 0.00452) or ANK3 model logP (p = 0.803, r = -0.00214) was significant and 
hence no further models were fitted. As with the SCZ model, the lack of significance 
in this dataset compared to the RNA-Seq dataset was attributed to the smaller 
dynamic range of microarray expression values observed when comparing the 
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expression of these two genes across the two technologies; see Appendix Figure 
8.17. 
 
Summary 
Genes whose expression profiles correlated with strongly associated BPD risk genes 
ANK3, CACNA1C, ODZ4 and SYNE1, identified in the largest GWAS, were found to be 
enriched for genes with common variants associated to SCZ and BPD. The 
enrichment was slightly stronger when identifying variation across development 
stages, compared to variation across brain regions.  Applying these methods to 
microarray data did not find the same enrichments, and as in Section 3.2.2 this was 
thought to be due to the smaller dynamic range of these expression values. The 
profiles of these genes share the same characteristics with the genes in the SCZ co-
expression model, shown statistically when the association of these two models was 
not independent, and were consistent with the results described in Section 3.2.1. 
 
3.2.4 Development stage characteristic gene expression and schizophrenia 
structural variants 
CNVs found in SCZ patients were compared to those found in healthy controls to see 
if the genes hit were more characteristic of a particular developmental stage. A 
logistic regression model was used, as described in Chapter 2, comparing the 
minimum, median and maximum characteristic score of the genes hit by each CNV 
for each development stage. Genes hit by SCZ CNVs were not more characteristic of 
any stage compared to those hit by control CNVs, further no significant results were 
found when testing the deletions or duplications. These results can be found in 
Appendix Table 8.7.   
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Figure 3.10: Logistic regression results testing CNV singleton status on development stage 
characteristic scores calculated in the BrainSpan RNA-Seq dataset. 
Panel A is all CNVs, panel B deletions, and panel C duplications. P values were corrected for 12 
development stages using Bonferroni’s method. Black dashed line is 0.05. 
 
Singleton SCZ CNVs were compared to all remaining SCZ CNVs to see if they were 
enriched for genes characteristic of any development stage. Only a couple of 
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marginally significant results were found with no obvious pattern to the results. The 
most significant result suggested singleton SCZ CNVs hit genes with higher early 
foetal A characteristic scores (median metric corrected p = 0.0145; maximum metric 
corrected p = 0.000788). This result was also found in the deletions (minimum metric 
corrected p = 0.00344; median metric corrected p = 0.00315; maximum metric 
corrected p = 0.00608).  
 
Technical validation with microarray dataset 
Repeating these analyses in the Kang microarray dataset showed no significant 
differences between the genes hit by case CNVs compared to control CNVs for any 
set of development stage characteristic scores, results in Appendix Table 8.9. When 
testing genes hit by singleton SCZ CNVs, again there was no pattern to the results 
however a significant result was found for early foetal A (median metric corrected p 
= 0.0327; maximum metric corrected p = 0.0109), see Figure 3.11. This was in the 
same direction as in the RNA-Seq data and was also significant when testing just the 
deletions. This result remained when excluding the PMI covariate results in Appendix 
Table 8.12 or Appendix Figure 8.18.  
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Figure 3.11: Logistic regression results testing CNV singleton status on development stage 
characteristic scores calculated in Kang microarray dataset. 
Panel A is all CNVs, panel B deletions, and panel C duplications. P values were corrected for 15 
development stages using Bonferroni’s method. Black dashed line is 0.05. 
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Summary 
Singleton SCZ CNVs were found to hit genes with higher early foetal A characteristic 
scores, compared to all remaining SCZ CNVs with characteristic scores calculated in 
either the RNA-Seq dataset or the microarray dataset. This was particularly the case 
for deletions. This suggests genes disrupted by singleton SCZ CNVs have increased 
expression in the brain during this early development stage. While a similar finding 
was reported for genes with common variants associated to SCZ, this was in later 
foetal stages, with no association found for early foetal A characteristic scores. 
 
3.2.5 Functional analysis of genes with enriched expression profiles 
As the SCZ co-expression model in the RNA-Seq dataset captured fundamentally the 
same enriched expression profile found through the separate development stage 
characteristic scores in Section 3.2.1 through one metric, p values from this model 
were used for functional analysis. Genes annotated to each functional category were 
compared to all remaining genes in the expression dataset to see if they were more 
closely co-expressed with SCZ risk genes. Of 3085 unique terms from the GO 
database with between 20 and 200 genes, 219 had significantly lower ranked model 
p values at a Bonferroni corrected threshold of 1.62 x 10-5. This set of terms was 
clustered in groups following the procedure described in the previous chapter.  
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Figure 3.12: Key annotation terms identified from set of significant GO terms with smaller SCZ risk genes co-expression model p values. 
Figure shows set of 54 GO terms that explained at least one other term in the set of significant pathways. Terms that did not explain any other term were not included in 
the Figure. Arrows point from explaining term to the merged pathway it explains i.e. the term pointed to, merged with all other terms it explains. Terms in red ovals are 
also present in Figures 2.6 and 2.7 in the previous chapter; terms in black boxes were grouped into common themes. 
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Fifty-four terms explained the enrichment of at least one other larger GO term or 
merged GO pathway. Figure 3.12 displays these terms where they have been 
manually grouped into five common themes: ‘Chromosome: structural modification 
& repair’, ‘Cell cycle (mitosis)’, ‘RNA processing’, ‘RNA/protein transport’, and ‘Signal 
transduction’. Similar to the set-based tests performed in the previous chapter, the 
combined association signal of genes with the temporal expression profile was 
compared between those in these functional categories against genes not in any 
pathway to confirm that these pathways did contain SCZ association signal. The set 
of genes with the most significantly smaller SCZ Brown’s gene-wide p values 
identified from the Mann-Whitney tests for the top 5-50% of genes ranked by their 
SCZ co-expression model p values, shown in Appendix Figure 8.15 panel A to be the 
top 25%, were taken as the set of genes with temporally variable expression.  
Separate set-based tests were then performed to identify which terms may be more 
important for SCZ aetiology. 
 
 
Schizophrenia Bipolar disorder 
Number of 
SNPs in 
pathway 
Adjusted p 
value 
Number of 
SNPs in 
pathway 
Adjusted p 
value 
Top 25% of 
SZ Model 
genes 
In pathways 93728 0.00195 177267 0.00325 
Not in pathways 28507 0.625 54006 0.271 
Cell cycle 
(mitosis) 
9131 0.00129 17400 0.148 
Chromosome: 
structural 
modification & 
repair 
23283 0.0262 42535 0.00390 
RNA/protein 
transport 
19394 0.206 38920 0.324 
RNA processing 10753 0.0706 19677 0.567 
Signal 
transduction 
38289 0.0543 73974 0.0206 
Table 3.11: Results of set-based tests for genes found in most enriched gene set from SCZ co-
expression model and in significantly enriched pathways.  
Set p values adjusted for number of SNPs in each set. 
 
Table 3.11 shows that genes with the temporal expression profile and in significant 
pathways were associated to both SCZ (adjusted p = 0.00195) and BPD (adjusted p = 
0.00325). In contrast genes with the temporal expression profile but not in an 
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enriched pathway, as a group, were not associated to either SCZ or BPD.  Of the 
pathway groups ‘Cell cycle (mitosis)’ and ‘Chromosome: structural modification & 
repair’ had a significant set-based p values when combining SCZ GWAS results. 
Interestingly ‘Chromosome: structural modification & repair’ and ‘Signal 
transduction’ were enriched for BPD GWAS signal. Two groups, ‘RNA/protein 
transport’ and ‘RNA processing’ were not significant for either SCZ or BPD.  
 
3.3 Discussion 
3.3.1 Identification of common developmental expression profile 
An expression profile that shows variation across development has been identified 
for SCZ risk genes. Gene sets identified with increased characteristic expression 
during early to late mid-foetal development, and gene sets with decreased 
characteristic expression in postnatal stages were enriched for common SCZ risk 
variants. These associations were found not to be independent suggesting there is 
an underlying common set of genes with both aspects of these expression profiles. 
 
Separate analyses showed that genes with expression that correlated closely with 
five strongly associated SCZ genes (CNNM2, NT5C2, TCF4, MMP16 and CSMD1) 
identified from the largest published GWAS (Ripke et al., 2011) were enriched for 
risk variants. Genes identified with this approach showed the same characteristic 
expression profile as the results in the first section of this chapter. Together, these 
two approaches suggest that risk genes for SCZ are characterised by a peak of 
expression during foetal development followed by a gradual decrease starting prior 
to birth and continuing through to the lowest values around early childhood, before 
beginning to increase again through adolescence.  
 
Additional analyses found that genes predicted as MIR137 targets were more similar 
to this developmental profile than remaining genes in the dataset. As these genes 
have previously been shown to be enriched for SCZ common variants (Ripke et al., 
2011, Ripke et al., 2013) this further supports the described temporal profile for SCZ 
associated genes.  
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While previous studies have suggested SCZ genes have age-related expression 
profiles (Colantuoni et al., 2008, Choi et al., 2009, Harris et al., 2009), these were 
based on samples covering a smaller period of brain development with entirely 
postnatal individuals. In addition, these were conducted prior to the GWAS era and 
the list of SCZ risk genes were primarily based on literature reviews. Therefore this 
work strengthens these findings, and extends them by describing the temporally 
variable profile identified.  
 
Gene sets identified with common spatial profiles in mid-foetal brains and enriched 
for SCZ and BPD common variants in Chapter 2 showed a developmental profile 
consistent with that identified here, see Figure 2.10. Two exome sequencing studies 
have looked at the temporal expression profile of genes with de novo mutations and 
observed higher expression in prenatal samples (Xu et al., 2012, Gulsuner et al., 
2013), in line with the findings reported here.  Another study using GWAS, CNV and 
SNV data to create networks of genes based on the likelihood of them contributing 
to SCZ aetiology, also reported higher prenatal expression for genes within the 
resulting clusters (Gilman et al., 2012). All of these studies used either the BrainSpan 
or Kang datasets and while it is encouraging to identify the same expression 
characteristics, replication in an independent expression dataset for this expression 
profile would still be warranted. These studies  
 
The temporal profile described is consistent with neurodevelopment models of SCZ 
which posit that a disruption early on in development interacts with normal 
maturational processes during adolescence (Weinberger, 1987). While upregulation 
of expression during foetal development has previously been reported, 
downregulation during early childhood is a novel finding for SCZ associated genes. If 
disruptions to a risk gene or genes during this time point were causative of SCZ, this 
would suggest that the window for developmental insults that increase the risk of 
SCZ extends beyond the period around birth. It would also imply that developmental 
delays would only occur after this time point, a hypothesis that could be investigated 
in a prospective birth cohort. An alternative hypothesis would be that altered gene 
131 
 
expression during this developmental period may be a result of an earlier disruption 
to brain development, and mediates the relationship between developmental insults 
and SCZ. 
 
Genes with this developmental expression profile were also enriched for BPD 
common variants. Fewer and less significant results were found when testing genes 
characteristic of each development stage with BPD gene-wide p values. As in the 
previous chapter this was probably due to the smaller sample size of the BPD PGC 
GWAS, however, the directions of effect were consistent with the SCZ results. Genes 
identified with the SCZ co-expression model also showed enrichment for BPD 
common variants. Further, a BPD co-expression model based on genome-wide 
significant BPD genes (ANK3, CACNA1C, ODZ4, SYNE1) captured genes with a similar 
temporal profile to the SCZ risk genes and was associated with more significant  SCZ 
and BPD gene-wide p values.  
 
A few significant results were found when looking at genes hit by singleton SCZ 
CNVs. While singleton deletions were found to hit genes with increased expression 
in early foetal A in both the RNA-Seq and microarray dataset, neither of these results 
was particularly strong.  This result was broadly in line with the general finding that 
SCZ risk genes have increased expression during early foetal development, although 
this was at a later developmental stage, perhaps suggesting that CNVs affect earlier 
developmental processes.  
 
3.3.2 Identification of functional pathways from enriched expression gene sets 
GO terms enriched for genes with this temporal profile were identified and grouped 
into broad themes including ‘Chromosome: structural modification and repair’, ‘RNA 
processing’ and ‘RNA/protein transport’, which suggests that these genes play a role 
in transcription and the control of related processes. Of these three groups only the 
‘Chromosome: structural modification and repair’ group, when intersected with 
genes with the temporal profile, showed association to SCZ and BPD. A second 
pathway group ‘Cell cycle (mitosis)’ when intersected with genes with the temporal 
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profile, was also enriched for SCZ common variants. Taken together these two 
pathway groups may suggest a role for abnormal cellular proliferation in SCZ during 
the division stage of the cell cycle. Increased cellular proliferation has been reported 
in olfactory neurosphere-derived cells from SCZ patients compared to controls, 
which may impact on the early stages of neurodevelopment (Fan et al., 2012). 
 
Thirteen individual GO terms that explained other terms overlapped with those 
identified in the previous chapter for genes with decreased expression in the HIP and 
THAL, highlighted in red in Figure 3.12. Due to the inter-dependence of the GO 
hierarchy it was not possible to test if this was more than would be expected by 
chance, however it provides some validation that not only did the different 
approaches in the two chapters converge on the same temporal profile, but that 
they also identified the same functional pathways. In particular the common 
pathways relate to epigenetic processes, which along with the temporal profile 
suggest that these genes may play a role in the regulation of human brain 
development. Therefore, they may be particularly vulnerable to early insults 
affecting the course of normal development. 
 
Two groups of pathways, ‘Cell cycle (mitosis)’ and ‘Signal transduction’ were only 
found in this chapter for genes whose expression correlated with the temporal 
profile and were not picked up with the foetal spatial profiles. Synaptic genes have 
previously been implicated in SCZ pathology (Kirov et al., 2012, Perez-Santiago et al., 
2012, Gulsuner et al., 2013), and alterations to synaptic machinery during  synapse 
formation and pruning, which continues into adulthood, have been proposed as part 
of the neurodevelopmental model (Mirnics et al., 2000, Mirnics et al., 2001). 
Although the ‘Signal transduction’ group contained a few terms relating to the 
synapse, the genes in these pathways with the temporal expression profile only 
showed a trend for SCZ GWAS signal.  
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3.3.3 Comparison of results with Brown’s and Simes’ gene-wide p values 
Two methods to summarise GWAS results into gene-wide p values were used in this 
chapter to test for association of expression profiles with either SCZ or BPD. 
Generally the Brown’s gene-wide p values were more significant particularly, with 
the RNA-Seq dataset, in Sections 3.2.1 and 3.2.2. This is consistent with the results in 
the previous chapter suggesting that using a p value that can take into account 
multiple signals is more powerful. Interestingly, the Simes’ p values were more 
significant when testing the BPD co-expression models in Section 3.2.3.  
 
3.3.4 Technical replication across RNA-Seq and microarray expression data 
Both RNA-Seq and microarray expression datasets, with an overlap of individuals, 
were used in this chapter. Significant results with the development stage 
characteristic scores calculated in the microarray dataset were consistent with the 
results profile found with the RNA-Seq data, although there were not as many 
significant stages. When previously analysed, two additional covariates were 
included for the microarray dataset and that same procedure was followed here, 
whereas no such covariates were provided with the BrainSpan data. The removal of 
the PMI covariate when calculating the characteristic scores produced a results 
profile more in line with that found with the RNA-Seq data suggesting that some of 
the temporal effects were being captured by this variable. As the majority of the 
samples overlapped the two datasets, it may therefore be that the differences in 
PMI caused the observed expression profile. This was unlikely to be the sole factor in 
producing the temporal profile as even after inclusion of this covariate, the results 
still showed enrichment for SCZ risk genes in those with increased expression during 
early and mid-foetal stages or decreased expression around early childhood. 
 
Technical replication was not found with the microarray data for any of the co-
expression models. The next-generation sequencing technologies used to generate 
RNA-Seq expression data are more sensitive than microarray approaches and 
produce a larger range of expression values (Wang et al., 2009), observed for the 
genes used in the co-expression models in Figures 3.7 and 8.17. Therefore the linear 
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model approach used here was not able to capture the subtle differences across 
development with the microarray data that could be picked up with the RNA-Seq 
data.  
 
One of the main strengths of this study was the use of the most comprehensive 
expression datasets covering human brain development with multiple samples for 
each individual. The scarce availability of post-mortem brain samples makes this sort 
of resource rare and therefore there was no independent expression dataset even 
close to covering the same developmental window, with the same range of brain 
regions.  
 
An alternative approach would be to use another GWAS dataset for genetic 
replication. Results presented here with BPD gene-wide p values support the findings 
for SCZ and provide a level of replication. The PGC GWAS results were used as the 
basis for the gene-wide p values as it was the largest available study. Since 
publication the PGC have recruited an additional 35 SCZ sample collections on top of 
the initial 17 studies to further increase the sample size. Access to this dataset was 
provided and preliminary results support the findings reported in this chapter. 
 
3.3.5 Summary of chapter findings 
This and the previous chapter have identified common spatial and temporal 
expression profiles of SCZ risk genes, and through these common biological 
pathways of potential relevance to SCZ. Moreover, the gene sets with common 
spatial profiles in the previous chapter had a developmental expression profile that 
matched the findings in this chapter for SCZ risk genes. Generally the results were 
more significant when testing Brown’s gene-wide p values compared to Simes’, 
particularly for the SCZ co-expression model in Section 3.2.2. This suggests that many 
of the genes identified with the developmental profile were better represented by a 
p value that takes into account multiple, semi-independent common variants that 
increase the risk of SCZ or BPD rather than a p value based on only the most 
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significant SNP. This is consistent with a polygenic contribution of these genes, which 
will be investigated in the next chapter. 
 
3.4 Methods 
Preliminary data processing: BrainSpan RNA-Seq 
The BrainSpan RNA-Seq expression dataset was downloaded from an online resource 
(http://www.brainspan.org) already normalised to RPKM (reads per kilobase of exon 
model per million mapped reads) units. Lowly expressed genes were removed as any 
gene with a maximum value less than 1. Alongside the expression values, gene 
annotations were provided including Entrez IDs. These were added to the dataset 
and genes without Entrez IDs or non-unique Entrez IDs were removed.  
 
Preliminary data processing: Kang microarray 
This dataset was downloaded from the GEO database accession number GSE25219. 
Genes were annotated and filtered following the procedure described in the 
previous chapter applied to all samples. 
 
Development stage characteristic scores 
A linear model was fitted to identify genes characteristic of each development stage, 
shown in Equation 3.1.  
 
expij =  brain regionj +  development stageik 
Equation 3.1 Regression model to calculate characteristic scores for development stage k, where exp ij 
is the expression value for individual i from brain region j, brain region is a categorical term and the 
development stage term is a binary indicator variable denoting whether individual i was classed in 
stage k or not. 
 
Separate models were fitted for each development stage, for each gene. Only 
samples taken from brain regions present in nine out of the twelve development 
stages were used when fitting the model, removing ten regions and leaving sixteen. 
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Most of those removed were proxies for regions not yet developed in the foetal 
brains and hence only present in the foetal individuals. Development stage 
characteristic scores were derived based on the same formula used in Chapter 2, 
denoting the magnitude of the differential expression as well as whether it was 
increased or decreased expression. A similar model was fitted for the Kang 
microarray dataset, including additional covariates for hemisphere, RIN and PMI. 
 
Testing for enrichment with gene-wide p values 
Brown’s and Simes’ logP, were tested in a linear regression framework predicted in 
turn by the characteristic scores for each development stage. Significant results were 
verified with a rank-based Mann-Whitney test. Genes were ranked by the absolute 
value of the characteristic score for each development stage and the top n% (5, 
10…50%) selected. Each set was then separated by the sign of the characteristic 
score into those with increased characteristic expression (positive coefficient) and 
decreased characteristic expression (negative coefficient). The relevant subset, 
depending of the direction of the association in the linear regression was then tested 
with a one-sided Mann-Whitney test against the bottom 50% for more significant 
gene-wide p values. Analyses were repeated removing genes located in the MHC 
region, specifically those found in the chr6:25000000-35000000 region. 
 
Schizophrenia co-expression models 
expij =  SCZ geneij + brain regionj + individuali 
expij = brain regionj + individuali 
Equation 3.2 Formula for regression models compared to obtain a model p value for co-expression 
with SCZ risk genes, where expij is the expression value from individual i and brain region j. SCZ geneij 
is the expression value for that risk gene in individual i and brain region j with categorical covariates 
to control for brain region and individual differences. 
Genes identified from the SCZ PGC GWAS (Ripke et al., 2011) were used as the basis 
to identify sets of co-expressed genes. For each risk gene, linear models of the form 
in Equations 3.2 were compared for all remaining genes in the dataset with an 
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ANOVA to obtain a p value for co-expression, referred to as the co-expression model 
p value. 
 
In the Kang dataset extra covariates for hemisphere, PMI and RIN were also 
included. Genes whose co-expression indexed association signal were combined into 
a single model shown in Equation 3.3, which was also compared with an ANOVA to a 
model without the five risk gene terms. 
 
expij =  CNNM2ij + CSMD1ij + MMP16ij + NT5C2ij + TCF4ij + brain regionj
+ individuali 
Equation 3.3 Formula for regression models with multiple SCZ risk genes to identify genes co-
expressed across development, where expij is the expression value from individual i and brain region j, 
CSMD1ij etc. is the expression value for that risk gene in individual i and brain region j with categorical 
covariates to control for brain region and individual differences. 
 
Linear models shown in Equation 3.4 were used to investigate co-expression across 
brain regions, where a brain region term in Equation 3.3 was replaced with a 
development stage term. A p value was calculated from an ANOVA for all remaining 
genes in the expression dataset as a measure of co-expression.  
 
expij =  CNNM2ij +  CSMD1ij + MMP16ij+ NT5C2ij + TCF4ij
+ development stagei + individuali 
Equation 3.4 Formula for regression models with multiple SCZ risk genes to identify genes co-
expressed across brain regions, where expij is the expression value from individual i and brain region j, 
CSMD1ij etc. is the expression value for that risk gene in individual i and brain region j with categorical 
covariates to control for development stage and individual differences. 
 
MIR137 targets 
A list of MIR137 predicted targets was obtained using TargetScan (Lewis et al., 2005) 
with a probability of conserved target set to greater than or equal to 0.9. Of the 301 
genes, 275 had a SCZ model p values derived from ANOVAs comparing Equations 3.3, 
with TCF4 and CSMD1 automatically excluded as they were used to fit the model. 
This set was tested with a one-sided Mann-Whitney test for more significant SCZ co-
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expression across development model p values compared to all other genes in the 
expression dataset. 
 
Bipolar disorder co-expression models 
Four genes identified in the BPD PGC GWAS (Sklar et al., 2011) were considered for 
the BPD co-expression models. All four of these genes were present in the BrainSpan 
dataset and the models in Equations 3.5 were compared to derive a p value for co-
expression across development for all remaining genes. 
 
expij =  BPD geneij + brain regionj + individuali 
expij = brain regionj + individuali 
Equation 3.5 Formula for regression models compared to obtain a model p value for co-expression 
with BPD risk genes, where expij is the expression value from individual i and brain region j. BPD geneij 
is the expression value for that risk gene in individual i and brain region j with categorical covariates 
to control for brain region and individual differences. 
 
Co-expression with all genes was found to predict BPD association; hence all four 
were combined into two models. Equation 3.6 was used to derive p values for co-
expression across development and Equation 3.7 was used to look at co-expression 
across brain regions.  
 
expij =  ANK3ij + CACNA1Cij + ODZ4ij + SYNE1ij + brain regionj + individuali 
Equation 3.6 Formula for regression models with multiple BPD risk genes to identify genes co-
expressed across development, where expij is the expression value from individual i and brain region j, 
ANK3ij etc. is the expression value for that risk gene in individual i and brain region j with categorical 
covariates to control for brain region and individual differences. 
 
expij = ANK3ij + CACNA1Cij + ODZ4ij + SYNE1ij + development stagei
+ individuali 
Equation 3.7 Formula for regression models with multiple BPD risk genes to identify genes co-
expressed across brain regions, where expij is the expression value from individual i and brain region j, 
ANK3ij etc. is the expression value for that risk gene in individual i and brain region j with categorical 
covariates to control for development stage and individual differences. 
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CNV logistic regression 
For each CNV from the ISC and MGS study, characteristic scores for all genes hit from 
both the BrainSpan and Kang datasets were collated and the minimum, median and 
maximum for each development stage identified. Logistic regression models as 
described in Chapter 2 Equations 2.2 and 2.3 were used to test for an association 
between the development stage characteristic scores and genes hit by SCZ CNVs. 
 
Functional analysis 
Model p values from the RNA-Seq SCZ co-expression model with CNNM2, CSMD1, 
MMP16, NT5C2 and TCF4, across development shown in Equation 3.3, were used to 
identify relevant functional pathways. Categories from the GO database were tested 
with one-sided Mann-Whitney tests for significantly smaller model p values. 
Adjusting for 3085 unique terms with between 20 and 2000 genes a Bonferroni 
corrected p value threshold of 1.62 x 10-5 was used to identify significant terms. This 
set of significant terms was merged into clusters following the procedure described 
in the previous chapter. The resulting clusters were manually grouped into common 
themes.  
 
Set-based tests 
Sets were based on the most significant set of genes with the temporal profile, 
identified as the top 25% from the Mann-Whitney tests shown in Appendix Figure 
8.15. This set was split into two subsets; genes that were annotated to one of the 
219 significant pathways and those that were not. Further sets for the five pathway 
groups in Figure 3.12 were created based on the intersect of genes in the top 25% 
identified through the SCZ co-expression model and genes annotated to any 
pathway within that group. 
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For each set a combined set-based p value was calculated from the PGC SCZ and BPD 
GWAS results, which was subsequently adjusted for the number of SNPs in each set 
based on the procedure described in the Methods section of the previous chapter.  
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Chapter 4: Developing the polygenic model for 
application to expression derived gene sets  
4.1  Introduction 
4.1.1 Background 
Technological advances in the form of genome-wide SNP chips provided new 
opportunities to those looking for genetic risk factors in psychiatric disorders, as 
candidate gene studies had proved to be limited in their success. By vastly increasing 
the number of genetic markers included in a single study, the threshold for statistical 
significance had to become more stringent to account for the number of tests 
performed. The effective number of independent tests per genome has been 
estimated (International HapMap Consortium, 2005, Dudbridge and Gusnanto, 2008) 
in order to establish an industry standard level of genome-wide significance, to 
minimise false positive findings that would not be replicated. Initial SCZ GWAS failed 
to identify markers at this threshold, with sample size the limiting factor.  
 
In 2009 three studies were published simultaneously, one of which, conducted by 
the ISC, obtained genome-wide significance for an imputed SNP in the MHC region 
(Purcell et al., 2009). Each of these three studies then incorporated the data from 
the other two studies to see if any of their top hits could attain genome-wide 
significance. SNPs that passed this threshold in the meta-analyses were located on 
chromosomes 6p22.1 part of the MHC region (Shi et al., 2009, Stefansson et al., 
2009), 11q24.2 (Stefansson et al., 2009) and 18q21.2 (Stefansson et al., 2009). The 
MGS study concluded that they had satisfactory power to detect any common 
variants of large effect (relative risk > 1.3) and the fact that they had not meant 
there were likely few, if any, to detect (Shi et al., 2009). Instead it was postulated 
that many common markers were involved, each with a small or moderate 
contribution to the risk of developing SCZ. 
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Using their GWAS results the ISC derived a simple mathematical model that 
demonstrated this polygenic effect of thousands of markers, each of small effect. 
The principle of this model was to calculate a score, termed the polygenic score, for 
each individual in an independent dataset as the sum of their risk alleles at each SNP, 
weighted by the log odds ratio obtained from the initial GWAS. These scores were 
shown to be significantly different between cases and controls explaining ~3% of the 
variance (Purcell et al., 2009).  
 
Simulations were used to narrow down the possible genetic models that could have 
produced these results. These considered the proportion of associated markers that 
were actually causal compared to those that just tagged the relevant marker, as well 
as the distributions of allele frequencies and effect sizes of the associated SNPs. The 
simulations consistent with the true results showed that a minimum of one third of 
the genetic heritability could be explained by the polygenic contribution of common 
SNPs (Purcell et al., 2009). This was much greater than the observed 3% which was 
impacted by the accumulation of sampling errors of the estimated effect sizes 
(Dudbridge, 2013). More recently this methodology was repeated with the PGC 
GWAS results derived from a sample with more than double the number of 
individuals and was found to explain 6% of the variance (Ripke et al., 2011). An 
increased sample size meant that more true variants would be included in the score 
and that the odds ratios would be more accurately estimated, therefore the 
proportion of variance explained was improved. 
 
In the previous chapters, sets of genes with common expression profiles across the 
mid-foetal brain or brain development have been shown to be enriched for SCZ 
association signal using gene level summarised p values. In this chapter, genes with a 
common expression profile were investigated further to see if they harboured a 
polygenic signal that could better discriminate between cases and controls than the 
genome-wide polygenic score. As described above, the current procedure for 
calculating polygenic scores is quite simplistic, so the initial sections in this chapter 
focus on developing this model. Three adaptions to the model were investigated to 
incorporate population information, LD relationships between markers or SNP-SNP 
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interactions to see if the addition of this information improved the discrimination 
between SCZ cases and controls. 
 
4.1.2 Outline 
Aim 
The main aim of this chapter was to compare polygenic scores calculated from gene 
sets identified in the previous chapters to those calculated across all available SNPs 
to see whether they capture any additional SCZ polygenic signal. In order to make 
the best possible estimate of the signal captured, a prior aim was to explore whether 
the inclusion of population information, LD between SNPs or SNP-SNP interactions 
could improve the fit of the polygenic model described by the ISC. 
 
Datasets 
Genotype data from both the ISC and MGS studies were available for use and in all 
applications the polygenic model was trained in the biggest GWAS, the ISC, to obtain 
the most accurate estimates of effect size, and the MGS dataset was used as the 
target or test dataset. To avoid overestimating the predictive ability of the polygenic 
scores it is important that the training and target dataset are entirely independent 
(Powell and Zietsch, 2011). The ISC dataset contained 3322 cases and 3587 controls 
combined from 8 separate studies (Purcell et al., 2009). Data were obtained post 
quality control to remove problematic SNPs and individuals, with 739995 SNPs left.  
The MGS European-American dataset contained 2681 cases and 2653 controls and 
had 671422 SNPs after quality control (Shi et al., 2009).  
 
Both datasets were filtered to the set of 661356 overlapping SNPs to ease 
subsequent model developments and make them comparable. This was different to 
the procedure described in the ISC paper, where SNP filtering and pruning were 
performed on all SNPs in the ISC data which meant that some of the SNPs used to 
calculate the polygenic scores would not be found in the MGS data. All subsequent 
filtering steps were performed using the same thresholds detailed by the ISC; all 
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SNPs with a MAF < 0.02 or a missing genotype rate > 0.01 in the ISC study were 
removed. This left 275265 SNPs, with the majority excluded because some studies in 
the ISC were genotyped on a different chip with only ~380000 SNPs.  
 
SNPs were then pruned in a pairwise manner based on their r2 statistic using a sliding 
window of 200 SNPs and 1000kb. The ISC chose a threshold of r2 < 0.25 to create an 
independent set of SNPs and hence that threshold was used here for comparison. A 
set of 42113 SNPs with no pairwise r2 > 0.25 and all with a SCZ association p value < 
0.5 were used to calculate polygenic scores. These will be referred to as the 
independently associated SNP set or SNPIA which was used to compare the 
adaptations of the polygenic model described in this chapter. 
 
Outline of analysis 
The first adaptation considered population stratification. In the original application, 
the two Swedish studies were combined into a single population and all remaining 
studies taken as six other populations. This population stratification was controlled 
for in the association test to produce a single odds ratio for each SNP. Here, the 
polygenic framework was reformulated to allow multiple odds ratios for these 
different populations and incorporate this extra population information. 
  
The second development described looked at including the LD structure between 
SNPs to allow the inclusion of more SNPs when calculating the polygenic scores. In 
the framework proposed by the ISC, stringent pruning was applied to ensure SNPs 
were independent and prevent overestimating the effects of correlated SNPs. Here 
an alternative method was implemented that allows for LD when estimating the 
odds ratios, meaning that more SNPs can be retained and ultimately more 
information included.  
 
Finally the method was extended to calculate a polygenic score based on 
interactions between independently associated SNPs. Polygenic scores were 
calculated for each individual in the MGS dataset for each adaptation to be 
146 
 
compared to those calculated as described in the original formulation. Each set of 
scores was tested to see how strongly they predicted case control status in a logistic 
regression test. P values and Nagelkerke’s R2 values (Nagelkerke, 1991) were used to 
compare the performance of each model to the original ISC framework. 
 
After identifying which adaptations of the polygenic model improved the prediction 
of case control status and the amount of variance explained, these were used to 
calculate polygenic scores for all SNPs within a set of genes with a common temporal 
expression profile identified as enriched for SCZ common variants in Chapter 3. The 
gene set polygenic scores were tested simultaneously with genome-wide scores in a 
logistic regression model to see if it was a significant predictor after allowing for the 
genome-wide score. This would inform whether this gene-set contained any SCZ 
signal not captured by the genome-wide score. 
 
4.2 Results 
4.2.1 Standard polygenic scores 
All SNPs in the SNPIA set were used to calculate polygenic scores as described by the 
ISC, referred to here as the standard polygenic. Odds ratios were estimated from a 
logistic regression model that predicted case control status by the number of minor 
alleles at each SNP and included covariates to control for the seven populations. 
Output from these association analyses was used to calculate the polygenic scores in 
PLINK (Purcell et al., 2007), which divides the final polygenic score by the number of 
SNPs to give a mean score per SNP. These scores were found to be significantly 
different between cases and controls, p = 5.41 x 10-31, R2 = 0.0345. This result was 
mildly more significant than that reported by the ISC, which was probably due to a 
larger set of SNPs, obtained from a slightly different filtering procedure, being used. 
This was the baseline result to which all subsequent modifications were compared. 
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4.2.2 Population weighted polygenic scores 
After implementing a strict quality control procedure to genotype data to remove 
many sources of possible false positives, population stratification becomes the main 
concern for spurious results in GWAS (Tian et al., 2008a). In a case control study 
design if the population background of the cases and controls are not well matched, 
differences in allele frequencies between these populations may incorrectly 
associate a SNP to the disorder (Knowler et al., 1988, Campbell et al., 2005). This can 
be particularly problematic when markers are thought to only confer a small or 
modest effect on disease risk and studies are therefore only looking for subtle 
differences in allele frequencies such as the case for SCZ. As a result, GWAS methods 
have been developed either to take into account ancestral information or to reduce 
the resulting inflation of test statistics (Devlin and Roeder, 1999, Pritchard et al., 
2000, Price et al., 2006). These considerations are now part of the routine of 
association analyses, as the ISC study was a collaboration of eight other studies a 
Cochran-Mantel-Haenszel test, which allows for known categorical populations, was 
used.  
 
In the polygenic model there is the assumption that the alleles identified in the 
training dataset are also associated with disease risk in the target dataset, with the 
same direction of effect. While this methodology has been shown to work across 
different ethnicities, demonstrated by the ISC between European Americans and 
African Americans, the results were stronger if individuals in both datasets come 
from the same population (Purcell et al., 2009). Both the ISC and MGS have been 
filtered to only contain European individuals, but even within European 
subpopulations allele frequencies are known to differ and can cause false positive 
results (Seldin et al., 2006, Tian et al., 2008b). Within the ISC each study represents a 
subpopulation whose individuals were shown to cluster together in a plot of the first 
two multidimensional scaling components calculated from their genotypes, see 
Figure 4.1.  This plot shows that the samples originating from the British Isles, either 
Scotland, England or Ireland, group together but also overlap, whereas the 
Bulgarian, Portuguese and Swedish samples form distinct groups away from each 
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other and the British Isles cluster. Taking account of this subpopulation structure, 
and therefore any associated differences, should produce a better estimate of 
disease susceptibility for each SNP, for each individual. In the first adaption, this 
subpopulation information was incorporated to calculate personalised odds ratios 
for each individual in the MGS based on how well their genotypes matched each of 
the populations in the ISC study. 
 
 
Figure 4.1: Multidimensional scaling plot of individuals in ISC dataset. 
This is a two dimensional representation of the ISC genotype data where samples that are most 
similar will be placed closest together, and samples that show the most differences furthest apart. 
Each point in this plot represents an individual that is coloured by the sample collection the individual 
originated from. Taken from Supplementary Figure S1 in (Purcell et al., 2009). 
 
Log odds ratios, θjk, for each population j and SNP k were estimated from logistic 
regression models only including individuals from that population. Seven likelihood 
values wij were then calculated for each individual i in the MGS data, using the 
probability of their genotypes occurring in population j of the ISC data, see Equation 
4.1. The genotype probabilities were taken from the ISC data and calculated for the 
pruned SNP set (r2 < 0.25).  If a genotype was not observed in a population, the 
probability for that SNP was set to a value less than if there had be a single 
occurrence, i.e. set to a value smaller than what could have been observed (Cardiff: 
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0.0008, Dublin: 0.0008, Edinburgh: 0.001, Portugal: 0.001, Sweden: 0.001, UCL: 
0.0009, Aberdeen: 0.0007).  
 
wij = ∑ −log(αijk)
k
 
Equation 4.1 Formula for calculation of population weights wij for individual i in population j, where 
αijk is the probability of individual i’s genotype at SNP k in population j; αijk were taken from the 
genotype frequencies in the ISC dataset which was used as the training dataset. 
 
These wij were then standardised so that the sum of the weights across all 
populations for each individual totalled 1. To calculate the weighted log odds ratio 
θwik for individual i at SNP k, the weight for each population was multiplied by the 
relevant population log odds ratio and summed across the populations (Equation 
4.2).  
 
θwik = ∑ wijθjk
j
 
Equation 4.2 Formula for the calculation of individual weighted log odds ratios θwik for individual i at 
SNP k, where wij is as in Equation 4.1 and θjk is the log odds ratio for population j at SNP k. 
 
Polygenic scores were calculated based on SNPs in the SNPIA subset (42118). For 
each individual a population weighted polygenic score or Pw was calculated using 
these weighted log odds ratios multiplied by the number of associated alleles at that 
SNP shown in Equation 4.3. If the genotype for an individual was missing at a 
particular SNP the expected value was calculated and multiplied by the weighted 
odds ratio. Consistent with the implementation in PLINK for polygenic scores the Pw 
were divided by the number of SNPs to create a mean score per SNP. 
 
Pwi = ∑ θwik  ηik
k
 
Equation 4.3 Formula for the calculation of population weighted polygenic scores Pwi for individual i, 
where θwik is as in Equation 4.2 and ηik is the number of associated alleles for individual i at SNP k. 
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The Pw were found to be significantly different between cases and controls; p = 7.48 
x 10-30; Nagelkerke’s R2 = 0.0331, which was marginally less significant than the 
standard polygenic baseline result. This population weighted approach assumes 
populations have different effect sizes at all SNPs. Therefore this method may be 
more beneficial when only applied to SNPs for which this was the case. Further, for 
SNPs that do not show any differences or only weak differences between 
populations, this method will introduce inaccuracies when estimating the effect sizes 
due to smaller sample sizes for the individual populations.  
 
To identify a relevant subset of SNPs to apply this approach to, two association 
regression models, shown in Equations 4.4, with and without interactions between 
the number of minor alleles and population covariates were compared. P values 
were taken from a chi squared 6 degree of freedom test used to compare the fit of 
these two models. Multiple p value thresholds (0.1, 0.05, 0.01, 0.005 and 0.001) 
were used to select SNPs to apply the population weighted approach to, with all 
remaining SNPs taking their odds ratios from Equation 4.4.A. 
 
status = nMA +  ω1  +  ω2 +  ω3 +  ω4 +  ω5 + ω6 A 
status = nMA +  ω1  +  ω2 +  ω3 +  ω4 +  ω5 + ω6 + nMA ∗ ω1 + nMA ∗ ω2 +
nMA ∗ ω3 + nMA ∗ ω4 + nMA ∗ ω5 + nMA ∗ ω6  B 
Equation 4.4 Formula for two regression models compared to identify SNPs with differences in effect 
sizes across populations and that population weighted log odds ratios should be calculated for, where 
status is SCZ case control status, nMA is the number of minor alleles at test SNP and ωj are binary 
covariates for population j. 
Table 4.1 shows that applying this population weighted approach to an informed 
subset of SNPs does marginally improve the significance compared to applying it to 
all SNPs and explains slightly more of the variance. The best result was obtained 
when using a threshold of 0.05 to select SNPs to apply the weighted approach to; 
however across the thresholds the results were broadly similar. In addition this 
result was also slightly more significant than the baseline polygenic result.  
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Threshold to 
select SNPs for 
weighted 
approach 
All SNPs P < 0.1 P < 0.05 P < 0.01 P < 0.005 P < 0.001 
Number of SNPs 
with weighted 
approach 
42113 4646 2374 480 258 51 
P value 6.43 x 10-30 3.28 x 10-31 2.98 x 10-31 4.46 x 10-31 3.52 x 10-31 4.99 x 10
-31 
Coeff. + + + + + + 
R2 0.0332 0.0348 0.0348 0.0346 0.0347 0.0346 
Table 4.1: Logistic regression results testing population weighted polygenic scores.  
Population weighted approach applied to subsets of SNPs with significant difference in effect sizes 
between populations for different significance thresholds. Compare to baseline result of p = 5.41 x 10-
31, R2 = 0.0345. 
The lack of a noticeable improvement of the population weighted model introduced 
here compared to the standard polygenic model could have been due to the inability 
to detect true differences between populations, either because there were none or 
there was not adequate power to detect them. Alternatively, it may be that taking 
these differences into account did not improve the model, perhaps because the 
differences are small. The number of SNPs detected with significant differences 
across the populations in the ISC data was compared to 100 random permutations 
where the population structure had been removed. Population was permuted within 
cases and within controls separately to retain the same number of cases and 
controls per population but remove population differences across the sample. 
Equations 4.4 were fitted for each SNP in the permuted dataset and the number of 
SNPs with significant differences was counted. 
 
Table 4.2 shows that at each threshold, the number of SNPs with population 
differences in the true ISC data was greater than any permutation, except p < 0.01 
where one permutation had at least as many significant SNPs. This result is 
consistent with polymorphisms affecting the different populations within the ISC 
study to different extents. Alternatively, these results may reflect differing LD 
relationships between the causal SNP and the tag SNP across the populations. Where 
this correlation is weaker, the evidence for association and effect size between the 
tag SNP and SCZ disease status would smaller. In these instances, the model used to 
detect population differences would be unable to distinguish if it was true effect size 
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difference or merely a result of differing LD relationships. In either scenario, the 
additional noise from estimating the effect size for each population from a smaller 
sample size, meant allowing for these differences in the polygenic framework did not 
greatly improve discrimination between SCZ cases and controls. 
 
Threshold for significant 
differences across populations 
0.1 0.05 0.01 0.005 0.001 
Number of SNPs in ISC with 
differences across populations 
8805 4491 923 499 106 
Empirical p value based on 100 
permutations 
< 0.01 < 0.01 0.01 < 0.01 < 0.01 
Table 4.2: Empirical p values for number of SNPs with significant differences in effect size across 
populations in the ISC. 
Tested by comparing models in Equation 4.4 and comparing results in true ISC data to 100 
permutations where population structure was randomised. 
 
4.2.3 LD adjusted polygenic scores 
In the current framework when summing across SNPs, any pair of SNPs in even 
moderate LD will cause an overestimation of the number of independent effects. To 
prevent this, the original application was performed on a set of stringently pruned 
SNPs, where no pair of SNPs had an r2 > 0.25. This reduced the set of SNPs that 
passed quality control by approximately 70%, losing information from SNPs that was 
not captured by those they were partially correlated with. This could be particularly 
relevant when calculating polygenic scores for gene sets later in this chapter, which 
were based on a smaller set of SNPs. Results reported in Chapter 3 were more 
significant when testing for enrichment with summarised p values based on Brown’s 
method, reflecting semi-independent effects from across the gene. Stringent pruning 
of SNPs within this set may therefore lose some of this information.  
 
When using logistic regression as the test for association analysis, case control status 
is regressed on the number of minor alleles for the test SNP, denoted here as SNPtest. 
Within this framework covariates can easily be included to control for population 
structure with scope to include any other possible confounders. In order to account 
for the correlation between SNPs, an extra covariate for a SNP in high LD with 
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SNPtest, was included in the regression framework as follows. SNPs were considered 
in the order they were located along each chromosome. The first SNPtest on each 
chromosome was treated as usual with its odds ratio estimated from a logistic 
regression model. For each subsequent SNPtest, the SNP within the previous 200 SNPs 
and 1000 kb that was in strongest LD with SNPtest (identified by r2 calculated in 
controls only) was taken, denoted from here as SNPLD1.  
 
status ~ SNPtest + SNPLD1 + ω 
Equation 4.5 Logistic regression model used to adjust SNPtest’s odds ratio for SNPLD, where status is SCZ 
case control status, SNPtest and SNPLD1 are the number of minor alleles at these SNPs and ω is the 
population covariates. 
 
The number of minor alleles of SNPLD1 was then included as a covariate in the 
association test for SNPtest so that the odds ratio would be adjusted for LD between 
these two SNPs, see Equation 4.5. Therefore, if both of these SNPs were included 
when calculating the polygenic scores, the effects should no longer be 
overestimated. These polygenic scores will be referred to as LD adjusted polygenic 
scores or PLD.  
 
As regression is not effective at estimating parameters for highly correlated 
variables, some LD based pruning was required. Pruning was applied at six r2 
thresholds (0.8, 0.82, 0.84, 0.86, 0.88 and 0.9) to see if this produced any variation in 
the results. Table 4.3 displays the number of SNPs in each set.  
 
Pruning threshold 0.8 0.82 0.84 0.86 0.88 0.9 
Number of SNPs after 
LD pruning 
161793 164722 167939 171251 174923 178899 
Number of LD pruned 
SNPs with p < 0.5 
84397 85954 87651 89405 91359 93475 
Table 4.3: Number of SNPs after LD based pruning in sets used to calculate LD adjusted polygenic 
scores. 
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For each of these six SNP sets the first polygenic model fitted was based on odds 
ratios from logistic regression models not adjusted for any LD SNPs, results in Table 
4.4. At all thresholds the polygenic scores were significantly higher in SCZ cases 
compared to controls, with the most significant difference at r2 < 0.84 (p = 3.35 x 10-
42). All of these results were more significant than the baseline result, and explained 
~4.7-4.8% of the variance compared to ~3.5% in the baseline model. The inclusion of 
extra SNPs to calculate polygenic scores will increase the significant difference 
between cases and controls, however these may be an overestimation of the true 
effects due to the inclusion of correlated SNPs. 
 
Pruning 
threshold 
0.8 0.82 0.84 0.86 0.88 0.9 
Number of 
SNPs 
84397 85954 87651 89405 91359 93475 
P value 1.10 x 10-41 1.72 x 10-41 3.35 x 10-42 1.39 x 10-41 1.56 x 10-41 3.00 x 10
-41 
Coeff. + + + + + + 
R2 0.0475 0.0473 0.0482 0.0474 0.0473 0.0470 
Table 4.4: Logistic regression results testing polygenic scores not adjusted for any LD SNPs.  
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
Pruning 
threshold 
0.8 0.82 0.84 0.86 0.88 0.9 
Total number of 
SNPs 
84397 85954 87651 89405 91359 93475 
P value 2.26 x 10-39 2.04 x 10-38 3.41 x 10-39 2.89 x 10-37 1.97 x 10-37 1.66 x 10
-36 
Coeff. + + + + + + 
R2 0.0447 0.0435 0.0445 0.0421 0.0423 0.0412 
Table 4.5: Logistic regression results testing LD adjusted polygenic scores, where all SNPs were 
adjusted for an LD SNP.  
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
PLD produced a more significant difference between cases and controls than the 
standard polygenic scores from an LD pruned subset (the baseline comparison 
model). Table 4.5 shows this was true for all SNP sets, which were LD pruned at 
different thresholds. Generally the results across these thresholds were fairly stable, 
but more significant for SNP sets with r2 < 0.8, 0.82 or 0.84. The variance explained 
with this method increased by up to 1% to 4.5% in the 0.8 and 0.84 pruned SNP sets 
compared to the baseline result.  
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Compared to the results in Table 4.4 for the same sets of SNPs, but not adjusted for 
any LD SNPs, the results in Table 4.5 were a couple of orders of magnitude less 
significant. While in theory the LD adjusted model should be more accurate, 
including extra covariates, particularly correlated covariates, reduces the accuracy of 
the effect size estimates. Therefore this model may be less significant compared to 
the unadjusted model with the same number of SNPs, as it has introduced additional 
errors.  
 
Within the SNP sets, some SNPs will effectively have no correlation with any other 
SNP. Theoretically the adjustment for LD SNPs with weak correlation should be 
minimal. To confirm that controlling unnecessarily for SNPs not in LD did not stifle 
the association, in a second iteration LD adjusted odds ratios were only calculated if 
there was a SNPLD1 with evidence of correlation with SNPtest, identified by r2 > 0.25. 
With this criterion, adjusted odds ratios were calculated for between 54% and 59% 
of SNPs with the percentage increasing as the pruning threshold became less 
conservative. 
 
Pruning 
threshold 
0.8 0.82 0.84 0.86 0.88 0.9 
Number of SNPs 
adjusted for an 
LD SNP 
46070 
(54.6%) 
47714 
(55.5%) 
49493 
(56.5%) 
51308 
(57.4%) 
53303 
(58.3%) 
55438 
(59.3%) 
P value 1.74 x 10-39 1.40 x 10-38 1.65 x 10-39 1.67 x 10-37 1.11 x 10-37 8.45 x 10
-37 
Coeff. + + + + + + 
R2 0.0448 0.0437 0.0449 0.0424 0.0426 0.0415 
Table 4.6: Logistic regression results testing LD adjusted polygenic scores, where SNPs where only 
adjusted for an LD SNP if r2 > 0.25.  
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
Only adjusting SNPs with a neighbouring SNP in sufficiently high LD produced 
nominally more significant differences between cases and controls compared to 
adjusting all SNPs, shown in Table 4.6. In principle and practice there was no benefit 
to accounting for weak correlation between SNPs. As it was possible that smaller r2 
values could have occurred by chance, in all subsequent applications a lower bound 
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was required when calculating adjusted odds ratios. This lower bound was set to r2 > 
0.25 as this was the pruning threshold used to create a set of independent SNPs. An 
additional benefit to this decision was a reduction in computation time.  
 
These results may still be an overestimate of the SCZ signal due to the aggregation of 
non-independent effects. Therefore this method was further extended to adjust the 
odds ratios for a second or even third LD SNP, denoted SNPLD2 and SNPLD3 
respectively. Partial correlations were used to identify the best SNPLD2 such that the 
correlation with SNPtest was independent to that already captured by SNPLD1, and 
SNPLD3 such that the correlation was independent to SNPLD1 and SNPLD2. SNPLD1, 
SNPLD2 and SNPLD3 were only included if there was evidence of LD with the SNPtest, 
identified as r2 or partial correlation greater than 0.25. Therefore SNPs were 
adjusted for zero, one, two or three other SNPs, depending on LD structure. In each 
pruning set pairs of SNPs with a partial correlation greater than the original pruning 
threshold were ignored.  
 
Pruning 
threshold 
0.8 0.82 0.84 0.86 0.88 0.9 
Total number 
of SNPs used 
in model 
84397 85954 87651 89405 91359 93475 
Number of 
SNPs adjusted 
for 2 LD SNPs 
12542 
(14.9%) 
12951 
(15.1%) 
13371 
(15.3%) 
13757 
(15.4%) 
14108 
(15.4%) 
14434 
(15.4%) 
P value 1.63 x 10-37 1.91 x 10-36 3.38 x 10-37 1.49 x 10-34 3.69 x 10-35 6.90 x 10
-34 
Coeff. + + + + + + 
R2 0.0424 0.0411 0.0420 0.0388 0.0396 0.0380 
Table 4.7: Logistic regression results testing LD adjusted polygenic scores, where SNPs were adjusted 
for up to two LD SNPs.  
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
For each pruning threshold ~15% of all SNPs included were adjusted for two LD SNPs, 
results presented in Table 4.7. Controlling for a second LD SNP continued to 
significantly discriminate cases from controls but a couple of orders of magnitude 
less significantly than including one LD SNP, with a lower estimate for the variance 
explained. As with controlling for one LD SNP, the results were fairly consistent 
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across the pruning thresholds and again the more conservative thresholds (0.8, 0.82 
and 0.84) had the most significant results. 
 
Pruning 
threshold 
0.8 0.82 0.84 0.86 0.88 0.9 
Number of 
SNPs adjusted 
for 3 LD SNPs 
2818 (3.3%) 2887 (3.4%) 2959 (3.4%) 3015 (3.4%) 3092 (3.4%) 3093 (3.3%) 
P value 1.47 x 10-36 1.00 x 10-34 2.54 x 10-36 4.46 x 10-34 1.06 x 10-33 1.30 x 10
-32 
Coeff. + + + + + + 
R2 0.0412 0.0390 0.0410 0.0382 0.0378 0.0365 
Table 4.8: Logistic regression results testing LD adjusted polygenic scores, where SNPS were adjusted 
for up to three LD SNPs.  
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
 
When controlling for a third LD SNP, SNPLD3, the proportion of SNPs for which three 
independent LD SNPs were identified was ~3%. This appears to have captured most 
of the LD structure for most SNPs in this dataset and hence no more LD SNPs were 
sought. The PLD were still significantly different between cases and controls, shown 
in Table 4.8, across all pruning thresholds although the variability of the results was 
greater than seen with zero, one or two LD SNPs.  
 
The decrease in significance of p values as a second and then a third LD SNP was 
included compared to the models adjusted for zero or one LD SNPs was again, likely 
due to increasingly poorly estimated effect sizes. However, even with poorly 
estimated effect sizes the increased number of SNPs in each of these sets meant all 
LD adjusted models were more significant than the baseline model on a more 
stringently pruned subset. The most significant result controlling for up to three LD 
SNPs in the r2 < 0.8 SNP set explained more than 4% of the variance, which was an 
improvement of half a per cent on the baseline comparison. 
 
Comparing pruning thresholds 
Regression models are known not to be good at handling highly correlated variables, 
which can cause unreliable estimates of the coefficients or effect size. The principle 
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here was to include SNPs in LD, i.e. those with a correlation between them, in the 
regression framework and take the coefficients from these as weights for the 
polygenic model. Therefore it was prudent to investigate the potential impact of this 
on the coefficient estimates. As an attempt to prevent extreme violations of this 
assumption, mild pruning based on the r2 statistic between SNPs was performed. 
Here the output of the logistic regression, in particular the standard errors (SE) of 
the coefficients for SNPtest, was examined to check the thresholds chosen were 
appropriate.  
 
Large SE can be caused by multicolinearity and signify that unreliable estimates of 
the odds ratio were used to calculate the polygenic scores. For regression models 
with one, two or three LD SNPs the distribution of SE were plotted for each pruning 
threshold and in particular the tails of the distribution were looked at for extreme 
SE. As the output of the logistic regression with no LD SNPs was the same across all 
pruning thresholds, the distributions were virtually identical, varying only by the 
number of SNPs (and which SNPs) included so just one plot with the most SNPs was 
produced for comparison. 
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Figure 4.2: Violin plots of SE for beta coefficients for SNPs in LD adjusted polygenic models. 
Each plot shows the range and frequency distribution of SE and represents a different polygenic 
model from Tables 4.6-4.8.Plots include SE from all SNPs used to calculate polygenic scores which will 
be adjusted for up to N SNPs on y axis. The violin plot at the top (yellow) is of SE from SNP set with r2 
< 0.9 not adjusted for any LD SNPs and is included for comparison. 
 
When no LD SNPs were included, no multicolinearity was introduced and the SE for 
the coefficient estimates were all less than 0.13, although the distribution shows a 
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long right tail with a 95th percentile of 0.089, see Figure 4.2. Generally the inclusion 
of LD SNPs shifts the distribution to the right, increases the inter-quartile range or 
spread of the data and the length of the right tail. This effect was intensified as the 
pruning threshold became more relaxed and the possibility of higher correlations 
between SNPs increases. Across the more conservative thresholds (0.8, 0.82 and 
0.84) the SE distributions were fairly similar when one, two or three SNPs were 
included in the regression.  For the less conservative thresholds (0.88 and 0.9) the 
inclusion of the second and third LD SNPs produced the longest tails, with the 0.86 
results intermediate to these two groups.  
 
Based on these observations and trying to retain as many SNPs as possible, a 
threshold of 0.84 appears the correct balance for these data as it did not have many 
SE larger than those observed at the more conservative thresholds. This SNP set 
produced only marginally less significant results when including any number of LD 
SNPs than the best results with the 0.8 threshold. In fact the three most conservative 
thresholds were always more significant than the three least conservative. Despite 
more relaxed pruning generating larger SNP sets, the higher SE associated with 
including more strongly correlated markers meant that the higher proportion of 
SNPs with unstable estimates of effect size introduced noise.  
 
The effect of correlated markers on estimates of the odds ratios will vary from 
dataset to dataset as larger samples will be able to handle multicolinearity, as well as 
multiple LD SNPs, better than smaller sample sizes. The size of the ISC sample 
appears to be big enough to avoid huge SE (> 1) even when including up to three 
extra SNPs correlated with the test SNP. However the increased error sizes appear to 
accumulate when summing over multiple SNPs and cause a decrease in significance 
as additional LD SNPs were included.  
 
4.2.4 SNP-SNP interaction polygenic scores 
The final adaptation to the polygenic model was to extend it to include interactions 
between pairs of SNPs. Significant interactions for all SNPs in the SNPIA set with 
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another independently associated SNP within this set were identified in the 
following manner. SNPs were ordered by their chromosomal position and for each 
SNP, taken as SNPtest, all SNPs with r2 < 0.25 from the preceding 200 and within 
1000kb were considered. Of these SNPint was selected as the one with the strongest 
individual evidence of association in the ISC GWAS, defined as the smallest 
association p value. As this SNPint is part of the SNPIA set its p value < 0.5 and 
therefore has some evidence of an association to SCZ. This approach ensures that for 
each SNP a unique interaction was considered. Equation 4.6 shows the logistic 
regression model fitted to estimate the odds ratios and significance of each 
interaction. 
 
status ~ SNPtest + SNPint + SNPtest ∗ SNPint +  ω 
Equation 4.6 Logistic regression model used to identify significant SNP-SNP interactions between 
SNPtest and SNPint, which are independently associated to SCZ and estimate the associated odds ratio , 
where status is SCZ case control status, SNPtest and SNPint are the number of minor alleles at these 
SNPs and ω is the population covariates. 
 
A SNP based polygenic score and interaction based polygenic score were calculated 
separately. The SNP score, SA, was calculated as described previously, shown in 
Equation 4.7, where for all SNPs without a significant interaction the odds ratios 
were taken from the standard logistic regression model used for testing association 
shown in Equation 4.4A. For SNPs with a significant interaction the odds ratios were 
taken from Equation 4.6 so that they were adjusted for the contribution of the 
interaction. 
 
SAi = ∑ βk ηik
k
 
Equation 4.7 Formula to calculate SNP based polygenic score SAi for individual i, where βk is the 
coefficient for SNPtest taken from Equation 4.6 for significant interactions or Equation 4.4A otherwise 
and ηik is the number of associated alleles for individual i at SNP k. 
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The interaction score, SI, was calculated for each significant interaction as the 
product of the number of minor alleles at each SNP multiplied by the natural 
logarithm of the associated odds ratio from Equation 4.6, shown in Equation 4.8. 
 
SIi = ∑ βintηintiηtesti
int
 
Equation 4.8: Formula to calculate interaction based polygenic score SIi for individual i, where ηtest is 
the number of associated alleles at SNPtest, ηint is the number of associated alleles at SNPint and βint is 
the coefficient for the interaction term from Equation 4.6. 
 
In any instance where the genotype was missing the expected value was taken based 
on the allele frequencies in the target dataset. The polygenic scores, as implemented 
in PLINK, are divided by the number of SNPs to give a mean score per SNP. Hence, SI 
was divided by the number of significant interactions to give the mean score per 
interaction. 
 
Interaction threshold 0.5 0.1 0.05 0.01 0.005 0.001 
Model 
testing 
SNP score: 
SA 
P value 1.84 x 10-19 1.18 x 10-19 6.31 x 10-21 1.33 x 10-30 1.86 x 10-30 4.19 x 10-31 
Coeff. + + + + + + 
R2 0.0203 0.0205 0.0219 0.0328 0.0326 0.0333 
Model 
testing 
interaction 
score: SI 
P value 0.284 0.286 0.289 0.293 0.293 0.285 
Coeff. - - - - - - 
R2 0.000288 0.000286 0.000283 0.000278 0.000277 0.000286 
Table 4.9: Logistic regression results testing polygenic SNP scores and polygenic interaction scores 
separately. 
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
Six thresholds (0.5, 0.1, 0.05, 0.01, 0.005 and 0.001) were used to identify significant 
interactions. The distribution of interaction p values was fairly uniform and at each 
threshold, the proportions that were significant were just less than would be 
expected by chance. Firstly the SA and SI were tested separately in logistic regression 
models predicting case control status. Table 4.9 shows the SNP scores, SA, all 
significantly predicted case control status, although less significantly than in the 
original framework. This discrepancy was due to a proportion of the SNPs using odds 
ratios adjusted for a significant interaction.  Fewer interactions will be found at more 
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stringent thresholds and therefore less of the SNP odds ratios will have been 
adjusted, meaning these SNP scores become closer to the baseline polygenic scores 
as the threshold became more significant. None of the interaction scores, SI, 
significantly predicted case control status, regardless of the threshold used to select 
interactions for inclusion.  
 
Both of these scores were then tested simultaneously in a joint model to see if the 
inclusion of the interaction term in addition to the SNP score improved the fit of the 
model, results presented in Table 4.10. Only at a threshold of 0.5 for significant 
interactions there was a trend for the interaction score to predict case control 
status. At all other thresholds the SNP score was significant but the interaction score 
was not. In sum, the inclusion of a polygenic score based on SNP-SNP interactions 
did not improve on just a SNP based score.  
 
Interaction threshold 0.5 0.1 0.05 0.01 0.005 0.001 
Joint 
model 
P value 3.44 x 10-19 8.30 x 10-19 7.02 x 10-20 1.56 x 10-29 1.53 x 10-29 2.44 x 10-30 
R2 0.0212 0.0207 0.0220 0.0329 0.0329 0.0338 
SNP score 
P value 5.27 x 10-20 1.28 x 10-19 1.05 x 10-20 1.89x 10-30 1.84 x 10-30 2.93 x 10-31 
Coeff. + + + + + + 
Interaction 
score 
P value 0.0571 0.319 0.714 0.515 0.287 0.175 
Coeff. + + + - - - 
Table 4.10: Logistic regression results testing polygenic SNP scores and polygenic interaction scores 
jointly. 
Compare to baseline result of p = 5.41 x 10-31, R2 = 0.0345. 
 
4.2.5 Summary of polygenic model adaptations 
Of the adaptations investigated here, the population weighted approach performed 
similarly to the baseline result and the inclusion of SNP-SNP interactions did not 
improve the model fit. Alternatively, including the LD relationships between SNPs 
meant that more than double the number of SNPs could be retained, which 
improved the significant difference in polygenic scores between cases and controls. 
Allowing for up to three LD SNPs captured the majority of the LD relationships and 
improved the variance explained by over half a per cent to more than 4%.   
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All of these approaches require large sample sizes to accurately estimate the odds 
ratios and may suffer from introducing additional inaccuracies. Despite this, in the LD 
adjusted model the relaxed LD pruning threshold meant more SNPs could be 
included and this outweighed the increased errors when estimating the effect sizes. 
In the next section the LD adjusted approach will be used to test gene sets identified 
from the expression work in the previous chapters. The pruning threshold of r2 < 
0.84 will be used as it was the best balance of maximising the number of SNPs and 
obtaining reasonable SE in the results presented so far. 
 
4.2.6 Application to gene set identified in Chapter 3 
In the previous chapter a temporal expression profile was identified for SCZ risk 
genes with increased expression during early and mid-foetal stages followed by a 
decrease of expression to the lowest values in early postnatal years before 
increasing though adolescence and adulthood. This was captured by identifying 
genes co-expressed with robustly associated SCZ genes over brain development 
through a linear model. Here the most enriched set, identified from the Mann-
Whitney tests shown in Appendix Figure 8.15 panel A as the top 25% of genes ranked 
by their SCZ co-expression model p values calculated from Equation 3.3, were taken 
and polygenic scores calculated for the set.  
 
These scores, calculated using the method as described by the ISC in a pruned SNP 
set (r2 < 0.25), were found to be significantly higher in SCZ cases compared to 
controls (p = 6.34 x 10-12; R2 = 0.0118).  This confirms the results in the previous 
chapter that genes identified with this common developmental expression profile 
harbour multiple common risk variants associated with SCZ. 
 
Scores calculated in a less stringently pruned SNP set  (r2 < 0.84) were a more 
significant predictor of case control status (p = 1.02 x 10-13; R2 = 0.0118) which was as 
to be expected, as more SNPs were included to calculate the score. Polygenic scores 
were also calculated using the LD adjusted method introduced in Section 4.2.3 for up 
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to three LD SNPs. Of these, presented in Table 4.11, the most significant result was 
when up to two LD SNPs were adjusted for (p = 3.97 x 10-9; R2 = 0.00866). Unlike with 
the genome-wide scores there was not a monotonic increase in p values as the 
number of LD SNPs included increased, further none of the LD adjusted results were 
more significant than the r2 < 0.25 pruned unadjusted result.  
 
Pruning 
threshold 
0.25 0.84 
Odds ratios 
adjusted for up 
to N SNPs 
0 0 1 2 3 
Number of 
SNPs used to 
calculate scores 
5362 10162 
10162 
(5019a) 
10162 
(3746a, 1273b) 
10162 
(3746a, 994b, 
279c) 
P value 6.34 x 10-12 1.02 x 10-13 1.38 x 10-7 3.97 x 10-9 6.59 x 10
-8 
Coeff. + + + + + 
R2 0.0118 0.0138 0.00695 0.00866 0.00730 
Table 4.11: Logistic regression results testing expression gene set polygenic scores using unadjusted 
and LD adjusted methods. 
 a number of SNPs adjusted for 1 LD SNP, b number of SNPs adjusted for 2 LD SNPs, c number of SNPs 
adjusted for 3 LD SNPs.  
Pruning threshold 0.25 0.84 
Odds ratios adjusted for 
up to N SNPs 
0 0 1 2 3 
Joint 
model 
P value 1.42 x 10-32 2.99 x 10-44 1.77 x 10-41 4.52 x 10-39 1.01 x 10-37 
R2 0.0363 0.0494 0.0463 0.0436 0.0421 
Genome-
wide 
polygenic 
score 
P value 2.01 x 10-23 1.98 x 10-33 1.19 x 10-36 9.84 x 10-33 1.44 x 10-32 
Coeff. + + + + + 
R2 0.0248 0.0361 0.0396 0.0352 0.350 
Gene set 
polygenic 
score 
P value 0.00673 0.0252 0.0152 0.0111 0.0315 
Coeff. + + + + + 
R2 0.000186 0.00127 0.00150 0.00164 0.000117 
Table 4.12: Logistic regression results jointly testing genome-wide and gene set polygenic scores.  
The final step was to see if these gene set polygenic scores captured anything 
additional to the whole-genome polygenic score. As it was calculated with more 
SNPs the whole-genome polygenic score was, as expected, the more significant 
term, see Table 4.12. However in all five models the gene set score also remained 
significant implying it captured some SCZ signal not present in the whole-genome 
score. The gene set score was most significant in the more stringently pruned 
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unadjusted method. However, overall, for all models presented in Table 4.11, using 
both scores to predict case control status only explained slightly more of the 
variance compared to just using the whole genome score.  
 
The gene set scores were also compared to genome-wide measures calculated only 
from genic SNPs, results shown in Table 4.13. In this scenario the gene set score was 
not a significant predictor when the whole genome score was included in any of the 
five models tested. This implies that the gene set score was a proxy for the genome-
wide genic score and that there was additional genic signal outside this set. It also 
suggests that there was a polygenic signal for SCZ in both genic and non-genic SNPs, 
although this was weaker in the latter set. Therefore when the gene set score was 
tested against the whole genome score, which included both genic and non-genic 
SNPs, it remained significant as the genome-wide score had introduced a weaker 
signal from the non-genic SNPs. Whereas when the gene set score was tested 
against a genome-wide score calculated from just genic SNPs it did not contain any 
signal not already captured and hence was not significant. 
 
Pruning threshold 0.25 0.84 
Odds ratios adjusted for 
up to N SNPs 
0 0 1 2 3 
Joint model 
P value 1.61 x 10-27 2.63 x 10-35 8.32 x 10-36 1.61 x 10-32 3.80 x 10-31 
R2 0.0306 0.0394 0.0399 0.0362 0.0347 
Genome-
wide 
polygenic 
score 
P value 2.61 x 10-18 2.08 x 10-24 6.12 x 10-31 4.01 x 10-26 6.25 x 10-26 
Coeff. + + + + + 
R2 0.0190 0.0259 0l.0332 0.0278 0.0276 
Gene set 
polygenic 
score 
P value 0.400 0.862 0.148 0.233 0.462 
Coeff. + + + + + 
R2 0.000179 7.62 x 10-6 0.000531 0.000361 0.000137 
Table 4.13: Logistic regression results jointly testing genic genome-wide and gene set polygenic 
scores. 
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4.3 Discussion 
4.3.1 Extensions of polygenic model 
Of the adaptations described here the most successful was the inclusion of LD 
relationships between markers. The main benefit of this method was that the initial 
pruning threshold to obtain a set of independent SNPs could be relaxed, and 
therefore more SNPs were included when calculating the scores. From these extra 
SNPs additional information was retained that previously may have been missed.   
 
Theoretically the LD adjusted model should be more accurate than a model based on 
the same set of SNPs that incorrectly assumes the association of each SNP is 
independent. However, the more complex LD adjusted model will be limited by 
poorer estimates of effect size. As additional LD SNPs were controlled for, from zero 
to three, the p values for predicting case control status became less significant. The 
inclusion of each additional SNP as a covariate in the logistic regression model 
introduced larger SE for the odds ratios with a higher proportion of SE at the 
extreme end of the distribution, see Figure 4.2. This effect will be further enhanced 
when the covariates are correlated, such as the case here. When summing across 
SNPs for the polygenic score, the combination of even small errors becomes 
significant (Dudbridge, 2013), while the SE only increased for the subset of SNPs 
adjusted for LD SNPs the accumulative impact of this will affect the predictive ability 
of the polygenic scores. This would be improved by larger sample sizes, which would 
improve the accuracy of the effect size estimates and be able to handle correlated 
covariates better. 
 
This application, however, has shown that this approach is plausible with real data, 
and that the inclusion of additional SNPs still improves the discrimination of the 
scores even if the effect sizes have been estimated with reduced accuracy when 
compared to the stringently pruned, unadjusted baseline result. Ideally, a 
simulations procedure would be performed to directly compare the approach 
introduced here to the simple pruned version introduced by the ISC in scenarios 
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where the true variants and LD structure is known. This was beyond the time-frame 
of this project but would be an interesting extension.  
 
Although SNP chips only contain a few hundred thousand SNPs, the markers are 
carefully selected to capture genetic variation across the majority of the genome 
(Hirschhorn and Daly, 2005).  Based on the genotypes identified from a SNP chip 
experiment, many other SNPs can be imputed using the relationships between the 
markers and probability models. Imputation will further increase the information 
available to calculate polygenic scores, but the LD structure will need to be taken 
into account as the number of correlated associations from a GWAS based on an 
imputed dataset will be greater. The LD adjusted method proposed in this thesis 
may, therefore, enable the polygenic score approach to be applied to studies where 
imputation has been used. 
 
For SCZ the polygenic model had already been shown to be highly significant, even 
for a stringently pruned SNP set.  The LD adjusted method with a more relaxed 
pruning threshold improved the significance of this result further, by a couple of 
orders of magnitude. The benefit of this approach may be more relevant for 
scenarios where polygenic scores were only nominally associated to an outcome 
measure and the inclusion of extra SNPs through less conservative SNP pruning may 
help identify true signals. Such scenarios could include taking GWAS results from one 
phenotype to predict a different trait or disorder, or testing the polygenic nature of a 
subset of genes for example from a functional pathway. Caution is advised however, 
and users would have to consider how far the pruning threshold could be relaxed 
and how many LD SNPs could be included given their sample size, particularly, if this 
was already a factor of the initial inconclusive results.  
 
Sample size was also a factor in the calculation of the population weighted and 
interaction polygenic scores. Subdividing the ISC into seven smaller subpopulations 
will have introduced inaccuracies when estimating the effect sizes for each 
population, which would have been further exacerbated when summed across 
populations to calculate the population weighted odds ratios, and then across SNPs 
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to calculate the final polygenic scores. To accurately estimate interaction odds ratios 
a much larger sample size is required relative to that needed when estimating SNP 
odds ratios, in particular for small effects which is what the polygenic model is 
designed to capture. In both of these approaches with the current sample size the 
inaccuracies of the effect sizes will have introduced noise deflating the significant 
difference between cases and controls and may explain why neither adaptation 
performed better than the baseline comparison model. 
 
SNP-SNP interactions have been suggested to explain some of the missing 
heritability of complex disorders (Manolio et al., 2009). It is likely in this dataset that 
there was not enough power to identify truly associated interactions. In the 
implementation described here the SNP-SNP interactions were selected as the 
strongest independent association from a set of neighbouring SNPs. This obviously 
ignored any possible interactions between SNPs on different chromosomes. 
Alternative ways of choosing pairs of SNPs could be further investigated and for 
example may look at interactions within the same gene, or between functionally 
related genes which may be more likely to be associated to disease. A score based 
on these may be more effective at discriminating between cases and controls.  
 
An additional consideration for all of these adaptations is the additional 
computational time required.   The polygenic method as described in the ISC paper is 
part of the PLINK analysis package (Purcell et al., 2007) and post GWAS is very quick 
to implement. Each adaptation here requires additional association analyses on top 
of the initial GWAS to obtain an alternative effect size estimate, although in each 
case this was only applied to a subset of SNPs. The population weighted approach 
was the most computationally intensive as it also requires the calculation of the 
population likelihood values for each individual in the target dataset. The LD 
adjusted method was the easiest to implement because after adjusting the relevant 
odds ratios the PLINK –-score function can be used to calculate the target individuals 
LD adjusted polygenic scores.  
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4.3.2 Assessing polygenic contribution of gene set identified from Chapter 3 
The rationale behind these extensions was to identify possible improvements to the 
polygenic framework for use with a set of genes informed as relevant for SCZ 
aetiology from the gene expression work in Chapters 2 and 3. Polygenic scores 
calculated based on such a gene set significantly predicted SCZ case control status. 
This was in line with the enrichment of this set for gene-wide p values combined 
using Brown’s approach, which takes in account multiple signals within a gene in 
Chapter 3. Comparing the gene set polygenic scores to scores calculated from SNPs 
across the genome showed that they were representative of a score based on all 
genic SNPs suggesting SCZ signal is concentrated in genes, consistent with another 
study showing enrichment of association signal in genic elements for many complex 
diseases including SCZ and BPD (Schork et al., 2013). While it has previously been 
shown that common variants associated through GWAS with SCZ are over-
represented in brain-expressed genes (Lee et al., 2012a), it would be of interest to 
see if the subset of genes with a temporal profile across brain development used 
here harbour more polygenic signal compared to random gene sets with similar 
numbers of SNPs. Set-based tests in Section 3.2.5 in the previous chapter, found that 
this set of genes contained SCZ association signal after correcting for the number of 
SNPs within the set,  suggesting that this would be the case. 
 
4.3.3 Summary of chapter findings 
In sum, this chapter has shown that genetic prediction based on a subset of genes 
identified through gene expression profiles as enriched for SCZ signal can be used to 
discriminate between cases and controls. This suggests that within this set of genes 
there are likely many variants that are currently sub-threshold but as sample sizes 
increase will be identified as associated to SCZ. This is consistent with the findings in 
the previous chapter that genes within this set, identified by their co-expression with 
SCZ risk genes, are good candidates for SCZ aetiology. Further, functional analysis on 
this set of genes, as performed in Chapter 3, may help understand the biological 
causes of SCZ. 
  
171 
 
  
172 
 
Chapter 5: Discussion 
5.1 Identification of temporal expression profile for schizophrenia risk 
genes 
SCZ is generally regarded as a neurodevelopmental disorder where aberrant brain 
development may cause symptoms to present later in life (Murray and Lewis, 1987, 
Weinberger, 1987). Increased rates of minor physical anomalies (Xu et al., 2011) and 
dermatoglyphic anomalies (Golembo-Smith et al., 2012) suggest that at least in some 
individuals a disruption occurs during gestation, prior to the formal onset of 
symptoms during adolescence. Further, association studies have identified genetic 
risk factors in genes related to brain development such as MIR137 (Ripke et al., 
2011) and genes hit by CNVs found in SCZ patients have been shown to be 
overrepresented in pathways relating to brain development (Walsh et al., 2008, 
Raychaudhuri et al., 2010).  
 
The purpose of this thesis was to investigate the neurodevelopmental hypothesis of 
SCZ, integrating transcriptomic, GWAS and CNV data to identify functional pathways. 
The main finding was a developmental expression profile for genes associated to 
SCZ. This was characterised by increased expression during foetal development, in 
particular during the second trimester, before a decrease prior to birth that 
continued to the lowest expression values around late infancy and early childhood 
before increasing through adolescence. This is supportive of the 
neurodevelopmental model for SCZ, where an insult during gestation, perhaps 
during the second trimester when gene expression values were greatest, may affect 
development to the extent that psychiatric symptoms present later in life. As 
discussed in Chapter 2, the second trimester has previously been suggested as a 
vulnerable time point for insults related to an increased risk of SCZ, with minor 
physical anomalies and dermatoglyphic abnormalities considered as markers for 
disruptions during this time frame (Lobato et al., 2001).  
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Previous studies have investigated the temporal profile of risk genes for SCZ 
(Colantuoni et al., 2008, Choi et al., 2009, Harris et al., 2009) however, this is the first 
study to include prenatal samples, covering the full range of human brain 
development up until late adulthood. Moreover, this study included multiple brain 
regions for each individual where previous studies have generally focused on 
samples from the prefrontal cortex. Chapter 2 focused on a period of mid-foetal 
development and identified spatial expression profiles, notably those with decreased 
expression in the HIP or THAL, enriched for both SCZ and BPD common variants. 
Gene sets with these expression patterns were also shown to have a variable 
expression profile across brain development with high expression during foetal 
development, which starts to decreases prior to birth to lower values during 
postnatal years until adolescence, shown in Figure 2.10.  
 
Chapter 3 identified the same developmental expression profile described in Chapter 
2 and extended it by considering samples up to late adulthood through two 
complementary approaches. Firstly, specific characteristic expression profiles across 
development were identified. Genes with increased expression during foetal 
development and decreased expression in early postnatal years were associated 
with more significant SCZ gene-wide p values. Secondly, sets of genes co-expressed 
with SCZ risk genes were shown to be enriched for SCZ common variants and their 
characteristic expression profiles matched the results of the first set of analyses. 
These results suggest that SCZ risk genes play a role in the development of the 
human brain, particularly during foetal stages when expression values were highest, 
but also during adolescence. 
 
Generally, previous studies have only considered linear relationships between 
expression values and age for SCZ risk genes in healthy post-mortem brains 
(Colantuoni et al., 2008, Choi et al., 2009). The strategy used here to identify genes 
characteristic of each development stage was more in line with that of Harris et al. 
who looked for genes with their maximum or minimum expression values during the 
period of onset for SCZ (Harris et al., 2009). The study presented in this thesis, 
however, considered fifteen separate development stages from early foetal through 
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to late adulthood. By using a regression framework for the analyses, sample 
differences or potential confounders could be taken into account. The enriched 
profile was non-linear, suggesting that to truly capture the variability of these genes 
simply correlating expression values with age is not sufficient. 
 
After identifying genes associated with age, only one other study did a formal 
analysis to demonstrate that age dependent genes were enriched for genes 
associated to SCZ (Choi et al., 2009).  All of these studies had identified SCZ risk 
genes from reviews of the literature before many, if any, robust associations had 
been reported, questioning the validity of these lists. In the analyses presented here, 
results from the largest published and therefore the most reliable GWAS to date 
were used as a measure of SCZ or BPD association. Therefore this study has 
extended these works by showing that genes associated to SCZ do vary across the 
full range of human life and has described the trajectory of these genes.  
 
Recently other studies have used the BrainSpan RNA-Seq or Kang microarray data to 
interpret their studies into the genetic causes of SCZ (Gilman et al., 2012, Xu et al., 
2012, Gulsuner et al., 2013). Their descriptions are consistent with the results 
reported here, finding relatively higher prenatal expression for SCZ risk genes 
(Gilman et al., 2012, Xu et al., 2012) as well as an increase during early adulthood 
(Gulsuner et al., 2013). These findings were based on simple comparisons of prenatal 
and postnatal expression (Gilman et al., 2012, Xu et al., 2012) or just descriptions of 
expression plots (Gulsuner et al., 2013).  In contrast, the techniques used in this 
thesis considered each development stage separately and therefore can be more 
specific about the developmental trajectory of these genes.  
 
Results in Chapters 3 and 4 showed that genes with this temporal profile contained 
multiple, independent common variants associated with an increased risk of SCZ. 
This is consistent with a previous finding that central nervous system (CNS) 
expressed genes are enriched for common variants associated to SCZ relative to their 
genomic length (Lee et al., 2012a). This study estimated that their set of CNS 
expressed genes contained around 7% of variation of liability to SCZ. Although the 
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gene set investigated in Chapter 4 was approximately the same size it only explained 
~1% of the variance. This value will be affected by the accuracy of the effect size 
estimates (Dudbridge, 2013) and is therefore an underestimate which will increase 
as the sample size of the discovery sample increases (Lee et al., 2012a).  
 
5.2 Identification of temporal expression profile for bipolar disorder 
risk genes 
While typically BPD has been considered an adult disorder, increasing evidence of an 
overlap with SCZ has meant that it has also been investigated for 
neurodevelopmental antecedents with currently inconclusive findings (Sanches et 
al., 2008). The developmental expression profile was primarily associated with more 
significant SCZ GWAS gene-wide p values. In Chapter 2, gene sets enriched for both 
SCZ and BPD common variants were observed to have this temporal expression 
profile. All results in Chapter 3 for BPD were consistent with the SCZ results but were 
generally less significant. The reduced significance in the BPD results can likely be 
explained by the GWAS results coming from a smaller study compared to SCZ, 
meaning that there was less power to detect associations for BPD in this study. 
However, this may also be evidence for a milder neurodevelopmental disruption 
compared to SCZ.  The results presented here suggest that genes associated with 
increased risk for BPD also exhibit this temporal expression pattern, consistent with 
the shared genetic aetiology between SCZ and BPD particularly for common variants. 
Interestingly when testing the SCZ and BPD co-expression models simultaneously, a 
stronger enrichment for SCZ variants was found with the SCZ co-expression model 
whereas a stronger enrichment for BPD variants was found with the BPD co-
expression model. Although these tests showed that both the SCZ and BPD co-
expression models were detecting similar sets of genes, these models may be 
capturing some genuine differences in risk genes and further investigation would be 
warranted to clarify this.   
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5.3 Identification of functional pathways from genes with common 
expression profiles 
Gene expression is seen as an intermediate between genotype and phenotype and 
therefore commonly used to infer biological mechanisms affected in SCZ aetiology 
(Hakak et al., 2001, Katsel et al., 2005b, Maycox et al., 2009). Part of the aim of this 
thesis was to identify functional pathways from the integration of GWAS, CNV and 
transcriptomic data; hence expression profiles associated with SCZ and BPD were 
subject to pathway analysis.  
 
Functional analysis of genes with the described temporal profile identified five 
groups of functional terms: ‘Chromosome: structural modification & repair’, ‘RNA 
processing’, ‘RNA/protein transport’, ‘Cell cycle (mitosis)’ and ‘Signal transduction’.  
Three of these were also identified in Chapter 2, however only genes within the 
‘Chromosome: structural modification & repair’ with the temporal profile or 
enriched spatial profiles in the mid-foetal brain had a significant SCZ association in 
both chapters. Therefore, these pathways were the most consistent across the two 
chapters, suggesting that SCZ risk genes play a role in epigenetic regulation through 
processes such as histone modification, methylation or acetylation. These 
mechanisms can either enhance or repress gene expression which, if disrupted, may 
impact on brain development and have functional consequences as the brain 
matures during adolescence.  
 
Two other pathway groups ‘RNA processing’, and ‘RNA/protein transport’, also 
relating to the control of gene expression, were identified in both Chapters 2 and 3 
but were only found to be enriched for SCZ association in Chapter 2. The lack of 
association in Chapter 3 may be explained by the fact that the spatial profile scores 
were calculated across two independent datasets to reduce the amount of noise and 
the number of spuriously associated terms. The temporal characteristic scores in 
Chapter 3 were only calculated within one dataset and therefore may contain some 
random variation, diffusing the SCZ association.  
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While predominantly interested in consistent themes across Chapters 2 and 3, the 
identification of the ‘Cell cycle (mitosis)’ functional group in Chapter 3 may also be 
relevant, as it was enriched for SCZ association. These terms are relevant to the 
production of neurons, which continues through the second trimester. Although 
these terms were not identified in the functional analysis in Chapter 2, Figure 2.10 
showed that the HIP and THAL characteristic genes had a peak of expression during 
the second trimester coinciding with the period of neurogenesis, suggesting that SCZ 
risk genes are involved in this process. During this period the rate of production of 
neurons is high, meaning disruptions could potentially impact on the structure and 
function of the mature brain (Miranda, 2012). 
 
5.4 Future work 
Although Chapter 3 used both microarray and RNA-Seq data to provide technical 
replication, these datasets were not independent. Moreover, not all results were 
verified across both technologies for example, testing the association of genes 
whose expression correlated with strongly associated SCZ genes in Section 3.1.2. As 
an independent expression dataset covering the same age range was not available, 
the primary objective of any future work would be replication of the described 
temporal profile for SCZ and BPD risk genes. 
 
The availability of an additional temporal expression dataset would also allow 
further investigation of two unanswered questions in this work. Firstly, it would 
ascertain if the temporal profile identified was an artefact of the different PMI 
between the prenatal and postnatal samples. Although including this variable as a 
covariate still supported the expression pattern described, it would be beneficial to 
confirm this in an independent dataset.  Secondly, the current expression dataset 
had few samples between 22 and 35 PCW. It was during this time frame that 
expression levels started to decrease and a dataset with more complete coverage of 
this developmental period would help specify further when the drop in expression 
occurs. 
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An alternative replication approach would be to use an independent GWAS dataset 
for replication, but again no such published independent dataset exists, at least one 
with the same level of confidence. The PGC have since expanded their SCZ mega-
analysis from 17 to 52 studies in version two, although this is yet to be published. 
This is obviously not independent to the GWAS already used here, but certainly is 
more powerful and is a useful resource to check the findings reported here hold up. 
Preliminary work shows that they do. 
 
The current work could easily be extended to incorporate sequencing data alongside 
the GWAS and CNV data. Exome sequencing and eventually whole genome 
sequencing data will become increasingly prevalent and will be able to identify a 
range of different mutations in those affected by SCZ or BPD (Gershon et al., 2011). 
The challenge will be distinguishing those that are disease causing from those that 
are part of natural variation; bioinformatic tools that predict the functional 
consequences of any mutation or variants that are found in multiple affected 
individuals may point researchers towards the right candidates (Ku et al., 2013). 
Current exome sequencing studies for SCZ have identified genes with de novo 
functional variants and have investigated the temporal expression of these genes (Xu 
et al., 2012, Gulsuner et al., 2013). An alternative approach would be to calculate 
gene-wide measures of rare variants through burden tests, or even a combined 
measure of rare and common variation for example using the Combined Multivariate 
and Collapsing test (Li and Leal, 2008) and test in a similar fashion to the gene-wide p 
values calculated from GWAS data used here. 
 
While this study included high-quality data from a variety of different studies, it 
remains a bioinformatics study. Functional mechanisms identified would need to be 
experimentally validated and tested to truly understand how they relate to SCZ 
aetiology. If the profile was confirmed in an independent dataset the next step 
would be to investigate how these findings relate to SCZ brains. One simple 
extension would be to see if genes with this temporal profile are differentially 
expressed between SCZ and control brains. Expression changes in SCZ brains can be 
influenced by many external factors, such as medication effects or lifestyle 
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differences such as alcohol or drug exposure, which makes it challenging to identify 
which changes are related to the primary disease processes from secondary 
responses. Ideally these issues would need to be addressed first in order to compile 
a list of genes that are truly dysregulated in SCZ before integrating with the analyses 
in this thesis.  
 
As a similar developmental study of SCZ brains would be impossible, an alternative 
would be to look in peripheral tissues such as blood, which could then be compared 
to healthy controls. One benefit to this approach would be that the same individual 
could be followed up over time, removing the issue of individual variation. As SCZ is 
not diagnosed until adolescence, this would need to be a prospective study based on 
a large population cohort such as the Avon Longitudinal Study of Parents and 
Children (ALSPAC) (Golding et al., 2001). Though even then, based on the prevalence 
of SCZ the number of cases is likely to be small. Such a study could lead to the 
identification of a biomarker which would have clinical utility (Gladkevich et al., 
2004, Chana et al., 2013). However, any findings would always need to be linked 
back to the tissue of interest, the brain, in order to develop our understanding of the 
causes of SCZ. 
 
A second alternative would be to look in animal models, which could be used to 
directly assess the impact of prenatal insults on gene expression.  Such studies have 
already been undertaken, with rodents subjected to in utero exposure to infection 
assessed for expression changes compared to control offspring. Despite many genes 
showing differences, these are rarely consistent across animal models (Schijndel and 
Martens, 2010). Further, any findings will also need to be related back to the human 
brain. 
 
The results presented in this thesis would recommend a follow-up investigation of 
expression quantitative trait loci or eQTLs in the developing human brain. This study 
has emphasised the importance of and the regulation of gene expression in brain 
development during mid-foetal and early childhood stages. If genotypes were 
available for the same samples, it could be tested whether expression at these time 
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points is genetically regulated. Further, it may be tested whether SNPs regulating 
gene expression at these time points are associated to SCZ in GWAS studies. These 
analyses would have the potential to explain some of the functional implications of 
genetic variants shown to increase risk of developing SCZ and would tie in with the 
transcriptional regulation themes arising from the GO analysis. 
 
Given the enrichment of these genes in terms relating to epigenetic processes, one 
direction would be to investigate epigenetic marks, such as histone methylation 
levels. Based ideally on the same sample, changes in methylation levels across 
development could be measured to see if these correlated with the expression 
findings. For example, histone methylation marks associated with repression of gene 
expression such as dimethylation of histone H3 at lysine 9 (H3K9me2) may be 
predicted to be associated with SCZ risk genes during postnatal years when 
expression values were lowest. Epigenetic mechanisms are dynamic processes 
throughout development that modify gene expression, generally through changes to 
chromatin structure or DNA methylation and play an important role in brain 
development (Fagiolini et al., 2009, Ma et al., 2010). Epigenetic changes have been 
reported as a result of prenatal stresses such as exposure to famine (Tobi et al., 
2009) and therefore may explain the link between these and SCZ risk.   Differences in 
DNA methylation have been found between SCZ post-mortem brains and control 
post-mortem brains (Mill et al., 2008) and it may be of interest to investigate if these 
epigenetic changes are related to the gene expression changes documented here.    
 
5.5 Concluding statement 
In sum, a developmental expression profile has been identified for genes containing 
common variants for SCZ and BPD. This profile and pathway analyses suggest that 
genes associated to SCZ and BPD play a role in human brain development and the 
regulation of related processes. This is consistent with the neurodevelopmental 
hypothesis where a disruption to these processes may impact on brain function in 
later life. 
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Chapter 7: Appendix A 
7.1 Additional tables for Chapter 2 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
DLPFC 
P value 
0.00161 
(0.0209) 
0.0194 
(0.252) 
0.439 0.304 
Correlation 
Coeff. 
-0.0275 -0.0211 -0.00662 -0.0093 
- - - - 
MPFC 
P value 
2.02 x 10-6 
(2.63 x 10-5) 
3.52 x 10-5 
(0.0005) 
0.00295 
(0.0384) 
0.0341 
(0.443) 
Correlation 
Coeff. 
0.0414 0.0374 0.0254 0.0192 
+ + + + 
OPFC 
 
P value 0.155 0.918 0.626 0.851 
Correlation 
Coeff. 
0.0124 0.000928 -0.00417 -0.00170 
+ + - - 
VLPFC 
P value 
0.0110 
(0.144) 
0.108 0.725 0.303 
Correlation 
Coeff. 
0.0221 0.0145 -0.00300 0.00931 
+ + - + 
MS 
P value 
0.00411 
(0.0535) 
3.71 x 10-6 
(4.83 x 10-5) 
2.84 x 10-8 
(3.69 x 10-7) 
6.06 x 10-5 
(0.000788) 
Correlation 
Coeff. 
0.0250 0.0418 0.0474 0.0363 
+ + + + 
PAS 
P value 
0.0719 
(0.935) 
0.0103 
(0.133) 
0.219 0.376 
Correlation 
Coeff. 
0.0157 0.0232 0.0105 0.00802 
+ + + + 
TAU 
P value 0.305 0.500 0.879 0.676 
Correlation 
Coeff. 
0.00894 0.00610 0.00113 0.00378 
+ + + + 
TAS 
P value 0.161 0.381 0.895 0.381 
Correlation 
Coeff. 
0.0122 0.00792 0.00113 -0.00792 
+ + + - 
OCC 
P value 0.120 0.153 
0.0165 
(0.214) 
0.997 
Correlation 
Coeff. 
0.0135 0.00129 0.0205 -3.65 x 10-5 
+ + + - 
HIP 
P value 
1.35 x 10-7 
(1.76 x 10-6) 
1.78 x 10-6 
(2.32 x 10-5) 
0.00143 
(0.0186) 
0.0283 
(0.368) 
Correlation 
Coeff. 
-0.0459 -0.0432 -0.0272 -0.0198 
- - - - 
STR 
P value 0.679 0.689 0.958 0.823 
Correlation 
Coeff. 
0.00360 0.00362 0.0187 -0.00202 
+ + + - 
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THAL 
P value 
0.00137 
(0.0178) 
2.37 x 10-5 
(0.000308) 
4.10 x 10-5 
(0.000534) 
0.00668 
(0.0868) 
Correlation 
Coeff. 
-0.0279 -0.0382 -0.0350 -0.0245 
- - - - 
CBL 
P value 
0.00865 
(0.112) 
0.0179 
(0.233) 
0.204 0.557 
Correlation 
Coeff. 
-0.0229 -0.0214 -0.0109 -0.00532 
- - - - 
Table 7.1: Linear regression results and correlation coefficients testing regional characteristic scores 
calculated in the Johnson dataset with gene-wide logP.  
P values in brackets have been corrected for 13 brain regions using Bonferroni’s method. 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
DLPFC 
P value 0.449  0.206 0.353 0.602 
Correlation 
Coeff. 
0.00657 0.0114 0.00412 0.00469 
+ + + + 
MPFC 
P value 0.997 0.324 
0.00195 
(0.0312) 
0.0203 
(0.324) 
Correlation 
Coeff. 
-3.17 x 10-5 0.00888 0.0133 0.0209 
- + + + 
OPFC 
P value 
0.0147 
(0.235) 
0.0553 
(0.884) 
0.0155 
(0.248) 
0.0740 
Correlation 
Coeff. 
0.0212 0.0173 0.0100 0.0161 
+ + + + 
VLPFC 
P value 0.390 0.624 0.632 0.351 
Correlation 
Coeff. 
0.00746 0.00442 0.00251 0.00839 
+ + + + 
M1C 
P value 0.714 0.601 
0.0327 
(0.523) 
0.175 
Correlation 
Coeff. 
-0.00318 -0.00471 0.00983 0.0122 
- - + + 
S1C 
P value 0.332 0.727 0.111 0.374 
Correlation 
Coeff. 
0.00842 0.00315 0.00880 0.00799 
+ + + + 
TAU 
P value 0.119 0.857 0.208 0.687 
Correlation 
Coeff. 
-0.0135 0.00162 -0.00596 -0.00363 
- + - - 
OCC 
P value 
3.57 x 10-8 
(5.70 x 10-7) 
5.04 x 10-8 
(8.06 x 10-7) 
7.34 x 10-5 
(0.00118) 
0.0105 
(0.168) 
Correlation 
Coeff. 
0.0478 0.0490 0.0102 0.0230 
+ + + + 
IPC 
P value 
0.000144 
(0.00230) 
4.98 x 10-5 
(0.000797) 
8.65 x 10-6 
(0.000138) 
0.00252 
(0.0403) 
Correlation 
Coeff. 
0.0330 0.0365 0.0186 0.0272 
+ + + + 
TAS 
P value 
0.00207 
(0.0331) 
0.00128 
(0.0205) 
0.0388 
(0.620) 
0.171 
Correlation 
Coeff. 
0.0267 0.0290 0.008110 0.0123 
+ + + + 
ITC 
P value 
0.0436 
(0.698) 
0.0220 
(0.353) 
0.0903 
0.0494 
(0.791) 
Correlation 
Coeff. 
0.0175 0.0206 -0.00913 -0.0177 
+ + - - 
HIP 
P value 
8.28 x 10-10 
(1.32 x 10-8) 
8.78 x 10-8 
(1.40 x 10-6) 
3.35 x 10-6 
(5.36 x 10-5) 
9.23 x 10-6 
(0.000148) 
Correlation 
Coeff. 
-0.0532 -0.0481 -0.00743 -0.0399 
- - - - 
AMY 
P value 0.319 0.249 0.208 0.182 
Correlation 
Coeff. 
0.00864 0.0104 0.00256 0.0120 
+ + + + 
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STR 
P value 0.141 0.756 0.858 0.852 
Correlation 
Coeff. 
0.0128 0.00280 -0.000188 0.00168 
+ + - + 
THAL 
P value 
2.66 x 10-5 
(0.000425) 
6.69 x 10-7 
(1.07 x 10-5) 
4.55 x 10-6 
(7.28 x 10-5) 
0.00293 
(0.0469) 
Correlation 
Coeff. 
-0.0364 -0.0447 -0.00390 -0.0268 
- - - - 
CBL 
P value 
0.00345 
(0.0552) 
0.0383 
(0.612) 
0.0906 0.462 
Correlation 
Coeff. 
-0.0254 -0.0187 -0.00119 -0.00663 
- - - + 
Table 7.2: Linear regression results and correlation coefficients testing regional characteristic scores 
calculated in the Kang dataset with gene-wide logP.  
P values in brackets have been corrected for 16 brain regions using Bonferroni’s method. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.99 0.780 0.519 0.166 0.285 0.476 0.419 0.543 0.883 
Coeff. + - - - - - + + + 
MPFC 
P value 0.569 1 0.802 0.274 0.547 0.808 0.742 0.342 0.484 
Coeff. + + + - - + + + + 
OPFC 
P value 0.477 0.851 0.244 0.206 0.171 0.212 0.635 0.170 
0.0501 
(0.651) 
Coeff. + - - + + + - - - 
VLPFC 
P value 0.547 0.264 0.268 0.144 0.163 0.280 0.914 0.669 0.808 
Coeff. - - - - - - - - - 
MS 
P value 0.917 0.680 0.462 0.0980 0.124 0.136 
0.0650 
(0.845) 
0.163 0.314 
Coeff. + - - - - - + + + 
PAS 
P value 0.174 0.313 0.704 0.539 0.543 0.595 0.197 0.241 0.533 
Coeff. + + + + + + + + + 
TAU 
P value 0.547 0.757 1 0.758 0.493 0.422 0.672 0.974 0.859 
Coeff. + + + + + + + + - 
TAS 
P value 0.100 0.162 0.241 0.168 0.115 
0.067 
(0.877) 
0.471 0.656 0.776 
Coeff. + + + + + + + + + 
OCC 
P value 0.750 0.365 0.246 0.792 0.804 0.933 0.866 0.448 0.294 
Coeff. - - - - - - - - - 
HIP 
P value 0.932 0.960 0.728 0.232 0.475 0.718 0.541 0.668 0.405 
Coeff. - - + - - - + + + 
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STR 
P value 0.425 0.420 0.428 0.945 0.556 0.288 0.208 0.100 0.078 
Coeff. - - - + + + - - - 
THAL 
P value 0.468 0.555 0.267 0.349 0.319 0.167 0.767 0.699 0.889 
Coeff. + + + + + + - - + 
CBL 
P value 0.988 0.472 0.292 0.851 0.708 0.365 0.381 0.875 0.686 
Coeff. + + + + + + - + + 
Table 7.3: Logistic regression results testing CNV case control status on regional characteristic scores calculated in the Johnson dataset. 
All p values in brackets were adjusted for 13 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.306 0.842 0.827 0.654 0.847 0.800 0.319 0.639 0.607 
Coeff. - - - - + + - - - 
MPFC 
P value 
0.0285 
(0.371) 
0.00983 
(0.128) 
0.0174 
(0.226) 
0.595 0.797 0.733 
0.000411 
(0.00535) 
0.000117 
(0.00152) 
0.000835 
(0.0109) 
Coeff. - - - + + + - - - 
OPFC 
P value 0.932 0.565 0.263 0.568 0.335 0.199 0.710 0.943 0.724 
Coeff. + + + + + + - - + 
VLPFC 
P value 
0.00278 
(0.0362) 
0.00434 
(0.0564) 
0.0117 
(0.152) 
0.180 0.265 0.463 0.00653 0.00518 0.00683 
Coeff. - - - - - - - - - 
MS 
P value 0.648 0.270 0.355 
0.00702 
(0.0912) 
0.00512 
(0.0665) 
0.00770 
(0.100) 
0.0860 0.326 0.346 
Coeff. + + + + + + - - - 
PAS 
P value 
0.0275 
(0.358) 
0.0307 
(0.399) 
0.0210 
(0.273) 
0.0109 
(0.142) 
0.0189 
(0.246) 
0.0253 
(0.329) 
0.463 0.412 0.237 
Coeff. + + + + + + + + + 
TAU 
P value 0.711 0.205 0.0322 
0.0627 
(0.815) 
0.0217 
(0.282) 
0.00703 
(0.0914) 
0.261 0.667 0.611 
Coeff. + + + + + + - - + 
TAS 
P value 0.361 0.992 0.540 0.319 0.506 0.342 0.771 0.468 0.931 
Coeff. - + - - - - - + + 
OCC 
P value 
0.00519 
(0.0675) 
0.0172 
(0.224) 
0.0547 
(0.711) 
0.133 0.244 0.329 
0.013 
(0.133) 
0.0159 
(0.207) 
0.0656 
(0.853) 
Coeff. + + + + + + + + + 
HIP 
P value 0.531 0.302 0.270 0.701 0.883 0.719 0.609 0.168 
0.0583 
(0.758) 
Coeff. + + + + + - + + + 
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STR 
P value 
0.0748 
(0.973) 
0.0676 
(0.878) 
0.233 0.637 0.734 0.946 
0.0514 
(0.668) 
0.0261 
(0.339) 
0.112 
Coeff. + + + + + + + + + 
THAL 
P value 
0.000284 
(0.00369) 
0.00878 
(0.114) 
0.0186 
(0.242) 
0.0385 
(0.501) 
0.0520 
(0.676) 
0.0174 
(0.226) 
0.00215 
(0.0280) 
0.0633 
(0.823) 
0.263 
Coeff. - - - - - - - - - 
CBL 
P value 0.0222 0.108 0.246 
0.00355 
(0.0461) 
0.00554 
(0.0720) 
0.0191 
(0.249) 
0.760 0.535 0.503 
Coeff. - - - - - - - + + 
Table 7.4: Logistic regression results testing CNV singleton status on regional characteristic scores calculated in the Johnson dataset.  
All p values in brackets were adjusted for 13 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
 
P value 0.298 0.178 0.0882 
0.0453 
(0.725) 
0.0338 
(0.541) 
0.0827 
 
0.990 0.964 0.619 
Coeff. - - - - - - + + - 
MPFC 
P value 0.770 0.484 0.356 
0.0308 
(0.493) 
0.0388 
(0.620) 
0.0547 
(0.875) 
0.111 0.243 0.384 
Coeff. - - - - - - + + + 
OPFC 
 
P value 0.942 0.730 0.599 0.434 0.306 0.508 0.732 0.596 0.854 
Coeff. - - - - - - + + + 
VLPFC 
P value 0.730 0.392 0.208 0.0739 
0.0477 
(0.763) 
0.0737 0.395 0.475 0.842 
Coeff. - - - - - - + + + 
M1C 
P value 0.635 0.521 0.761 
0.0259 
(0.415) 
0.0255 
(0.409) 
0.187 0.190 0.146 0.228 
Coeff. - - - - - - + + + 
S1C 
P value 0.636 0.843 0.798 0.475 0.530 0.655 0.236 0.283 0.522 
Coeff. + + - - - - + + + 
TAU 
P value 0.316 0.207 0.425 0.649 0.621 0.419 0.188 0.197 0.409 
Coeff. + + + - + + + + + 
OCC 
P value 0.171 0.112 0.0819 0.413 0.710 0.838 0.265 0.127 
0.0532 
(0.851) 
Coeff. - - - - - + - - - 
IPC 
P value 0.0848 0.215 0.149 0.920 0.756 0.731 
0.0372 
(0.595) 
0.0480 
(0.768) 
0.0576 
(0.921) 
Coeff. + + + - - + + + + 
TAS 
P value 0.290 0.187 0.149 0.676 0.397 0.174 0.417 0.233 0.230 
Coeff. + + + + + + + + + 
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ITC 
P value 0.326 0.332 0.381 
0.0456 
(0.729) 
0.00722 
(0.116) 
0.00614 
(0.0983) 
0.430 0.200 0.338 
Coeff. + + + + + + - - - 
HIP 
P value 0.455 0.646 0.890 0.324 0.357 0.486 0.143 0.178 0.357 
Coeff. + + + - - - + + + 
AMY 
P value 0.433 0.352 0.724 0.381 0.140 0.162 0.872 0.893 0.876 
Coeff. + + + + + + + + + 
STR 
P value 0.873 0.381 0.312 0.665 0.829 0.450 0.411 0.162 0.0956 
Coeff. - - - + + + - - - 
THAL 
P value 0.557 0.909 0.926 0.900 0.536 0.317 0.312 0.402 0.535 
Coeff. - - + - + + - - - 
CBL 
P value 0.916 0.858 0.939 0.673 0.795 0.697 0.286 0.586 0.638 
Coeff. + + + + + + - - + 
Table 7.5: Logistic regression results testing CNV case control status on regional characteristic scores calculated in the Kang dataset.  
All p values in brackets were adjusted for 16 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.249 0.203 0.148 0.910 0.869 0.977 0.141 0.0844 0.0767 
Coeff. - - - + + + - - - 
MPFC 
P value 0.190 0.842 0.890 0.0123 0.0654 0.0872 0.518 0.132 0.178 
Coeff. + + + + + + - - - 
OPFC 
P value 0.151 0.0836 
0.0560 
(0.895) 
0.883 0.846 0.816 0.0877 
0.0353 
(0.565) 
0.0289 
(0.463) 
Coeff. - - - - - - - - - 
VLPFC 
P value 0.131 0.102 
0.0139 
(0.222) 
0.858 0.986 0.446 
0.0433 
(0.692) 
0.0395 
(0.632) 
0.0139 
(0.223) 
Coeff. - - - + - - - - - 
M1C 
P value 0.575 0.760 0.495 0.391 0.373 0.172 0.995 0.707 0.859 
Coeff. + + + + + + + - - 
S1C 
P value 0.127 0.264 0.549 0.569 0.663 0.815 0.120 0.257 0.513 
Coeff. - - - - - - - - - 
TAU 
P value 0.974 0.986 0.647 0.444 0.570 0.750 0.498 0.640 0.442 
Coeff. + - + - - - + + + 
OCC 
P value 0.0322 0.159 0.443 0.0297 0.0275 0.0659 0.366 0.799 0.478 
Coeff. + + + + + + + - - 
IPC 
P value 0.743 0.201 0.0646 0.802 0.762 0.984 0.807 0.146 
0.0132 
(0.211) 
Coeff. + + + + + + + + + 
TAS 
P value 0.202 0.237 0.0302 0.596 0.651 0.629 0.200 0.227 0.0126 
Coeff. + + + + + + + + + 
ITC 
P value 0.441 0.377 0.776 0.832 0.763 0.793 0.198 0.0987 0.523 
Coeff. + + + - - - + + + 
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HIP 
P value 0.237 0.220 0.187 0.148 0.309 0.524 0.689 0.414 0.204 
Coeff. + + + + + + + + + 
AMY 
P value 0.660 0.708 0.281 0.830 0.951 0.809 0.442 0.620 0.259 
Coeff. - - - + + + - - - 
STR 
P value 0.213 0.143 0.318 0.698 0.777 0.917 0.192 0.0914 0.174 
Coeff. + + + + + - + + + 
THAL 
P value 0.147 0.663 0.717 0.526 0.604 0.883 0.0183 0.321 0.578 
Coeff. - - - + + + - - - 
CBL 
P value 
0.0311 
(0.497) 
0.0706 0.0675 0.00401 0.00414 0.0104 0.956 0.622 0.945 
Coeff. - - - - - - - + - 
Table 7.6: Logistic regression results testing CNV singleton status on regional characteristic scores calculated in the Kang dataset.  
All p values in brackets were adjusted for 16 brain regions using Bonferroni’s method, where missing corrected p value was 1.
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
DLPFC 
P value 
0.00988 
(0.128) 
0.712 0.987 0.270 
Correlation 
Coeff. 
0.0226 0.00336 0.000145 0.0100 
+ + + + 
MPFC 
P value 0.326 0.399 0.233 
0.0325 
(0.422) 
Correlation 
Coeff. 
0.00861 0.00767 0.0102 0.0195 
+ + + + 
OPFC 
P value 0.184 
0.0141 
(0.183) 
0.578 0.902 
Correlation 
Coeff. 
0.0116 0.0223 -0.00477 0.00112 
+ + - + 
VLPFC 
P value 
0.0444 
(0.5777) 
0.0213 
(0.277) 
0.354 0.499 
Correlation 
Coeff. 
0.0176 0.0209 0.00797 0.00615 
+ + - + 
MS 
P value 
0.0270 
(0.350) 
0.0886 0.160 0.109 
Correlation 
Coeff. 
0.0194 0.0155 0.0121 0.0146 
+ + + + 
PAS 
P value 0.810 0.532 0.919 0.484 
Correlation 
Coeff. 
0.00210 0.00568 0.000879 0.00637 
+ + + + 
TAU 
P value 0.370 0.375 0.854 0.563 
Correlation 
Coeff. 
-0.00786 -0.00806 0.00158 0.00527 
- - + + 
TAS 
P value 
0.00417 
(0.0542) 
0.0199 
(0.259) 
0.613 0.267 
Correlation 
Coeff. 
0.0251 0.0212 0.00435 0.0101 
+ + + + 
OCC 
P value 0.360 0.232 0.216 0.507 
Correlation 
Coeff. 
0.00801 0.0109 0.0116 0.00604 
+ + + + 
HIP 
P value 
0.0443 
(0.575) 
0.516 0.738 0.792 
Correlation 
Coeff. 
0.0176 0.00591 0.00287 -0.00240 
+ + + - 
STR 
P value 0.415 
0.0269 
(0.349) 
0.560 0.237 
Correlation 
Coeff. 
0.00715 0.0201 0.00501 0.0108 
+ + + + 
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THAL 
P value 0.839 0.116 0.658 0.344 
Correlation 
Coeff. 
0.00178 0.0143 -0.00380 0.00862 
+ + - + 
CBL 
P value 
0.00651 
(0.0846) 
0.0601 
(0.781) 
0.124 
0.00476 
(0.0619) 
Correlation 
Coeff. 
-0.0238 -0.0171 0.0132 0.0257 
- - + + 
Table 7.7: Linear regression results and correlation coefficients testing regional splicing logP 
calculated in the Johnson dataset with gene-wide logP.  
P values in brackets have been corrected for 13 brain regions using Bonferroni’s method. 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
DLPFC 
P value 0.258 0.116 0.612 0.277 
Correlation 
Coeff. 
-0.00985 -0.0142 0.00433 0.00981 
- - + + 
MPFC 
P value 
0.0139 
(0.223) 
0.186 0.759 0.816 
Correlation 
Coeff. 
-0.0214 -0.0119 -0.00262 0.00210 
- - - + 
OPFC 
 
P value 0.0718 0.643 0.117 0.507 
Correlation 
Coeff. 
-0.0157 -0.00419 -0.0134 -0.00599 
- - - - 
VLPFC 
P value 0.762 0.434 0.563 0.284 
Correlation 
Coeff. 
-0.00264 -0.00707 0.00494 0.00967 
- - - + 
M1C 
P value 0.498 0.333 0.527 0.608 
Correlation 
Coeff. 
0.00590 -0.00874 0.00540 0.00463 
+ - + + 
S1C 
P value 0.338 0.552 0.780 0.718 
Correlation 
Coeff. 
-0.00834 -0.00537 -0.00238 -0.00326 
- - + - 
TAU 
P value 0.703 0.823 0.661 0.109 
Correlation 
Coeff. 
-0.00332 0.00202 -0.00375 -0.0145 
- + - - 
OCC 
P value 
0.00318 
(0.0508) 
0.0487 
(0.780) 
0.891 0.687 
Correlation 
Coeff. 
0.0257 0.01789 -0.00117 -0.00364 
+ + - - 
IPC 
P value 
0.00150 
(0.0240) 
0.00132 
(0.0211) 
0.556 0.504 
Correlation 
Coeff. 
-0.0276 -0.0290 -0.00502 -0.00603 
- - - - 
TAS 
P value 0.0652 0.702 0.778 0.526 
Correlation 
Coeff. 
0.0160 0.00346 -0.00241 0.00572 
+ + - + 
ITC 
P value 0.152 0.222 0.884 0.951 
Correlation 
Coeff. 
-0.0124 -0.0110 0.00125 0.000550 
- - + + 
HIP 
P value 
0.00324 
(0.0518) 
0.0248 
(0.396) 
0.482 0.319 
Correlation 
Coeff. 
0.0256 0.0203 0.00600 0.00899 
+ + + + 
AMY 
P value 0.291 0.861 0.198 0.866 
Correlation 
Coeff. 
-0.00919 0.00158 -0.0110 -0.00153 
- + - - 
STR 
P value 0.756 0.665 0.583 0.546 
Correlation 
Coeff. 
-0.00270 0.00392 -0.00469 0.00546 
- + - + 
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THAL 
P value 
0.0275 
(0.441) 
0.0893 
0.016 
(0.254) 
0.0347 
(0.556) 
Correlation 
Coeff. 
0.0192 0.0153 0.0206 0.0191 
+ + + + 
CBL 
P value 
0.0502 
(0.803) 
0.493 0.878 0.114 
Correlation 
Coeff. 
-0.0170 -0.00619 0.00131 0.0143 
- - + + 
Table 7.8: Linear regression results and correlation coefficients testing regional splicing logP 
calculated in the Kang dataset with gene-wide logP.  
P values in brackets have been corrected for 16 brain regions using Bonferroni’s method. 
228 
 
 
All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.465 0.609 0.886 0.130 0.163 0.607 0.936 0.681 0.647 
Coeff. - - - - - - + + + 
MPFC 
P value 0.177 0.261 0.995 0.983 0.655 0.305 
0.0440 
(0.572) 
0.0613 
(0.797) 
0.718 
Coeff. - - + - + + - - - 
OPFC 
P value 0.241 0.220 0.0789 0.177 0.115 
0.0122 
(0.159) 
0.643 0.757 0.891 
Coeff. - - - - - - - - - 
VLPFC 
P value 0.0434 0.113 0.698 0.156 0.209 0.352 0.135 0.331 0.261 
Coeff. - - - - - + - - - 
MS 
P value 0.894 0.959 0.973 0.704 0.664 0.787 0.465 0.393 0.961 
Coeff. + - + + + + - - + 
PAS 
P value 0.436 0.424 0.651 0.272 0.508 0.987 0.678 0.574 0.817 
Coeff. - - - - - - - - - 
TAU 
P value 0.628 0.640 0.459 0.701 0.878 0.815 0.535 0.555 0.134 
Coeff. + + + - - - + + + 
TAS 
P value 0.424 0.283 0.495 0.428 0.421 0.876 0.700 0.680 0.829 
Coeff. - - - - - + - - - 
OCC 
P value 0.798 0.474 0.448 0.671 0.591 0.930 0.789 0.507 0.441 
Coeff. - - - - - - - - - 
HIP 
P value 0.937 0.926 0.389 0.274 0.684 0.620 0.457 0.858 0.312 
Coeff. + - + - - + + + + 
STR 
P value 0.991 0.821 0.812 0.761 0.843 0.917 0.956 0.834 0.987 
Coeff. + - - + + - - - + 
THAL 
P value 0.318 0.388 0.0790 0.288 0.294 
0.0670 
(0.871) 
0.759 0.745 0.234 
Coeff. + + + + + + + + + 
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CBL 
P value 0.657 0.625 0.582 0.758 0.802 0.910 0.226 0.283 0.526 
Coeff. - - - + + + - - - 
Table 7.9: Logistic regression results testing CNV case control status on regional splicing logP calculated in the Johnson dataset.  
All p values in brackets were adjusted for 13 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.213 0.186 0.260 
0.0556 
(0.723) 
0.431 0.970 0.973 0.254 0.0118 
Coeff. + + + + + - + + + 
MPFC 
P value 0.265 0.0828 
0.00212 
(0.0275) 
0.302 0.232 0.0826 0.589 0.202 0.0132 
Coeff. + + + + + + + + + 
OPFC 
P value 
0.0493 
(0.0641) 
0.112 0.890 0.539 0.528 0.761 
0.0515 
(0.670) 
0.150 0.980 
Coeff. - - - - - - - - - 
VLPFC 
P value 
0.0230 
(0.300) 
0.000523 
(0.00680) 
0.0469 
(0.609) 
0.0455 
(0.591) 
0.0335 
(0.436) 
0.149 0.186 
0.00522 
(0.0679) 
0.0940 
Coeff. + + + + + + + + + 
MS 
P value 0.0105 0.0986 0.804 
0.000975 
(0.0127) 
0.00162 
(0.0211) 
0.0324 
(0.421) 
0.843 0.166 
0.0365 
(0.475) 
Coeff. - - + - - - + + + 
PAS 
P value 
0.00700 
(0.0910) 
0.0175 
(0.227) 
0.0288 
(0.0374) 
0.0184 
(0.239) 
0.0162 
(0.210) 
0.00162 
(0.0211) 
0.119 0.283 0.681 
Coeff. - - - - - - - - - 
TAU 
P value 0.764 0.347 
0.0300 
(0.390) 
0.304 0.475 0.510 0.184 
0.0548 
(0.713) 
0.00381 
(0.0495) 
Coeff. + + + - - - + + + 
TAS 
P value 
0.0356 
(0.462) 
0.0117 
(0.152) 
0.0769 
 
5.51 x 10-7 
(7.16 x 10-6) 
6.29 x 10-7 
(8.18 x 10-6) 
7.38 x 10-5 
(0.000959) 
0.197 0.535 0.598 
Coeff. + + + + + + - - - 
OCC 
P value 
0.000222 
(0.00289) 
0.000193 
(0.00251) 
0.0153 
(0.199) 
0.0599 
(0.779) 
0.0940 0.115 
0.000471 
(0.00612) 
0.000169 
(0.00220) 
0.0619 
(0.804) 
Coeff. - - - - - - - - - 
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HIP 
P value 0.138 0.138 0.0868 0.348 0.297 0.0896 0.246 0.310 0.468 
Coeff. - - - - - - - - - 
STR 
P value 
0.0358 
(0.466) 
0.0784 
0.0733 
(0.953) 
0.00644 
(0.0837) 
0.00256 
(0.0332) 
0.00373 
(0.0485) 
0.00180 
(0.235) 
0.00338 
(0.0439) 
0.00254 
(0.0330) 
Coeff. - - - + + + - - - 
THAL 
P value 0.694 0.339 0.589 
0.0359 
(0.467) 
0.0223 
(0.289) 
0.0590 
(0.767) 
0.212 0.516 0.429 
Coeff. + + + + + + - - - 
CBL 
P value 0.885 0.991 0.367 0.936 0.626 0.650 0.821 0.668 0.136 
Coeff. - - + - - - - + + 
Table 7.10: Logistic regression results testing CNV singleton status on regional splicing logP calculated in the Johnson dataset.  
All p values in brackets were adjusted for 13 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
P value 0.166 0.305 0.752 0.364 0.676 0.583 0.380 0.384 0.324 
Coeff. + + + + + - + + + 
MPFC 
P value 0.118 0.141 0.628 0.207 0.265 0.180 0.458 0.373 0.911 
Coeff. + + + + + + + + - 
OPFC 
P value 0.503 0.284 0.140 0.170 0.169 0.239 0.846 0.828 0.533 
Coeff. - - - + - - + - - 
VLPFC 
P value 0.537 0.371 0.235 0.215 0.209 0.115 0.926 0.832 0.640 
Coeff. - - - - - - + + + 
M1C 
P value 
0.00306 
(0.0490) 
0.000386 
(0.00617) 
0.000638 
(0.0102) 
0.00112 
(0.0180) 
0.00139 
(0.0222) 
0.00599 
(0.0958) 
0.212 
0.0502 
(0.804) 
0.0457 
(0.731) 
Coeff. - - - - - - - - - 
S1C 
P value 0.0743 
0.0250 
(0.400) 
0.920 0.632 0.495 0.370 
0.0290 
(0.465) 
0.0131 
(0.210) 
0.214 
Coeff. - - - - - + - - - 
TAU 
P value 0.0645 
0.0540 
(0.864) 
0.156 0.287 0.353 0.237 0.226 0.109 0.416 
Coeff. + + + + + + + + + 
OCC 
P value 0.157 0.205 0.262 0.632 0.424 0.319 0.0110 0.0197 0.0401 
Coeff. - - - + + + - - - 
IPC 
P value 0.405 0.208 0.757 0.846 0.940 0.840 0.107 0.0658 0.597 
Coeff. - - - + - + - - - 
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TAS 
P value 0.506 0.732 0.878 0.549 0.545 0.968 0.974 0.846 0.571 
Coeff. + + + + + - + - + 
ITC 
P value 0.249 0.0704 0.314 0.0414 0.0332 0.581 0.854 0.535 0.452 
Coeff. - - - - - - + - - 
HIP 
P value 0.896 0.815 0.589 0.341 0.422 0.854 0.496 0.709 0.235 
Coeff. + - + - - - + + + 
AMY 
P value 0.778 0.982 0.704 0.583 0.527 0.847 0.481 0.555 0.387 
Coeff. + + + - - - + + + 
STR 
P value 0.805 0.641 0.889 0.554 0.436 0.486 0.986 0.967 0.736 
Coeff. - - - - - - + - + 
THAL 
P value 0.0503 0.480 0.0988 0.697 0.499 0.180 0.656 0.578 0.107 
Coeff. + + + + + + + + + 
CBL 
P value 0.502 0.496 0.499 0.933 0.939 0.918 0.135 0.192 0.346 
Coeff. - - - - - + - - - 
Table 7.11: Logistic regression results testing CNV case control status on regional splicing logP calculated in the Kang dataset.  
All p values in brackets were adjusted for 16 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
DLPFC 
 
P value 
0.000566 
(0.00906) 
0.00677 
(0.108) 
0.0995 
0.0297 
(0.475) 
0.0911 0.377 
0.00862 
(0.138) 
0.0347 
(0.555) 
0.130 
Coeff. - - - - - - - - - 
MPFC 
P value 0.382 0.171 0.113 0.385 0.323 0.234 0.750 0.340 0.295 
Coeff. + + + + + + + + + 
OPFC 
 
P value 
0.000367 
(0.00587) 
0.000111 
(0.00177) 
6.25 x 10-5 
(0.00100) 
0.000229 
(0.00367) 
1.77 x 10-5 
(0.000282) 
1.27 x 10-7 
(2.03 x 10-6) 
0.109 0.123 0.150 
Coeff. + + + + + + + + + 
VLPFC 
P value 0.0770 0.784 0.584 0.988 0.683 0.299 0.0216 0.410 0.712 
Coeff. - - + - + + - - - 
M1C 
P value 0.975 0.856 0.344 0.580 0.615 0.956 0.611 0.884 0.303 
Coeff. - + + + + + - - + 
S1C 
P value 0.177 0.348 0.0445 0.152 0.493 
0.0459 
(0.734) 
0.652 0.513 0.817 
Coeff. - - + - - + - - + 
TAU 
P value 
6.77 x10-7 
(1.08 x 10-5) 
2.27 x 10-6 
(3.64 x 10-5) 
0.00268 
(0.0428) 
3.46 x 10-5 
(5.53 x 10-4) 
2.69 x 10-5 
(4.30 x 10-4) 
0.00125 
(0.0200) 
0.0142 
(0.227) 
0.0634 0.352 
Coeff. - - - - - - - - - 
OCC 
P value 0.750 0.704 0.239 0.478 0.444 0.143 0.889 0.874 0.773 
Coeff. + + + + + + - - + 
IPC 
P value 0.198 0.185 0.877 
0.0247 
(0.396) 
0.0449 
(0.719) 
0.0781 0.556 0.809 0.0794 
Coeff. - - + - - - + + + 
TAS 
P value 
0.00322 
(0.0516) 
0.0116 
(0.185) 
0.0203 
(0.325) 
0.0106 
(0.170) 
0.0638 0.130 0.129 0.0816 0.0936 
Coeff. + + + + + + + + + 
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ITC 
P value 0.245 0.184 0.400 0.818 0.909 0.565 
0.0621 
(0.993) 
0.0935 0.566 
Coeff. - - - + - - - - - 
HIP 
P value 
0.0212 
(0.339) 
0.222 0.884 0.271 0.403 0.782 
0.0406 
(0.650) 
0.397 0.685 
Coeff. - - + - - - - - + 
AMY 
P value 0.588 0.623 0.667 0.676 0.605 0.613 0.730 0.853 0.355 
Coeff. - - + - - - - - + 
STR 
P value 0.901 0.845 0.554 
0.0248 
(0.396) 
0.0322 
(0.515) 
0.0482 
(0.772) 
0.195 0.384 0.772 
Coeff. - + + + + + - - - 
THAL 
P value 0.358 0.615 0.795 0.0738 0.0731 0.163 
0.00509 
(0.0814) 
0.0241 
(0.385) 
0.150 
Coeff. - - - + + + - - - 
CBL 
P value 0.184 0.200 0.215 0.205 0.154 0.167 0.510 0.691 0.616 
Coeff. - - - - - - - - - 
Table 7.12: Logistic regression results testing CNV singleton status on regional splicing logP calculated in the Kang dataset.  
All p values in brackets were adjusted for 16 brain regions using Bonferroni’s method, where missing corrected p value was 1. 
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7.2 Additional figures for Chapter 2 
 
Figure 7.1: Scatterplots of relationships between global metrics calculated in the Johnson dataset and 
Simes’ gene-wide p values. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Simes’ logP 
against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and D 
plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
. 
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Figure 7.2: Scatterplots of relationships between testing global metrics calculated within neocortical 
regions in the Johnson dataset and Simes’ gene-wide p values. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Simes’ logP 
against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and D 
plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
238 
 
 
Figure 7.3: Scatterplots of relationships between global metrics calculated in the Kang dataset and 
Simes’ gene-wide p values. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Simes’ logP 
against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and D 
plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
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Figure 7.4: Scatterplots of relationships between testing global metrics calculated within neocortical 
regions in the Kang dataset and Simes’ gene-wide p values. 
Panels A, C and E plot SCZ Brown’s logP against global metrics; panels B, D and F plot BPD Simes’ logP 
against global metrics. Panels A and B plot mean expression across mid-foetal brain; panels C and D 
plot scaled mean; panels E and F plot coefficient of variation against gene-wide logP. 
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Figure 7.5: Results from Mann-Whitney tests for genes ranked by global metrics calculated in the 
Johnson and Kang datasets, excluding MHC genes.  
Panels A & B are results testing top n% of genes ranked by each global metric in turn against the 
bottom 50% for smaller SCZ p values; panels C & D are results testing for smaller BPD p values. Panels 
A & C global metrics were calculated in the Johnson dataset; panels B & D were calculated in Kang 
dataset. Analyses were run excluding MHC genes. Black dashed line is 0.05. 
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Figure 7.6: Results from Mann-Whitney tests for genes ranked by global metrics within neocortical 
regions calculated in the Johnson and Kang datasets, excluding MHC genes.  
Panels A & B are results testing top n% of genes ranked by each global metric in turn against the 
bottom 50% for smaller SCZ p values; panels C & D are results testing for smaller BPD p values. Panels 
A & C global metrics were calculated in the Johnson dataset; panels B & D were calculated in the Kang 
dataset. Analyses were run excluding MHC genes. Black dashed line is 0.05.  
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Chapter 8: Appendix B 
8.1 Additional tables for Chapter 3 
 
Schizophrenia Bipolar disorder Parkinson’s Alzheimer’s 
Brown’s Simes’ Brown’s Simes’ Brown’s Brown’s 
Early foetal A 
P value 0.844 0.401 0.475 0.0977 0.368 0.408 
Correlation 
Coeff. 
0.0130 -0.00772 -0.00621 -0.0153 -0.00791 -0.00683 
+ - - - - - 
Early foetal B 
P value 
0.000147 
(0.00176) 
0.00791 
(0.0950) 
0.575 0.314 0.237 0.569 
Correlation 
Coeff. 
0.0293 0.0244 -0.00488 -0.00928 -0.0104 -0.00470 
+ + - - - - 
Early mid-foetal A 
P value 
7.80 x 10-10 
(9.36 x 10-9) 
1.14 x 10-8 
(1.36 x 10-7) 
0.0480 
(0.576) 
0.167 0.895 0.182 
Correlation 
Coeff. 
0.0562 0.0525 0.0172 0.0127 -0.00116 -0.0110 
+ + + + - - 
Early mid-foetal B 
P value 
4.40 x 10-8 
(5.28 x 10-7) 
1.13 x 10-6 
(1.36 x 10-5) 
0.00737 
(0.0884) 
0.0236 
(0.283) 
0.309 0.321 
Correlation 
Coeff. 
0.0538 0.0448 0.0233 0.0209 0.00893 -0.00819 
+ + + + + - 
Late mid-foetal 
P value 
4.45 x 10-5 
(0.000534) 
1.14 x 10-5 
(0.000137) 
0.0133 
(0.160) 
0.00458 
(0.0550) 
0.117 0.923 
Correlation 
Coeff. 
0.0263 0.0404 0.0215 0.0261 0.0138 0.000800 
+ + + + + + 
Late foetal 
P value 
0.000324 
(0.00389) 
0.00228 
(0.0274) 
0.00188 
(0.0225) 
0.00688 
(0.0826) 
0.800 0.109 
Correlation 
Coeff. 
-0.0277 -0.281 -0.0270 -0.0249 -0.00223 -0.0132 
- - - - - - 
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Neonatal and early 
infancy 
P value 
0.0246 
(0.295) 
0.142 0.862 0.457 0.127 0.575 
Correlation 
Coeff. 
-0.0305 -0.0135 -0.00151 0.00685 0.0134 0.00462 
- - - - + + 
Late infancy 
P value 
6.09 x 10-5 
(0.000731) 
0.00547 
(0.0656) 
0.0407 
(0.489) 
0.221 0.258 0.846 
Correlation 
Coeff. 
-0.0365 -0.0256 -0.0178 -0.0113 -0.00993 0.00160 
- - - - - + 
Early childhood 
P value 
1.29 x 10-16 
(1.55 x 10-15) 
1.24 x 10-8 
(1.49 x 10-7) 
0.00301 
(0.0361) 
0.0467 
(0.561) 
0.127 0.258 
Correlation 
Coeff. 
-0.0616 -0.0524 -0.0258 -0.0183 -0.0134 0.00932 
- - - - - + 
Middle and late 
childhood 
P value 
1.06 x 10-6 
(1.27 x 10-5) 
1.32 x 10-6 
(1.58 x 10-5) 
0.0491 
(0.589) 
0.0791 
(0.949) 
0.751 0.774 
Correlation 
Coeff. 
-0.0426 -0.0445 -0.0171 -0.0162 0.00279 0.00237 
- - - - + + 
Adolescence 
P value 
2.91 x 10-5 
(0.000350) 
8.87 x 10-5 
(0.00106) 
0.264 0.376 0.912 0.453 
Correlation 
Coeff. 
-0.0375 -0.0361 -0.00970 -0.00816 -0.000966 0.00619 
- - - - - + 
Young adulthood 
P value 
0.0405 
(0.486) 
0.0583 
(0.700) 
0.497 0.394 0.770 0.300 
Correlation 
Coeff. 
-0.0231 -0.0174 0.00590 0.00785 -0.00257 0.00854 
- - + - - + 
Table 8.1: Linear regression results and correlation coefficients testing development stage characteristic scores calculated in the BrainSpan RNA-Seq dataset with gene-
wide logP. 
P values in brackets corrected for 12 development stages, where missing corrected p value was 1. 
244 
 
 
 
Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Early foetal A 
P value 0.784 0.199 0.339 
0.0535 
(0.643) 
Correlation 
Coeff. 
-0.00244 -0.0119 -0.00835 -0.0179 
- - - - 
Early foetal B 
P value 
0.00143 
(0.0228) 
0.00999 
(0.120) 
0.575 0.318 
Correlation 
Coeff. 
0.0285 0.0239 -0.00491 -0.00927 
+ + - - 
Early mid-foetal 
A 
P value 
3.54 x 10-8 
(5.67 x 10-7) 
6.97 x 10-7 
(8.36 x 10-6) 
0.0618 
(0.741) 
0.233 
Correlation 
Coeff. 
0.0492 0.0460 0.0163 0.0111 
+ + + + 
Early mid-foetal 
B 
P value 
1.04 x 10-6 
(1.66 x 10-5) 
0.000167 
(0.00201) 
0.0112 
(0.135) 
0.0380 
(0.456) 
Correlation 
Coeff. 
0.0436 0.0349 0.0222 0.0192 
+ + + + 
Late mid-foetal 
P value 
0.000377 
(0.00603) 
0.000237 
(0.00284) 
0.0175 
(0.210) 
0.00504 
(0.0604) 
Correlation 
Coeff. 
0.0317 0.0341 0.0208 0.0260 
+ + + + 
Late foetal 
P value 
0.000203 
(0.00324) 
0.00451 
(0.0542) 
0.00202 
(0.0243) 
0.00990 
(0.119) 
Correlation 
Coeff. 
-0.0332 -0.0263 -0.0270 -0.0239 
- - - - 
Neonatal and 
early infancy 
P value 0.258 0.779 0.904 0.298 
Correlation 
Coeff. 
-0.101 0.00260 0.00105 0.00965 
- + + + 
Late Infancy 
P value 
9.14 x 10-7 
(1.46 x 10-5) 
0.000106 
(0.00127) 
0.0294 
(0.353) 
0.173 
Correlation 
Coeff. 
-0.0438 -0.0359 -0.0190 -0.012 
- - - - 
Early childhood 
P value 
1.22 x 10-17 
(1.95 x 10-16) 
4.22 x 10-10 
(5.07 x 10-9) 
0.00292 
(0.0351) 
0.0419 
(0.503) 
Correlation 
Coeff. 
-0.0763 -0.0579 -0.0260 -0.0189 
- - - - 
Middle and late 
childhood 
P value 
2.78 x 10-5 
(0.000445) 
5.66 x 10-5 
(0.000679) 
0.0524 
(0.629) 
0.0727 
(0.872) 
Correlation 
Coeff. 
-0.0374 -0.0373 -0.0170 -0.0166 
- - - - 
Adolescence 
P value 
0.000417 
(0.00667) 
0.00111 
(0.0133) 
0.383 0.573 
Correlation 
Coeff. 
-0.0315 -0.0302 -0.00763 -0.00522 
- - - - 
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Young adulthood 
P value 0.126 0.116 0.428 0.328 
Correlation 
Coeff. 
-0.0136 -0.0145 0.00693 0.00907 
- - + + 
Table 8.2: Linear regression results and correlation coefficients testing development stage 
characteristic scores calculated in the BrainSpan RNA-Seq dataset with gene-wide logP, excluding 
MHC genes.  
P values in brackets corrected for 12 development stages, where missing corrected p value was 1.
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Schizophrenia Bipolar disorder Parkinson’s Alzheimer’s 
Brown’s Simes’ Brown’s Simes’ Brown’s Brown’s 
Embryonic 
P value 0.881 
0.000784 
(0.0118) 
0.454 0.123 0.298 0.222 
Correlation 
Coeff. 
0.00130 -0.0293 0.00641 -0.0135 -0.00896 -0.00986 
+ - + - - - 
Early foetal A 
P value 0.655 
0.0544 
(0.816) 
0.800 0.220 0.174 0.261 
Correlation 
Coeff. 
-0.00390 -0.0168 0.00216 -0.0108 -0.0117 -0.00906 
- - + - - - 
Early foetal B 
P value 
0.000452 
(0.00678) 
0.291 0.581 0.135 0.227 0.567 
Correlation 
Coeff. 
0.0306 0.00920 0.00472 -0.0131 -0.0104 -0.00462 
+ + + - - - 
Early mid-foetal A 
P value 0.493 0.602 0.446 0.938 0.953 0.505 
Correlation 
Coeff. 
0.00597 0.00454 0.00651 -0.000677 0.000506 0.00538 
+ + + - + + 
Early mid-foetal B 
P value 
0.0277 
(0.415) 
0.000825 
(0.0124) 
0.0405 
(0.607) 
0.00207 
(0.0311) 
0.0938 0.506 
Correlation 
Coeff. 
0.0192 0.0291 0.0175 0.0270 0.0144 -0.00536 
+ + + + + - 
Late mid-foetal 
P value 0.142 
0.00196 
(0.0293) 
0.926 0.518 0.264 0.721 
Correlation 
Coeff. 
0.0128 0.0270 -0.000798 0.00566 -0.00961 -0.00288 
+ + - + - - 
Late foetal 
P value 0.382 0.751 0.461 0.859 0.960 
0.0654 
(0.980) 
Correlation 
Coeff. 
-0.00762 0.00277 -0.00631 -0.00155 0.000434 0.0149 
- + - - + + 
Neonatal and early 
infancy 
P value 
0.00447 
(0.0670) 
0.513 0.905 0.538 0.583 0.356 
Correlation -0.0248 -0.00570 -0.00102 0.00540 -0.00473 0.00745 
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Table 8.3: Linear regression results and correlation coefficients testing development stage characteristic scores calculated in the Kang microarray dataset with gene-wide 
logP. 
P values in brackets corrected for 15 development stages, where missing corrected p value was 1. 
Coeff. - - - + - + 
Late infancy 
P value 0.171 0.869 0.381 0.818 0.372 0.742 
Correlation 
Coeff. 
-0.0119 -0.00144 -0.00749 0.00202 -0.00769 0.00265 
- - - + - + 
Early childhood 
P value 
0.000382 
(0.00573) 
0.00174 
(0.0261) 
0.219 0.244 0.658 0.548 
Correlation 
Coeff. 
-0.0310 -0.0273 -0.0105 -0.0102 0.00381 0.00484 
- - - - + + 
Middle and late 
childhood 
P value 0.194 
0.00691 
(0.104) 
0.000102 
(0.00153) 
0.000148 
(0.00222) 
0.521 0.0917 
Correlation 
Coeff. 
-0.0113 -0.0235 -0.0332 -0.0332 -0.00553 -0.0136 
- - - - - - 
Adolescence 
P value 
0.00341 
(0.0511) 
0.0850 0.592 0.983 0.262 0.335 
Correlation 
Coeff. 
0.0255 0.0150 0.00459 0.000189 0.00967 -0.00778 
+ + + + + - 
Young adulthood 
P value 
6.13 x 10-5 
(0.000919) 
0.0572 
(0.859) 
0.0553 
(0.830) 
0.207 0.154 0.182 
Correlation 
Coeff. 
0.0349 0.0166 0.0164 0.011 0.0123 -0.0108 
+ + + + + - 
Middle adulthood 
P value 
0.00447 
(0.0670) 
0.000761 
(0.0114) 
0.0327 
(0.490) 
0.154 0.359 0.460 
Correlation 
Coeff. 
-0.0248 -0.0293 -0.0183 -0.0125 0.00790 0.00595 
- - - - + + 
Late adulthood 
P value 
0.000423 
(0.00634) 
0.000282 
(0.00423) 
0.161 0.432 0.845 0.746 
Correlation 
Coeff. 
-0.0307 -0.0317 -0.0120 -0.00689 -0.00169 0.00261 
- - - - - + 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Embryonic 
P value 0.680 
9.37 x 10-7 
(1.41 x 10-5) 
0.515 
0.0619 
(0.928) 
Correlation 
Coeff. 
-0.00362 -0.0430 0.00560 -0.0165 
- - + - 
Early foetal A 
P value 0.414 
0.00318 
(0.0478) 
0.841 0.130 
Correlation 
Coeff. 
-0.00716 -0.0259 0.00173 -0.0134 
- - + - 
Early foetal B 
P value 
0.00663 
(0.0995) 
0.907 0.614 0.126 
Correlation 
Coeff. 
0.0238 0.00102 0.00434 -0.0135 
+ + + - 
Early mid-foetal A 
P value 0.725 0.947 0.460 0.910 
Correlation 
Coeff. 
0.00308 0.000586 0.00636 -0.00100 
+ + + - 
Early mid-foetal B 
P value 
0.0263 
(0.394) 
0.000674 
(0.0101) 
0.0700 0.00487 
Correlation 
Coeff. 
0.0195 0.0298 0.0156 0.0248 
+ + + + 
Late mid-foetal 
P value 0.281 
0.00160 
(0.0249) 
0.991 0.384 
Coeff. 
0.00946 0.0276 9.63 x 10-5 0.00768 
+ + + + 
Late foetal 
P value 0.118 0.329 0.351 0.686 
Correlation 
Coeff. 
-0.0137 -0.00857 -0.00802 -0.00356 
- - - - 
Neonatal and early 
infancy 
P value 
0.00601 
(0.0902) 
0.532 0.920 0.524 
Correlation 
Coeff. 
-0.0241 -0.00549 -0.000863 0.00562 
- - - + 
Late infancy 
P value 0.158 0.991 0.344 0.827 
Correlation 
Coeff. 
-0.0124 0.000101 -0.00814 0.00193 
- + - + 
Early childhood 
P value 
0.00412 
(0.0619) 
0.0194 
(0.291) 
0.257 0.313 
Correlation 
Coeff. 
-0.0251 -0.0205 -0.00975 -0.00890 
- - - - 
Middle and late 
childhood 
P value 0.420 
0.0306 
(0.459) 
0.000208 
(0.00312) 
0.000340 
(0.00510) 
Correlation 
Coeff. 
-0.00707 -0.0190 -0.0319 -0.0316 
- - - - 
Adolescence 
P value 
2.87 x 10-5 
(0.000430) 
0.000229 
(0.00343) 
0.359 0.645 
Correlation 
Coeff. 
0.00367 0.0323 0.00790 0.00406 
+ + + + 
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Young adulthood 
P value 
5.08 x 10-5 
(0.000763) 
0.0246 
(0.369) 
0.0494 
(0.740) 
0.220 
Correlation 
Coeff. 
0.0355 0.0197 0.0169 0.0108 
+ + + + 
Middle adulthood 
P value 
0.0255 
(0.383) 
0.0317 
(0.476) 
0.0267 
(0.401) 
0.134 
Correlation 
Coeff. 
-0.0196 -0.0189 -0.0191 -0.0132 
- - - - 
Late adulthood 
P value 
0.000331 
(0.00496) 
9.21 x 10-5 0.158 0.396 
Correlation 
Coeff. 
-0.0315 -0.0343 -0.0121 -0.00749 
- - - - 
Table 8.4: Linear regression results and correlation coefficients testing development stage 
characteristic scores calculated in the Kang microarray dataset with gene-wide logP, excluding MHC 
genes.  
P values in brackets corrected for 15 development stages, where missing corrected p value was 1. 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Embryonic 
P value 0.776 
9.50 x 10-5 
(0.00143) 
0.678 0.0886 
Correlation 
Coeff. 
-0.00248 -0.0340 0.00355 -0.0149 
- - + - 
Early foetal A 
P value 0.907 0.152 0.735 0.165 
Correlation 
Coeff. 
0.00102 -0.0125 0.00290 -0.0122 
+ - + - 
Early foetal B 
P value 
4.77 x 10-5 
(0.000715) 
0.0354 
(0.532) 
0.200 0.667 
Correlation 
Coeff. 
0.0355 0.0183 0.0110 -0.00378 
+ + + - 
Early mid-foetal A 
P value 
5.00 x 10-5 
(0.000750) 
0.00116 
(0.0174) 
0.123 0.917 
Correlation 
Coeff. 
0.0354 0.0283 0.0132 -0.000913 
+ + + - 
Early mid-foetal B 
P value 
2.39 x 10-7 
(8.59 x 10-8) 
8.59 x 10-8 
(1.29 x 10-6) 
0.00115 
(0.0173) 
0.00812 
(0.122) 
Correlation 
Coeff. 
0.0450 0.0467 0.0278 0.0232 
+ + + + 
Late mid-foetal 
P value 
0.0152 
(0.228) 
0.000628 
(0.00942) 
0.535 0.510 
Correlation 
Coeff. 
0.0212 0.0298 0.00531 0.00577 
+ + + + 
Late foetal 
P value 0.264 0.597 0.467 0.770 
Correlation 
Coeff. 
-0.00974 0.00460 -0.00622 -0.00256 
- + - - 
Neonatal and early 
infancy 
P value 
0.00138 
(0.0207) 
0.356 0.704 0.166 
Correlation 
Coeff. 
-0.0279 -0.0099 0.00325 0.0121 
- - + + 
Late infancy 
P value 
2.27 x 10-6 
(3.41 x 10-5) 
1.83 x 10-5 
(2.74 x 10-4) 
0.00650 
(0.0976) 
0.268 
Correlation 
Coeff. 
-0.0412 -0.0373 -0.0233 -0.00971 
- - - - 
Early childhood 
P value 
0.000691 
(0.0104) 
0.000575 
(0.00862) 
0.00418 
(0.0627) 
0.00467 
(0.0700) 
Correlation 
Coeff. 
-0.0296 -0.0300 -0.0245 -0.0248 
- - - - 
Middle and late 
childhood 
P value 
0.00454 
(0.0680) 
6.29 x 10-5 
(0.000943) 
0.00326 
(0.0490) 
0.0115 
(0.172) 
Correlation 
Coeff. 
-0.0247 -0.0349 -0.0252 -0.0221 
- - - - 
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Adolescence 
P value 
0.0241 
(0.361) 
0.0565 
(0.848) 
0.769 0.701 
Correlation 
Coeff. 
-0.0197 -0.0166 -0.00252 0.00337 
- - - + 
Young adulthood 
P value 0.831 0.298 0.666 0.593 
Correlation 
Coeff. 
-0.00186 -0.00907 0.00370 0.00469 
- - + + 
Middle adulthood 
P value 
1.95 x 10-5 
(0.000293) 
1.65 x 10-5 
(0.000248) 
0.0152 0.143 
Correlation 
Coeff. 
-0.0372 -0.0375 -0.0208 -0.0128 
- - - - 
Late adulthood 
P value 
0.0146 
(0.219) 
0.143 0.186 0.452 
Correlation 
Coeff. 
-0.0213 -0.0255 -0.0113 -0.00659 
- - - - 
Table 8.5: Linear regression results and correlation coefficients testing development stage 
characteristic scores calculated in the Kang microarray dataset without PMI covariate with gene-wide 
logP.  
P values in brackets corrected for 15 development stages, where missing corrected p value was 1 
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Schizophrenia Bipolar disorder 
Brown’s Simes’ Brown’s Simes’ 
Embryonic 
P value 0.442 
1.29 x 10-7 
(1.94 x 10-6) 
0.732 
0.0554 
(0.831) 
Correlation 
Coeff. 
-0.00674 -0.0463 0.00295 -0.0169 
- - + - 
Early foetal A 
P value 0.722 
0.00843 
(0.126) 
0.829 0.0815 
Correlation 
Coeff. 
-0.00312 -0.0231 0.00186 -0.0154 
- - + - 
Early foetal B 
P value 
0.00218 
(0.0326) 
0.394 0.241 0.583 
Correlation 
Coeff. 
0.0269 0.00748 0.0101 -0.00484 
+ + + - 
Early mid-foetal A 
P value 
0.00218 
(0.0326) 
0.0817 0.188 0.724 
Correlation 
Coeff. 
0.0266 0.0153 0.0113 -0.00312 
+ + + - 
Early mid-foetal B 
P value 
4.87 x 10-5 
(0.000730) 
0.000209 
(0.00313) 
0.00433 
(0.0649) 
0.0267 
(0.401) 
Correlation 
Coeff. 
0.0356 0.0325 0.0245 0.0195 
+ + + + 
Late mid-foetal 
P value 0.0818 
0.00461 
(0.0691) 
0.566 0.467 
Correlation 
Coeff. 
0.0153 0.0249 0.00493 0.00642 
+ + + + 
Late foetal 
P value 0.0617 0.502 0.356 0.582 
Correlation 
Coeff. 
-0.0164 -0.00590 -0.00794 -0.00486 
- - - - 
Neonatal and early 
infancy 
P value 
0.0273 
(0.409) 
0.925 0.651 0.133 
Correlation 
Coeff. 
-0.0194 0.000826 0.00389 0.0132 
- + + + 
Late infancy 
P value 
8.07 x 10-5 
(0.00121) 
0.000861 
(0.0129) 
0.00902 
(0.135) 
0.365 
Correlation 
Coeff. 
-0.0345 -0.0292 -0.0225 -0.00799 
- - - - 
Early childhood 
P value 
0.00157 
(0.0236) 
0.000637 
(0.00956) 
0.00414 
(0.0621) 
0.00493 
(0.0740) 
Correlation 
Coeff. 
-0.0277 -0.0300 -0.0247 -0.0248 
- - - - 
Middle and late 
childhood 
P value 0.132 
0.0225 
(0.338) 
0.00681 
(0.102) 
0.0244 
(0.366) 
Correlation 
Coeff. 
-0.0132 -0.0200 -0.0233 -0.0199 
- - - - 
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Adolescence 
P value 0.221 0.904 0.916 0.497 
Correlation 
Coeff. 
-0.0107 -0.00106 -0.000911 0.00599 
- - - + 
Young adulthood 
P value 0.651 0.916 0.541 0.524 
Correlation 
Coeff. 
0.00396 -0.000930 0.00526 0.00563 
+ - + + 
Middle adulthood 
P value 
0.000151 
(0.00227) 
0.000540 
(0.00810) 
0.0210 
(0.314) 
0.176 
Correlation 
Coeff. 
-0.0332 -0.0304 -0.0199 -0.0119 
- - - - 
Late adulthood 
P value 
0.0133 
(0.200) 
0.000867 
(0.0130) 
0.215 0.491 
Correlation 
Coeff. 
-0.0217 -0.0292 -0.0107 -0.00607 
- - - - 
Table 8.6: Linear regression results and correlation coefficients testing development stage 
characteristic scores calculated in the Kang microarray dataset without PMI covariate with gene-wide 
logP, excluding MHC genes.  
P values in brackets corrected for 15 development stages, where missing corrected p value was 1.
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Early foetal A 
P value 0.248 0.511 0.705 
0.0644 
(0.772) 
0.0773 0.118 0.981 0.692 0.166 
Coeff. + + - + + + + - - 
Early foetal B 
P value 0.329 0.462 0.510 0.434 0.571 0.783 0.455 0.729 0.882 
Coeff. - - - - - - - - - 
Early mid-
foetal A 
P value 0.945 0.864 0.381 0.651 0.815 0.669 0.895 0.581 0.201 
Coeff. - + + - - + + + + 
Early mid-
foetal B 
P value 0.513 0.932 0.828 0.089 0.204 0.501 0.617 0.237 0.176 
Coeff. - - + - - - + + + 
Late mid-foetal 
P value 0.269 0.357 0.445 
0.052 
(0.628) 
0.072 
(0.868) 
0.133 0.910 0.627 0.512 
Coeff. - - - - - - + + + 
Late foetal 
P value 0.437 0.169 0.170 0.282 0.197 0.278 0.725 0.650 0.349 
Coeff. + + + + + + - + + 
Neonatal and 
early infancy 
P value 0.475 0.306 0.216 0.433 0.178 0.036 0.918 0.795 0.900 
Coeff. + + + + + + + + + 
Late infancy 
P value 0.529 0.938 0.712 0.308 0.626 0.879 0.727 0.618 0.473 
Coeff. - + + - - + - + + 
Early childhood 
P value 0.780 0.771 0.554 0.662 0.865 0.235 0.794 0.852 0.997 
Coeff. + + + - + + + + + 
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Middle and 
late childhood 
P value 0.691 0.857 0.539 0.569 0.184 0.099 0.517 0.213 0.832 
Coeff. + + + + + + - - - 
Adolescence 
P value 0.530 0.695 0.850 0.647 0.826 0.993 0.382 0.612 0.958 
Coeff. - - - - - - - - + 
Young 
adulthood 
P value 0.606 0.578 0.912 0.736 0.660 0.781 0.329 0.513 0.895 
Coeff. - - - - - - - - + 
Table 8.7: Logistic regression results testing CNV case control status on development stage characteristic score calculated in the BrainSpan RNA-Seq dataset.  
P values in brackets corrected for 12 development stages, where missing corrected p value was 1.  
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All CNVs Deletions Duplications 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Early foetal A 
P value 
0.00986 
(0.118) 
0.00121 
(0.0145) 
6.56 x 10-5 
(0.000788) 
0.000287 
(0.00344) 
0.000263 
(0.00315) 
0.000506 
(0.00608) 
0.748 0.231 
0.0149 
(0.179) 
Coeff. + + + + + + + + + 
Early foetal B 
P value 0.916 0.808 0.763 0.589 0.444 0.296 0.793 0.754 0.623 
Coeff. + + + + + + - - - 
Early mid-
foetal A 
P value 0.265 0.148 
0.0127 
(0.152) 
0.100 0.0818 0.0141 0.883 0.655 0.218 
Coeff. + + + + + + + + + 
Early mid-
foetal B 
P value 0.163 0.314 0.329 0.866 0.864 0.925 0.117 0.163 0.233 
Coeff. - - - - + - - - - 
Late mid-foetal 
P value 0.200 0.145 0.149 0.701 0.799 0.853 0.190 0.0895 
0.0714 
(0.857) 
Coeff. - - - - - - - - - 
Late foetal 
P value 0.885 0.541 0.355 0.600 0.402 0.206 0.783 0.943 0.757 
Coeff. + + + + + + - + + 
Neonatal and 
early infancy 
P value 0.989 0.310 
0.00198 
(0.0238) 
0.644 0.979 0.121 0.688 0.198 
0.00573 
(0.0687) 
Coeff. + + + - + + + + + 
Late infancy 
P value 0.968 0.151 0.0851 0.373 0.779 0.796 0.427 
0.0314 
(0.376) 
0.0679 
Coeff. + + + - - + + + + 
Early childhood 
P value 0.987 0.494 0.561 0.937 0.777 0.364 0.970 0.561 0.958 
Coeff. - + + - + + + + - 
Middle and 
late childhood 
P value 0.369 0.0512 
0.00132 
(0.0158) 
0.609 0.209 0.0214 0.444 0.143 0.0381 
Coeff. + + + + + + + + + 
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Adolescence 
P value 0.216 0.580 0.907 0.553 0.717 0.996 0.281 0.680 0.978 
Coeff. - - + - - + - - - 
Young 
adulthood 
P value 0.083 0.182 0.346 
0.0489 
(0.587) 
0.0620 
(0.744) 
0.0675 
(0.809) 
0.685 0.969 0.775 
Coeff. - - - - - - - + + 
Table 8.8: Logistic regression results testing CNV singleton status on development stage characteristic scores calculated in the BrainSpan RNA-Seq dataset.  
P values in brackets corrected for 12 development stages, where missing corrected p value was 1.  
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All CNVs Deletion CNVs Duplication CNVs 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Embryonic 
P value 0.982 0.874 0.409 0.638 0.923 0.979 0.357 0.417 0.523 
Coeff. + + - - - - + + - 
Early foetal A 
P value 0.532 0.495 0.721 0.704 0.536 0.519 0.605 0.576 0.897 
Coeff. + + + + + + + + + 
Early foetal B 
P value 0.465 0.746 0.855 0.947 0.719 0.708 0.321 0.673 0.688 
Coeff. + + + - + + + + + 
Early mid-
foetal A 
P value 0.514 0.257 0.487 0.426 0.613 0.887 0.934 0.444 0.748 
Coeff. - - - - - - - - - 
Early mid-
foetal B 
P value 0.676 0.457 0.834 0.304 0.382 0.806 0.864 0.646 0.993 
Coeff. - - - - - - - - + 
Late mid-foetal 
P value 0.835 0.914 0.650 0.424 0.513 0.838 0.601 0.533 0.605 
Coeff. + + + - - + + + + 
Late foetal 
P value 0.806 0.495 0.746 0.341 0.801 0.673 0.738 0.185 0.224 
Coeff. - + + - - - + + + 
Neonatal and 
early infancy 
P value 0.131 0.0869 
0.0221 
(0.332) 
0.989 0.507 0.138 0.111 0.100 0.0815 
Coeff. + + + + + + + + + 
Late infancy 
P value 0.342 0.393 0.778 0.764 0.576 0.178 0.181 0.487 0.618 
Coeff. + + + - + + + + - 
Early childhood 
P value 0.816 0.682 0.748 0.966 0.593 0.263 0.984 0.920 0.937 
Coeff. + + + - + + + + - 
Middle and 
late childhood 
P value 0.584 0.456 0.475 0.849 0.587 0.366 0.384 0.132 0.191 
Coeff. - - - - + + - - - 
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Adolescence 
P value 0.254 0.646 0.780 0.683 0.457 0.202 
0.0457 
(0.686) 
0.210 0.338 
Coeff. - - - + + + - - - 
Young 
adulthood 
P value 0.294 0.134 0.123 0.425 0.362 0.889 0.267 0.179 
0.0578 
(0.867) 
Coeff. - - - - - + - - - 
Middle 
adulthood 
P value 0.484 0.434 0.745 0.160 0.489 0.830 0.755 0.671 0.889 
Coeff. - - - - - - + - + 
Late adulthood 
P value 0.712 0.614 0.623 0.780 0.472 0.125 0.522 0.121 0.544 
Coeff. - - + - + + - - - 
Table 8.9: Logistic regression results testing CNV case control status on development stage characteristic scores calculated in the Kang microarray dataset. 
 P values in brackets corrected for 15 development stages.  
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All CNVs Deletion CNVs Duplication CNVs 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Embryonic 
P value 0.371 0.160 0.353 0.303 0.310 0.329 0.880 0.257 0.631 
Coeff. + + + + + + + + + 
Early foetal A 
P value 
0.0351 
(0.527) 
0.00218 
(0.0327) 
0.000724 
(0.0109) 
0.00113 
(0.0170) 
0.000446 
(0.00669) 
0.000648 
(0.00972) 
0.965 0.287 0.0896 
Coeff. + + + + + + + + + 
Early foetal B 
P value 0.121 0.0722 
0.0262 
(0.393) 
0.0361 
(0.541) 
0.0205 
(0.308) 
0.0540 
(0.810) 
0.726 0.634 0.155 
Coeff. + + + + + + + + + 
Early mid-
foetal A 
P value 0.253 0.264 0.487 0.186 0.290 0.478 0.738 0.572 0.713 
Coeff. + + + + + + + + + 
Early mid-
foetal B 
P value 
0.000133 
(0.00200) 
6.24 x 10-5 
(0.000937) 
0.000750 
(0.0113) 
0.000382 
(0.00573) 
0.000524 
(0.00785) 
0.00483 
(0.0725) 
0.0581 
(0.871) 
0.0278 
(0.416) 
0.0394 
(0.591) 
Coeff. - - - - - - - - - 
Late mid-foetal 
P value 0.112 0.454 0.684 0.459 0.404 0.300 0.141 0.799 0.676 
Coeff. - - - - - - - - + 
Late foetal 
P value 0.397 0.242 0.207 0.719 0.371 0.547 0.183 0.410 0.262 
Coeff. - + + + + + - + + 
Neonatal and 
early infancy 
P value 0.0735 0.159 0.825 0.367 0.636 0.803 0.122 0.146 0.562 
Coeff. + + + + + - + + + 
Late infancy 
P value 0.991 0.740 0.616 0.517 0.473 0.753 0.517 0.266 0.394 
Coeff. - - - + + + - - - 
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Early childhood 
P value 0.408 0.135 
0.00181 
(0.0272) 
0.351 0.189 
0.0636 
(0.953) 
0.739 0.395 
0.0132 
(0.198) 
Coeff. + + + + + + + + + 
Middle and 
late childhood 
P value 
0.0111 
(0.166) 
0.114 0.0703 0.302 0.753 0.514 
0.0163 
(0.244) 
0.0777 0.0913 
Coeff. - - - - - - - - - 
Adolescence 
P value 0.947 0.353 
0.0114 
(0.171) 
0.481 0.349 
0.0477 
(0.715) 
0.532 0.681 0.100 
Coeff. - + + + + + - + + 
Young 
adulthood 
P value 0.196 0.122 0.419 0.361 0.118 0.116 0.340 0.480 0.828 
Coeff. - - - - - - - - + 
Middle 
adulthood 
P value 0.447 0.515 0.745 0.464 0.563 0.664 0.846 0.750 0.908 
Coeff. + - - + - - + - - 
Late adulthood 
P value 0.136 0.184 0.151 0.999 0.891 0.550 
0.0289 
(0.434) 
0.0726 0.177 
Coeff. - - - + - - - - - 
Table 8.10: Logistic regression results testing CNV singleton status on development stage characteristic scores calculated in the Kang microarray dataset.  
P values in brackets corrected for 15 development stages, where missing corrected p value was 1.  
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All CNVs Deletion CNVs Duplication CNVs 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Embryonic 
P value 0.945 0.869 0.400 0.506 0.768 0.816 0.271 0.249 0.583 
Coeff. - + - - - - + + - 
Early foetal A 
P value 0.486 0.392 0.910 0.652 0.470 0.473 0.516 0.435 0.811 
Coeff. + + + + + + + + - 
Early foetal B 
P value 0.894 0.876 0.784 0.356 0.538 0.601 0.352 0.510 0.545 
Coeff. + - + - - - + + + 
Early mid-
foetal A 
P value 0.839 0.686 0.678 0.295 0.505 0.861 0.583 0.719 0.879 
Coeff. - - - - - - + + + 
Early mid-
foetal B 
P value 0.863 0.789 0.651 0.350 0.583 0.886 0.330 0.223 0.239 
Coeff. + + + - - - + + + 
Late mid-foetal 
P value 0.936 0.903 0.850 0.279 0.444 0.821 0.465 0.597 0.841 
Coeff. + - - - - - + + + 
Late foetal 
P value 0.927 0.813 0.987 0.436 0.672 0.786 0.771 0.388 0.473 
Coeff. - + - - - - + + + 
Neonatal and 
early infancy 
P value 0.219 0.128 0.178 0.979 0.410 0.118 0.309 0.273 0.678 
Coeff. + + + - + + + + + 
Late infancy 
P value 0.999 0.941 0.944 0.755 0.655 0.323 0.845 0.698 0.565 
Coeff. + + - - + + - - - 
Early childhood 
P value 0.822 0.245 0.436 0.811 0.426 0.401 0.987 0.258 0.369 
Coeff. + + + + + + + + + 
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Middle and 
late childhood 
P value 0.282 0.368 0.301 0.176 0.0581 0.0146 0.758 0.402 0.562 
Coeff. + + + + + + - - - 
Adolescence 
P value 0.421 0.646 0.908 0.590 0.525 0.462 0.998 0.782 0.553 
Coeff. + + - + + + + - - 
Young 
adulthood 
P value 0.983 0.392 0.455 0.680 0.996 0.394 0.374 0.150 0.116 
Coeff. + - - + - + - - - 
Middle 
adulthood 
P value 0.767 0.482 0.320 0.335 0.798 0.845 0.923 0.327 0.164 
Coeff. - - - - - + + - - 
Late adulthood 
P value 0.310 0.310 0.958 0.447 0.965 0.304 0.303 0.097 0.397 
Coeff. - - + - + + - - - 
Table 8.11: Logistic regression results testing CNV case control status on development stage characteristic scores calculated in the Kang microarray dataset without PMI 
covariate. 
 P values in brackets corrected for 15 development stages, where missing corrected p value was 1.  
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All CNVs Deletion CNVs Duplication CNVs 
Min. Med. Max. Min. Med. Max. Min. Med. Max. 
Embryonic 
P value 0.374 0.156 0.443 0.354 0.352 0.374 0.792 0.184 0.704 
Coeff. + + + + + + + + + 
Early foetal A 
P value 
0.0129 
(0.194) 
0.000358 
(0.00537) 
0.000153 
(0.00229) 
0.000292 
(0.00438) 
0.000426 
(0.00640) 
0.00152 
(0.0228) 
0.867 0.089 
0.0136 
(0.204) 
Coeff. + + + + + + + + + 
Early foetal B 
P value 0.0713 
0.0358 
(0.537) 
0.0953 
0.0137 
(0.0228) 
0.0161 
(0.242) 
0.0850 0.686 0.410 0.367 
Coeff. + + + + + + + + + 
Early mid-
foetal A 
P value 0.562 0.174 0.442 
0.0505 
(0.758) 
0.0592 
(0.887) 
0.173 0.423 0.823 0.998 
Coeff. + + + + + + - - - 
Early mid-
foetal B 
P value 0.344 0.518 0.932 0.904 0.947 0.865 0.265 0.416 0.971 
Coeff. - - + - - + - - - 
Late mid-foetal 
P value 0.107 0.294 0.377 0.416 0.277 0.223 0.143 0.681 0.939 
Coeff. - - - - - - - - - 
Late foetal 
P value 0.0750 0.737 0.867 0.580 0.989 0.650 0.0706 0.622 0.587 
Coeff. - + + - - - - + + 
Neonatal and 
early infancy 
P value 0.165 0.283 0.0808 0.111 0.302 
0.0417 
(0.626) 
0.531 0.562 0.578 
Coeff. - - - - - - - - - 
Late infancy 
P value 
0.0177 
(0.266) 
0.0841 0.326 0.207 0.303 0.475 
0.0396 
(0.593) 
0.172 0.513 
Coeff. - - - - - - - - - 
Early childhood 
P value 
6.89 x 10-6 
(0.000103) 
1.17 x 10-5 
(0.000175) 
5.93 x 10-5 
(0.000890) 
1.24 x 10-5 
(0.000186) 
6.05 x 10-6 
(9.08 x 10-5) 
4.80 x 10-7 
(7.20 x 10-6) 
0.0193 
(0.289) 
0.0652 
(0.978) 
0.337 
Coeff. + + + + + + + + + 
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Middle and 
late childhood 
P value 0.0874 0.698 0.495 0.586 0.938 0.517 
0.0590 
(0.884) 
0.592 0.162 
Coeff. - - + - - - - - + 
Adolescence 
P value 0.857 0.814 0.534 0.588 0.727 0.734 0.534 0.557 0.329 
Coeff. - - - - - - + + + 
Young 
adulthood 
P value 0.163 0.183 0.450 0.208 0.197 0.0720 0.467 0.515 0.594 
Coeff. - - - - - - - - + 
Middle 
adulthood 
P value 0.368 0.551 0.812 0.136 0.531 0.808 0.701 0.878 0.573 
Coeff. + + - + + + - + - 
Late adulthood 
P value 0.116 0.214 
0.0343 
(0.514) 
0.694 0.540 0.129 
0.0451 
(0.677) 
0.214 0.154 
Coeff. - - - - - - - - - 
Table 8.12: Logistic regression results testing CNV singleton status on development stage characteristic scores calculated in the Kang microarray dataset without PMI 
covariate. 
P values in brackets corrected for 15 development stages, where missing corrected p value was 1. 
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8.2 Additional figures for Chapter 3 
 
Figure 8.1: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the  BrainSpan RNA-Seq dataset and Brown’s p values. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.1 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panel A tested positive subset; panels B & C tested negative 
subset.  Panels A & B tested for smaller SCZ Brown’s p values; panel C tested for smaller BPD Brown’s p values. 
Black dashed line is p = 0.05. 
 
Figure 8.2: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset and SCZ Simes’ p values.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.1 was tested in a one-
sided Mann-Whitney test against the bottom 50% for smaller SCZ Simes’ p values, panel A tested positive 
subset; panel B tested negative subset. Black dashed line is p = 0.05. 
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Figure 8.3: Results from linear regression of development stage characteristic scores calculated in the 
BrainSpan RNA-Seq dataset, excluding MHC genes.  
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above the origin 
indicate positive regression coefficients; bars below the origin indicate negative regression coefficients.  Panel 
A tested Brown’s logP; panel B tested Simes’ logP. All p values were corrected for 12 development stages using 
Bonferroni’s method. Black dashed line is p = 0.05. 
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Figure 8.4: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset and Brown’s p values, excluding MHC 
genes. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 8.3 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panel A tested positive subset; panels B & C tested negative 
subset. Panels A & B tested SCZ Brown’s p values; panel C tested BPD Brown’s p values. Black dashed line is p = 
0.05.  
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Figure 8.5: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the BrainSpan RNA-Seq dataset and SCZ Simes’ p values, excluding 
MHC genes.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 8.3 was tested in a one-
sided Mann-Whitney test against the bottom 50% for smaller SCZ Simes’ p values, panel A tested positive 
subset; panel B tested negative subset. Black dashed line is p = 0.05. 
 
Figure 8.6: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset and Brown’s p values.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.2 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panel A test positive subset; panels B & C tested negative 
subset. Panels A & B tested SCZ Brown’s p values; panel C tested BPD Brown’s p values. Black dashed line is p = 
0.05. 
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Figure 8.7: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset and Simes’ p values. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.2 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panels A & C tested positive subsets; panels B & D tested 
negative subsets. Panels A & B tested SCZ Simes’ p values; panels C & D tested BPD Simes’ p values. Black 
dashed line is p = 0.05. 
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Figure 8.8: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset and Brown’s p values, excluding MHC 
genes.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.3 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panel A tested positive subset; panels B & C tested negative 
subset. Panels A & B tested SCZ Brown’s p values; panel C tested BPD Brown’s p values. Black dashed line is p = 
0.05. 
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Figure 8.9: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset and Simes’ p values, excluding MHC 
genes. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.3 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panel A tested positive subset; panels B & C tested negative 
subset. Panels A & B tested SCZ Simes’ p values; panel C tested BPD Simes’ p values. Black dashed line is p = 
0.05. 
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Figure 8.10: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the  Kang microarray dataset without PMI covariate  and Brown’s p 
values. 
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.4 was tested in a one-
sided Mann-Whitney test against the bottom 50%, panels A & C tested positive subset; panels B & D tested 
negative subset. Panels A & B tested SCZ Brown’s p values; panels C & D tested BPD Brown’s p values. Black 
dashed line is p = 0.05. 
 
Figure 8.11: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset without PMI covariate and SCZ Simes’ p 
values.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 3.4 was tested in a one-
sided Mann-Whitney test against the bottom 50% for smaller SCZ Simes’ p values, panel A tested positive 
subset; panel B tested negative subset. Black dashed line is p = 0.05. 
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Figure 8.12: Results from linear regression of development stage characteristic scores calculated in the Kang 
microarray dataset without PMI covariate, excluding MHC genes. 
P values were –log10 transformed and multiplied by the sign of the coefficient, therefore bars above the origin 
indicate positive regression coefficients; bars below the origin indicate negative regression coefficients. Panel 
A tested Brown’s logP; panel B tested Simes’ logP. All P values were corrected for 15 development stages using 
Bonferroni’s method. Black dashed line is p = 0.05. 
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Figure 8.13: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset without PMI covariate and SCZ Brown’s p 
values, excluding MHC genes.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 8.12 was tested in a one-
sided Mann-Whitney test against the bottom 50% for smaller SCZ Brown’s p values, panel A tested positive 
subset; panel B tested negative subset. Black dashed line is p = 0.05. 
 
 
Figure 8.14: Results from Mann-Whitney tests to verify significant regression models between development 
stage characteristic scores calculated in the Kang microarray dataset without PMI covariate and SCZ Simes’ p 
values, excluding MHC genes.  
Genes were ranked by absolute characteristic scores and the top n% split into positive and negative subsets. 
The subset consistent with the direction of the significant regression model in Figure 8.12 was tested in a one-
sided Mann-Whitney test against the bottom 50% for smaller SCZ Brown’s p values, panel A tested positive 
subset; panel B tested negative subset. Black dashed line is p = 0.05. 
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Figure 8.15: Results from Mann-Whitney tests for genes ranked by SCZ risk genes co-expression model p values 
calculated in the BrainSpan RNA-Seq dataset. 
Genes ranked by co-expression model p values and top n% tested against bottom 50%. Panels A & B tested for 
smaller SCZ p values; panels C & D tested for smaller BPD p values. Panels A & C tested all genes, panels B & D 
excluded MHC genes. Black dashed line is 0.05. 
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Figure 8.16: Results from Mann-Whitney tests for genes ranked by BPD risk genes co-expression model p 
values calculated in the BrainSpan RNA-Seq dataset. 
Genes ranked by co-expression model p values and top n% tested against bottom 50%. Panels A & B tested for 
smaller SCZ p values; panels C & D tested for smaller BPD p values. Panels A & C tested all genes; panels B & D 
excluded MHC genes. Black dashed line is 0.05. 
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Figure 8.17: BPD risk genes comparing microarray and RNA-Seq expression values.   
Risk genes identified from PGC GWAS whose co-expression indexed association in the RNA-Seq dataset and 
were present in the microarray dataset. Median expression values calculated for each development stage, 
scale on left for RNA-Seq data, scale on right for microarray data. 
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Figure 8.18: Logistic regression results testing CNV singleton status on development stage characteristic scores 
calculated in the Kang microarray dataset without PMI covariate. 
Panel A is all CNVs, panel B deletions, and panel C duplications. P values were corrected for 15 development 
stages using Bonferroni’s method. Black dashed line is 0.05. 
 
 
